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Abstract 
 
 
 
Over the last two decades concern about influenza has increased worldwide due to 
the rising number of human infections caused by an avian virus, H5N1, and the 
2009-pandemic of swine-origin H1N1 virus. Counter-measures, for example the 
selective administration of antivirals to infected individuals, their hospitalization, and 
the culling of large numbers of infected animals require a prompt and reliable 
diagnosis, that ideally identifies the type and subtype of the virus and can be carried 
out at the Point-of-Care (POC). Nowadays instead diagnosis is still largely 
laboratory-bound, as the available POC-suitable tests are hampered by poor and 
very variable clinical sensitivity. 
This PhD was developed in the frame of a European joint effort (Fluarray) that aimed 
at constructing an automated diagnostic system for the rapid influenza diagnosis. 
Key technology of the system is an antibody microarray technology that permits the 
simultaneous analysis of hundreds of antigen-antibody interactions. This research 
investigated ways to detect the influenza virus using a panel of monoclonal 
antibodies that were purified, characterized and integrated into the microarray 
platform. The optimised immunoassay detects and differentiates the influenza 
nucleoproteins of type A and B at concentrations in the order of few nanograms/ml. 
A panel of influenza viruses were detected and their type identified within 1 hour 
hands-on time. The developed microarray platform will soon be integrated into an 
Automated Diagnostic Analyser for Microarrays (ADAM) developed by the 
collaborating partner Microtest Matrices. It is envisaged that the system will be a 
consistent aid in the influenza diagnosis and sensibly facilitate and speed up 
diagnostic procedures. 
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1.1 Influenza, reasons for concern and 
importance of surveillance 
 
Influenza, commonly referred to as ‘flu’, is a contagious viral infection of the upper 
respiratory tract. Severity of the disease depends on both the pathogenicity of the 
causative strain, and the susceptibility of the host.  
Seasonal influenza results in mild illness whose main symptoms include high fever, 
headache, cough, sore throat, and rhinitis. In most cases, these tend to disappear 
within one week from onset without medical treatment. However, for very young 
individuals, as well as for the elderly and for individuals who suffer from concomitant 
diseases (i.e. diabetes, cancer, lung diseases, heart problems), consequences can 
be much more severe, and include death. It is estimated that 5-15% of the worldwide 
population in industrialised countries is affected by seasonal epidemics every year, 
and between 300,000 and 500,000 of these die (Girard et al., 2005). The recurrent 
epidemics are responsible of a significant economic burden in the industrialised 
world. In the USA for example, the costs associated to the loss of working days of 
the infected individuals, and hospitalisations and health care spending for clinical 
treatment were estimated at approximately $87 billion (Molinari et al., 2007). In 
England and Wales, the disease was estimated by Pitman and colleagues to cause 
between 19,000 to 31,000 hospital admissions per year (Pitman et al., 2007). 
Reoccurrence of seasonal epidemics is caused by viral strains that present 
mutations in the external proteins, and as such they present an antigenic profile that 
eludes the immune defences. 
More alarming than the seasonal influenza is the sporadic emergence of pandemic 
strains. Contrary to those that cause epidemics, the pandemic viruses arise upon 
more drastic mutational events in the viral genome. The new antigenic variants can 
spread worldwide, as no immunity is typically available in the host organisms. 
Concern about pandemics is due to both the rapidity of diffusion, and to the high 
mortality rate normally associated with the new infection. Such large-scale events 
occurred in several instances over the last few centuries, and three were very well 
reported, in 1918, 1957, and 1968. The 1918 pandemic, particularly, killed between 
 18 
50 and 100 million people worldwide. These pandemics were caused by avian 
influenza viruses that crossed the species barrier to man and spread in the whole 
world within months.  
Additional, however, limited outbreaks from avian strains have been reported in man 
in the last fifty years, caused by the influenza subtypes H5N1, H7N2, H7N3, H7N7, 
H9N2, and H10N7. Since 1997 human infections associated to the subtype H5N1 
were reported in several countries in Asia in an increasing fashion. In the years 
following 2003, and as of 10th of August 2012, the World Health Organization has 
reported a total of 608 confirmed worldwide human infections caused by H5N1, with 
a mortality rate of about 60% (WHO/GIP data as of 10 of August 2012, Cumulative 
number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 
2003-2012). The limited number of human infections indicates that the avian strains 
are still unable to establish a sustained infection and transmission cycle in humans. 
Nevertheless, the very high mortality rate thus far recorded for H5N1 along with the 
possibility of evolution of the genetic and antigenic asset with consequent adaptation 
to humans make zoonotic transfer a serious concern for the worldwide community. 
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Figure 1.1. Worldwide spread of influenza H5N1 since 2003.  
Although the majority of H5N1 human infection cases were reported in five Asian countries, 
Indonesia, Vietnam, China, Thailand, and Cambodia, infections were also recorded in Western Asian 
countries as well as in Egypt and Nigeria. Figure reproduced with permission of WHO (WHO/FLUNET 
Global Health Observatory Map Gallery, 2012). 
 
The danger of zoonotic transfer was confirmed in 2009 when a new influenza virus, 
originated in swine, infected humans in several countries worldwide. The pathogen, 
swine-origin influenza virus (S-OIV), caused a first outbreak in humans in April 2009 
and, following widespread diffusion, the WHO officially declared the new pandemic 
(11th of June 2009). By December of the same year 622,482 people had been 
infected, and at least 7826 of them had been killed by the new pathogen (WHO 
2009, Pandemic (H1N1) 2009-update 76). In September 2010, the pandemic status 
was lifted (WHO, Influenza update 10 September 2010), and however, the WHO 
called for continued vigilance against a new outbreak of the pandemic strain. 
Nowadays, prevention of transmission and infection mainly relies on vaccines. 
However, while vaccination provides a good degree of protection against similar 
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strains, it confers limited, or no protection at all against novel variants of the virus. A 
second means for influenza control is represented by the administration of antiviral 
drugs. These can reduce the severity of the symptoms, and contribute to decrease 
the risk of infection. Antivirals, however, must be administered 24-48 hours after 
infection onset to be effective, and they should be chosen on the base of specific 
information on the infective strain. Additionally, late administration will reduce the 
effectiveness of the drug. 
In a typical pandemic scenario, where both the vaccination and the administration of 
antiviral drugs are typically inadequate to combat the novel strains, healthcare 
authorities may implement different measures to prevent large-scale transmission.  
For example, infected individuals may be quarantined, or treated with higher-doses 
of antiviral drugs, and large numbers of infected animals may be culled in an attempt 
to destroy the natural reservoir of a new pathogen. However, for such measures to 
be taken in an effective time frame, rapidity of the diagnosis is crucial. Indeed, both 
the late implementation as well as the application of available countermeasures 
without diagnostic information on the causing agent, drastically reduces the 
effectiveness of preventive actions. Additionally, if undetected, infected individuals 
become vectors of the pathogen among the population, and facilitate viral spread.  
Current diagnostic methods are not adequate to confront a pandemic scenario, as 
the techniques available are neither fast nor scalable enough to handle high volumes 
of samples. Indeed, analysis is still largely laboratory-bound, and the transport to 
appropriate facilities constitutes a major bottleneck for the current diagnostics. For 
an effective control of influenza, diagnosis should ideally be carried out at the point-
of-care (POC), including border posts, schools, airports, and medical outposts. 
Although rapid tests exists, that are designed for use at a POC, their clinical 
performance is still limited and variable, and therefore diagnosis still relies on 
techniques that require considerable hands-on time of trained professionals, and 
appropriate and expensive laboratory structures.  
At the time of writing, the methods that are most investigated as a suitable option for 
POC-diagnostics are based either on the capture and discrimination of pathogen-
specific viral antigens, or on the amplification of nucleic acids. Automation of these 
techniques has made consistent steps forward over the last few years, and yet, a 
fast, POC-suitable diagnostic system with reliable clinical and analytical parameters 
is unavailable. In the absence of a reliable POC system, the world is still relying on 
 21 
laboratory-based techniques that are not feasible for large-scale screening. In the 
occurrence of a pandemic episode then, the world may be unprepared, and the 
consequences be dramatic. 
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1.2 Biology of influenza 
 
 
1.2.1 Overview of the structural organization and classification 
 
Influenza is a negative sense, single-stranded RNA virus classified in the family 
Orthomyxoviridae (International Committee on Taxonomy of, 1995).  
Phylogenetically and structurally related to the order of the Mononegavirales (that 
includes the rabies, measles, and the Ebola viruses), the members of the 
Orthomyxoviridae family are hallmarked by a segmented genome composed of 
discrete molecules of (-)ssRNA.  
The virus particles (referred to as virions) are mainly pleomorphic, however 
predominantly spherical in shape, and they are constituted of three integrated 
components, the nucleocapsid, the matrix coat, and the envelope (Figure 1.2).  
 
 
Figure 1.2. Model of the structure of the influenza virus.  
The virion of influenza contains a central compartment, the nucleocapsid,that hosts eight 
ribonucleoproteins of different size. These are composed of the nucleproteins, the three subunits of 
the RNA polymerase and RNA. The nucleocapsid is delimitated by a coat of matrix proteins indicated 
by the pink ring and the lipid envelope, indicated by the grey ring. Three trans-membrane proteins 
cross the envelope: the hemagglutinin, the neuraminidase, and the ion-channel.
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The nucleocapsid, the core compartment, hosts the ribonucleoproteins (RNP). These 
are constituted of RNA molecules associated to the nucleoprotein (NP) and the three 
subunits of the RNA-dependent RNA polymerase (RdRp), the basic proteins PB1 
and PB2, and the PA. The matrix coat, composed of matrix proteins (M1), surrounds 
the nucleocapsid, and is encircled by the envelope. This is a lipid bilayer that 
contains three transmembrane proteins: the haemagglutinin (HA), the neuraminidase 
(NA), and the M2 ion-channel (M2). While the hemagglutinin and the neuraminidase 
constitute 80% and 17% of the envelope proteins respectively, M2 is a minor 
component, represented by about 20 molecules per virion.  
The RNA genome is composed of approximately 13500 bp located on eight different 
RNA-associated segments whose length varies from about 900 to 2400 bp.  
Influenza viruses are serologically divided in three different types, or genera, or A, B, 
and C, on the base of the specific nucleoprotein they carry inside.  
Influenza A is further divided in subtypes on the base of the specific HA and NA 
variants, which give the pathogen antigenic variability. Nowadays, 16 different HA 
(indicated as H1-H16) and 9 different NA variants (indicated as N1-N9) are known, 
and the viral subtype is defined by the combination of the two. Of the possible 
theoretical HA-NA combinations, 105 have been discovered up to date; all variants 
are endemic in water birds (ducks, geese and shore birds) although they do not 
normally cause illness in these animals. Tropism alteration, then, caused some 
subtypes A to adapt to other birds, such as chickens, and to mammals, including 
horses, pigs, and humans. Three subtypes, H1N1, H2N2 and H3N2, adapted and 
spread through man during the last century causing the three worldwide pandemics 
that counted millions of deaths worldwide.  
Influenza B shows a lower degree of variability than type A; it segregates into two 
lineages, Victoria/2/87-like (“Vic87”) and B/Yamagata/16/88-like (“Yam88”), and it 
has a narrower host range, normally restricted to humans and seals. Type B shows a 
lower mutational rate compared to A, although the reason for this is not well 
understood yet (Nobusawa and Sato, 2006). Humans acquire a degree of type B 
immunity at an early age. Nevertheless, despite the low mutational rate, the 
capability of the virus to accumulate mutations renders long lasting immunity not 
possible, thus causing influenza B local epidemics to occur periodically. Being 
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antigenically distinct, types A and B do not exhibit cross-immunity and can co-
circulate among human communities.  
Influenza C clinical features have only been described in a few reports (Sugawara et 
al., 2006, Matsuzaki et al., 2006). This type causes much milder illnesses than A and 
B viruses, and the predominant natural hosts are humans and pigs. As suggested by 
seroepidemiological studies, the majority of humans acquire antibodies for C virus in 
the early years of life, thus indicating that this type widely circulates through humans.  
 
 
 
1.2.2 The viral cycle 
 
The spread of influenza viruses through human communities occurs via droplets 
emitted by infected individuals through sneezing or coughing, and when the inhaled 
virus-loaded droplets reach the respiratory tract, they settle on the mucus blanket. 
The innate immune defences present at this location are mainly constituted by 
mucus and molecular inhibitors such as, for example, sialic acids. While the mucus 
traps those foreign particles that manage to access the bronco-alveolar tissues, 
sialic acids can bind certain types of hemagglutinins, and competitively prevent the 
virus from binding the target cells. Although this first, non-specific immune response 
normally neutralizes the majority of the viral particles, a consistent fraction can 
escape and reach the epithelial cells lining the lower respiratory tract.   
The influenza replication cycle is represented by progressive steps, which can be 
summarised as follows (Figure 1.3). 
1) Adhesion to the host cell and internalisation 
2) Localisation in the cytoplasm and transport to the nucleus 
3) Generation of the new viral components  
4) Assembly and budding of the viral progeny 
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Figure 1.3. Life cycle of influenza.  
The viral cycle is composed of four key phases. Firstly, infecting virions bind the cell surface through 
cellular receptors and are internalised inside the endosomes (1). The virions remain confined in the 
endosomes until biochemical triggers cause the release of the ribonucleoproteins along with the RNA 
molecules in the cytoplasm, thereby allowing their translocation to the nucleus (2). During the 
following synthesis of the viral components the mRNAs are transcribed and then translated into the 
viral proteins, while the viral RNAs are copied into progeny genomes (3). Some proteins, indicated as 
‘early proteins’, are transported in the nucleus where they are essential for the replication and 
transcription phases. Others proteins indicated as ‘late proteins’ are transported to the cell membrane 
and associate with the other viral components. The viral components assemble during and after 
translocation to the cell surface. From here the progeny virions bud and are released (4). Two 
proteins indicated in this figure, the NS1 and PB1-F2, are not described in the text. NS2 is indicated 
along the text as NEP. Figure reproduced by permission from Macmillan Publishers Ltd: Nature, 2009 
(Neumann et al., 2009).  
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1.2.2.1 Adhesion to the host cell and internalisation 
The influenza virions adhere to the surface of epithelial cells through the interaction 
between the viral hemagglutinin and the sialic acid receptors on the cell surface. 
Sialic acids are a family of monosaccharides derivatives of the neuraminic acid, 
linked to the end of the glycan chains of glycoproteins or glycolipids. Although they 
exist in a variety of chemical forms, they are predominantly linked to the final 
galactose residue of the glycan chain with either !-2,3-, or !-2,6-linkages (Figure 
1.4). Different influenza strains preferentially recognize either conformation: while 
avian viruses predominantly bind the !-2,3 sialic acid, human strains bind !-2,6 
forms (Kimble et al., 2010, Matrosovich et al., 1997, Rogers et al., 1983). Although this 
preference is not absolute, it constitutes a limit for the host range of the pathogen, and it 
is the key determinant for the adhesion to the cell surface. 
 
Figure 1.4. Sialic acids recognised by influenza.  
Sialic acids constitute the end of the glicoconjugates of cellular proteins and lipids and are 
predominantly bound to galactose. Two linkage conformations are recognised by influenza, the !-2,3-, 
and the !-2,6-. The nature of this linkage is an essential determinant of the virus tropism. Figure 
reprinted from Archives of Medical Research 40, 643-654, with permission from Elsevier (Arias et al., 
2009).  
 
The binding of the hemagglutinin to the sialic acids triggers an internalisation 
process. The molecular pathway proposed for this step, the clathrin-mediated 
endocytosis (CME) was postulated following the observation of virus particles inside 
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clathrin-coated vesicles upon analysis by transmission electron microscopy (White et 
al., 1981, Matlin et al., 1981). In the CME the cell membrane forms an inward 
invagination towards the cytoplasm and draws the ligand-receptor complex inside. 
The invagination is coated with clathrin and becomes a vesicle, which then fuses 
with other similar vesicles and forms an endosome. The existence of different, non-
clathrin mediated endocytosis mechanisms have been hypothesized, however not yet 
fully elucidated (Sieczkarski and Whittaker, 2002) .  
The endocytosis results in localisation of the influenza particles inside the 
endosomes compartment, where the virion remains confined until the next step.  
 
1.2.2.2 Localisation in the cytoplasm and transport to the nucleus 
 
The viral RNPs are released in the cytoplasm following the fusion of the viral 
envelope with the endosome membrane, and the concomitant disaggregation of the 
matrix coat. The acidic environment of the endosome (pH 5-6) is an essential trigger 
for this phase.  
The low pH-induced M2 viral protein conducts protons from the lumen of the 
endosome across the envelope in a pH dependent fashion, thereby causing the 
acidification of the nucleocapsid. The low pH causes a major structural 
rearrangement of the subunits of the hemagglutinin. One element of each subunit, 
called  ‘fusion peptide’, relocates away from its original location inside the protein, 
moves towards the endosome membrane, and irreversibly pulls it close to the viral 
envelope, causing the two lipid bilayers to fuse and dismantle (details of this 
mechanism will be described in paragraph 1.2.3.3). Additionally, the acidification of 
the nucleocapsid weakens the protein-protein interactions between the subunits of 
the matrix coat. Following its dissociation, the RNPs are released and diffuse to the 
cytoplasm (Grambas et al., 1992, Wang et al., 1995).  
From here they are then transported in the nucleus by facilitated translocation 
(Babcock et al., 2004, Wu et al., 2007). In this GTP-dependent transport mode, 
specific Nuclear Localisation Sequences (NLSs) localised on the target proteins are 
recognized by cellular proteins of the importin family, which then mediate the access 
to the nucleus via the Nuclear Pore Complex. Two such NLSs, located on the 
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nucleoprotein, NLS1 and the NLS2, mediate the transport of the full influenza vRNPs 
to the nucleus (Wu and Pante, 2009). 
 
1.2.2.3 Generation of the new viral components 
All the viral components, with the exception of the mRNA and the progeny genomes 
are generated using the biosynthetic machinery of the cell.  
The viral mRNAs are transcribed with a process that is unique to the 
Orthomixoviridae and Bunyaviridae called ‘cap-snatching’ (Figure 1.5). A short 
stretch of cellular mRNA is bound by the subunits of the viral RdRp, cleaved, and 
used as primer in the synthesis of the viral mRNA. Precisely, the PB2 subunit of the 
RdRp binds the capped 5’-end of a cellular mRNA. Then, the PA subunit cleaves it 
10-14 nucleotides downstream of the cap. In the following elongation phase, the PB1 
subunit copies the vRNA by adding cellular dNTPs to the 3’-end of the capped 
primer. The elongation terminates when the polymerase reaches a polyadenilation 
sequence composed of uracyle residues located near the 3’ terminal (Bouloy et al., 
1978, Lee et al., 2003, Plotch et al., 1979).  
The completed mRNAs are exported to the ribosomal sites in the cytoplasm and are 
translated by the cellular biosynthetic machinery. Translated viral proteins undergo 
post-translational modifications in the endoplasmatic reticulum and the trans-Golgi 
system, and then they are transported to different cellular locations. The surface 
proteins HA, NA, M2, as well as part of the M1 proteins are directed to the apical 
membrane of the cell. The NPs, the PB1, PB2, and PA subunits of the RdRp, and a 
fraction of the M1 instead, are actively transported to the nucleus where they are 
assembled with the viral RNAs to produce the RNPs of the viral progeny.  
The replication of the viral RNAs is also carried out by the RdRp. The RNAs are first 
copied into complementary sequences, and these are used as templates for the 
generation of the genome of the viral progeny. Contrary to the transcription process, 
the replication mechanism is primer-independent (Figure 1.5).  
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Figure 1.5. Transcription and replication mechanisms of the influenza RNA.  
Transcription of the viral mRNAs follows the ‘cap-snatching’ mechanism, where a cellular mRNA is 
cleaved by the endonuclease activity of the RdRp and used as primer for the synthesis of the viral 
mRNA. The elongation terminates when a poly-uracil sequence is met. The replication phase instead, 
is primer-independent and produces full-length copies of viral RNA. Figure adapted with permission of 
the copyright owner, John Wiley and Sons (Nagata et al., 2008). 
 
The export of the RNPs from the nucleus is mediated by the viral proteins M1 and 
NEP and by cellular CRM1/exportin-1, a nuclear transport receptor that belongs to 
the importin-" family. The M1 proteins simultaneously bind the RNPs and NEP. This 
complex associates to a second complex constituted by the CRM1/exportin-1 and 
the GTPase protein ‘Ran’. The two complexes interact through NEP, which 
simultaneously binds the CRM1/exportin-1 and M1. The resulting structure, termed 
‘daisy-chain complex’, interacts with Ran-GTP and is exported to the cytoplasm 
(Akarsu et al., 2003, O'Neill et al., 1998, Watanabe et al., 2001).  
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1.2.2.4 Assembly and budding of the new viral particles 
The structural components of the viral progeny are assembled together at different 
times during or after their translocation to the cell membrane. Through a highly 
regulated mechanism of directional transfer the new virions bud selectively through 
the apical side of the cell. Apical sorting sequences have been identified in the trans-
membrane domains of NA and HA (Barman and Nayak, 2000, Kundu et al., 1996, 
Lin et al., 1998). Both proteins are found associated with lipid rafts, which have been 
indicated as non-proteic determinants that aid in directing the proteins to them to the 
apical membrane (Keller and Simons, 1998, Scheiffele et al., 1997). M1 hasn’t been 
shown to contain any apical sorting sequence; however, it interacts with HA and NA, 
and it also associates to lipid rafts (Ali et al., 2000). Interactions between M1 and 
NP, M1 and M2, and M1 and the RNPs have been also demonstrated, as well as the 
association of RNPs and M1 to actin filaments of the cell (Avalos et al., 1997, Baudin 
et al., 2001, Noton et al., 2007). Nevertheless, despite this wealth of information on 
the network of molecular interactions, an exhaustive and detailed model for the 
assembly and the directional transfer is still missing. 
Virions bud on the outer surface of the cell membrane. After closure of the buds 
however, they are bound by the sialic acids through the HA proteins. The cleavage 
of this linkage is catalyzed by the enzymatic activity of NA, and is essential to set the 
virus free in the extracellular space from where the infection spreads. 
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1.2.3 Dissection of key structural and functional components 
of the virus 
 
1.2.3.1 The ribonucleoprotein 
The essential component of the viral core of influenza is the RNP. The morphological 
features have been analysed with electron microscopy observation of both artificial 
RNPs, assembled with recombinant NPs, PB1, PB2, PA, and vRNA (Ortega et al., 
2000, Martin-Benito et al., 2001) and with RNPs purified from virions. This rod-like 
shaped element is a helical polymer folded back upon itself that presents a loop at 
one end (Figure 1.6). While the diameter is typically 13 nm, the length depends on 
the size of the bound RNA filament, and three size classes have been reported, 30-
50nm, 60-90nm, and 90-110nm (Compans et al., 1972, Ruigrok and Baudin, 1995). 
The backbone of the RNP is represented by a variable number of nucleoproteins, 
and is completed by the three subunits of the RdRp bound to one end of the rod 
(Ruigrok and Baudin, 1995). The RNA filament is wrapped around the NPs with the 
nucleotide bases exposed outside of the RNP, and the phosphate backbone 
contacting basic amino acid residues of the NP. Each NP monomer binds 24 
nucleotides of RNA without sequence specificity.  
 
Figure 1.6. Model structure of a ribonucleoprotein (RNP).  
The RNP is composed of a backbone of nucleoprotein subunits (indicated in yellow) and the three 
subunits of the RNA polymerase (indicated in blu, green, and red). The viral RNA, represented by a 
red filament, is wrapped around the backbone of the ribonucleoprotein. 
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1.2.3.2 The nucleoprotein 
The nucleoprotein (NP) plays an important role in at least three aspects of the 
influenza life cycle. Firstly, it represents the key structural component of the RNPs, 
and it is the most abundant protein in the viral core. Secondly, by interacting with the 
PB1 and PB2 subunits of the RdRp it modulates the transcription and the replication 
of viral genes (Beaton and Krug, 1986, Honda et al., 1988). Thirdly, the NP mediates 
the import to the nucleus of the infective RNPs by interacting with the cellular 
proteins of the importin-! family (O'Neill et al., 1998). 
Three types of influenza nucleoprotein have been reported to be alternatively 
included in the nucleocapsid: type A, the most deeply investigated, type B, and C. 
Presence of either type defines the virus as influenza A, B or C. While the NPA is 
composed of 498 amino acids, the NPB and NPC are 560 and 565 amino acids long, 
respectively (Londo et al., 1983, Nakada et al., 1984). The extra amino acids are 
located on the N-terminal of the protein and are highly conserved among viruses of 
the same type (Stevens and Barclay, 1998). 
The NPs have a diameter of 3.5 nm and a length of 6.2 nm (Ruigrok and Baudin, 
1995); they tend to form homo-oligomers with one, two, or three other monomers. 
The atomic structures of an in-vitro generated trimer with NPs from two different 
influenza A viruses have brought significant insights in the structure of this protein 
(Ye et al., 2006, Ng et al., 2009). Each NP monomer (Figure 1.7) includes a head 
domain, a body domain, and a tail loop/linker.  
While the head domain is highly conserved, the body shows higher variability. The 
NP trimers are generated upon insertion of the tail loop linker of one subunit into a 
specific region of another NP and this association is maintained thanks to the 
contribute of salt bridges (Jorba et al., 2008). The first 148 amino acids lay in the 
body domain, followed by residues 150 to 263 in the head domain and by a loop 
region that links the head to a second body domain (residues 277-396). Then, the 
polypeptide forms a tail loop/linker (residues 397-436) essential for the NP-NP 
interaction. Finally, the amino acid chain crosses the head domain and terminates 
with its C-terminus in the body domain.  
The secondary structure of the NP includes 19 alpha helices, and 8 beta strands, 
and the remaining residues constitute loops. While helices 6 and 7 present 100% 
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conservation, helices 4, 9, and 10 present 80% conservation. Additionally, the 
primary sequence of the nucleoprotein is phosphorylated (Kistner et al., 1989). While 
the predicted isoelectric point for the overall structure is 9.3, the C-terminal 30 amino 
acids present an acidic isoelectric point of pH 3.7.  
 
 
Figure 1.7. Crystal structure of influenza nucleoprotein.  
The monomer of the nucleoprotein contains three essential domains, the head and the body domains 
and a tail loop/linker essential for the interaction with the neighbouring monomers. Image reproduced 
with kind permission from the Springer Science and Business Media (Ng et al., 2009).  
 
 
RNA binding occurs in a sequence-independent fashion with one NP interacting with 
approximately 24-27 nucleotides (Martin-Benito et al., 2001). The binding results 
from the interaction of basic amino acids, mainly arginine residues scattered on the 
NP surface, with the phosphate backbone; the RNA association is particularly strong 
in the N-terminal region of the NP (Medcalf et al., 1999, Elton et al., 1999). 
Additionally, the NP also interacts with several viral as well as cellular proteins. A 
map of these interactions is illustrated in figure 1.8 and table 1.1. 
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Figure 1.8. Map of the nucleoprotein showing interaction with other viral elements.  
The nucleoproteins forms essential interactions with several proteins as well as the viral RNA. 
Interactions with other NP monomers are localised in two regions, between amino acids 189 and 358 
and amino acids 371 and 498. Interactions with the RNA filament take place in locations scattered 
along the entire surface of the NP. However, the majority of them seem to be located in N-terminal 
area. Three clusters of amino acids are responsible for the interaction with the PB2 subunits of the 
viral polymerase. During the different steps of the life cycle then, the nucleoprotein associates with 
several cellular proteins, among these the actin filaments involved in translocation of viral 
components. Two amino acid sequences essential for the transport of the nucleoproteins to the 
nucleus are the NLS I and NLS II (Portela and Digard 2002). 
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Domain Helix Residue Conservation (%) Function 
1 23-47 72 RNA binding, PB2 binding 
2 50-69 60 RNA binding, PB2 binding 
3 113-123 54.6 RNA binding, PB2 binding 
Body 
4 130-148 84.2 RNA binding, PB2 binding 
5 150-157 87.5 RNA binding, PB2 binding 
6 160-167 100 RNA binding 
7 177-182 100 NP-NP oligomerization 
8 185-202 61.1 NP-NP oligomerization 
9 210-230 85.7 NP-NP oligomerization 
10 232-244 84.6 NP-NP oligomerization 
Head 
11 249-263 80 NP-NP oligomerization, PB2 binding 
12 277-287 54.6 NP-NP oligomerization, PB2 binding 
13 290-295 83.3 NP-NP oligomerization, PB2 binding 
14 301-309 66.7 NP-NP oligomerization, PB2 binding 
15 321-334 78.6 NP-NP oligomerization, PB2 binding 
16 340-349 60 NP-NP oligomerization, PB2 binding 
Body 
17 354-358 80 NP-NP oligomerization, PB2 binding 
Tail loop 18 421-428 50 NP-NP oligomerization, PB2 binding 
Head 19 437-451 60 NP-NP oligomerization, PB2 binding 
Table 1.1. List of functions associated to different regions of the nucleoprotein. Table reproduced with 
kind permission from the Springer Science and Business Media (Ng et al., 2009).  
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While the NPs of type A, B, and C show consistent differences in the amino acid 
sequence and size, NPs of the same type show a degree of conservation higher 
than 90% (Figure 1.9) 
 
 
Figure 1.9. Sequence comparison of two nucleoproteins A.  
The full-length amino acid sequences of the nucleoprotein of a H1N1 virus, A/Brevig Mission/1/1918 
(GenBank: AAV48837.1) and a H3N2 virus, A/Wisconsin/67/2005 (GenBank: ABW81628.1) are 
compared with BLAST analysis. The amino acid identity is 93% and a total of 98% amino acids result 
in positive scores, thus indicating substitutions with similar residues. 
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1.2.3.3 The hemagglutinin 
The hemagglutinin (HA) plays a key role in two vital steps of the viral cycle. In the 
initial phase of the infection HA mediates the attachment of the viral particles to the 
cell surface by binding the sialic acid receptors. Following internalization of the virion 
then, HA mediates the fusion of the viral envelope with the endosome membrane 
thereby allowing the release of the RNPs in the cytoplasm and their transport to the 
nucleus.  
Classified as type I trans-membrane glycoprotein, HA is a 84kDa protein composed 
of 549 amino acids (Braakman et al., 1991) and present on the surface of the virion 
as homo-trimer. It is generated as inactive precursor, termed HA0. that trimerizes 
prior to transport to the budding site. HA0 is then proteolytically cleaved to produce 
two polypeptides, HA1 and HA2 that undergo major structural rearrangements during 
the membrane-fusion phase. The crystal structures of the inactive HA0 precursor, 
the cleaved HA1-HA2, and the rearranged post-fusion protein have been determined 
and studied in detail (Bullough et al., 1994, Chen et al., 1998, Wilson et al., 1981). 
The uncleaved HA0 trimers are constituted of a hydrophobic trans-membrane 
domain, a stalk region that protrudes 135Å out of the viral envelope, and a globular 
head domain on top (Fig. 1.10a). While the head is composed entirely of residues of 
HA1, the rest of the protein contains both HA1 and HA2 amino acids (Braakman et 
al., 1991). A conserved region located in a cavity in the head binds the sialic acid 
receptors. As this interaction is crucial for the viral infectivity and tropism, details of 
the receptor pocket have been well defined (Eisen et al., 1997, Sauter et al., 1992, 
Watowich et al., 1994, Weis et al., 1988).  
Cleavage of HA0 is essential to activate the fusogenic state of the hemagglutinin. 
Host proteases recognize specific amino acid sequences on HA0, and generate the 
two disulphide-linked subunits, HA1 and HA2, 328 aa and 221 aa long respectively. 
The structure of the HA0 precursor and that of the cleaved protein are very similar. In 
the cleaved protein, however, 12 residues next to the N-terminus of the HA2 subunit 
are shifted towards the inside of the protein where they fill a cavity lined up with ionic 
residues. This relocation buries the ionic residues and represents a key step in the 
activation of the HA fusogenic activity (Wilson et al., 1981). Crucially then, the 
following events of the fusion phase are triggered by an acidic pH, typically between 
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5 and 6.  
The first event determined by the acidification of the endosome is a relaxation of the 
head domains that renders the trimer less tightly associated (Figure 1.10, panel b). 
The relaxation is triggered by protonation of the trimer, as indicated by Huang and 
colleagues upon molecular modelling of the X-ray structure of the HA from X31 
(Huang et al., 2002). At neutral pH, the HA1 domains have a predominant positive 
charge. The HA2 domains instead are predominantly negative. This creates an 
electrostatic repulsion at the HA1-HA1 and HA2-HA2 interfaces within the trimer, and 
an electrostatic attraction at the interfaces between HA1 and HA2. At acidic pH, 
protonation of the HA1 increases the positive charge of the domain, thereby causing 
the intra-HA1 electrostatic repulsive components to take over (Huang et al., 2002). 
Accordingly, electron cryo-microscopy three-dimensional reconstructions of the 
hemagglutinin at both the neutral and fusogenic pH show a reorientation of the 
globular domains and the formation of a pore along the x-axis (Boettcher et al., 
1999). 
 In the second phase, the N-terminal region of HA2 protrudes outside the virion, 
towards the endosome membrane (Fig. 1.10b). This mechanism has been 
investigated by comparing pre- and post- fusion crystal structures of HA. These 
show that, in HA, an internal helix within HA2 (aa 76 -105) is connected to a second, 
smaller helix (aa 38-55) by a short loop (aa 56-75). During the fusion phase the loop 
assumes an alpha helical conformation, and consequently relocates towards the top 
of the stalk region together with the 38-55 helix and the N-terminal amino acids. A 
short N-terminal peptide, composed of hydrophobic residues directly engages the 
lipid bilayer of the endosome and functions as a ‘fusion peptide’ in the process (Fig. 
1.10b). 
In the third and final rearrangement, caused by the intrinsic instability of the 
structure, the C-terminal domain of HA2 undergoes a 180 rotation. This ‘jack-knife’ 
movement locates the endosome-bound fusion peptide and the trans-membrane 
domain of HA in very close proximity. At the same time, the viral envelope and 
endosome membrane are dragged close to one another and they undergo lipid 
mixing and, eventually, melt. 
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Figure 1.10. Structure and conformational changes of the hemagglutinin during the membrane 
fusion.  
The hemagglutinin is a trimeric trans-membran protein anchored to the viral envelope and spiking out 
of the viral surface (a). During the initial phases of the viral infection, the hemagglutinin undergoes 
dramatic conformational rearrangements (b) activated by the acidic pH of the endosome lumen. The 
different steps of this complex modifications are numbered in panel b. Initially, the head domains of 
the hemagglutinin dissociate (b 1). Then, two internal alpha-elical polipeptide undergo a 
rearrangement whereby on ‘fusion peptide is extruded towards the outside of the viral envelope (b 2-
3). The fusion peptides contacts the endosome membrane (b 3). The newly formed structure is highly 
unstable and collapses (b 4). By collapsing, the hemagglutinin brings the viral envelope and the 
endosome membrane together, thereby facilitating lipid mixing. Image reprinted by permission from 
Macmillan Publishers Ltd: Nature Structural & Molecular Biology, 2008, (Harrison 2008). 
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The localization on the surface of the envelope renders the hemagglutinin one of the 
main targets of the host immune defences. Antibody binding can prevent the 
conformational changes needed to mediate viral entry, and the immune pressure 
facilitates the selection of new antigenic variants. Nowadays, 16 different subtypes of 
hemagglutinin have been reported and isolated from humans, horses, pigs, and 
avian species (H1-H16). The subtype classification is based on the reaction pattern 
against hyper-immune anti-HA sera generated against reference strains. Whilst 
certain areas of the HA amino acidic sequence, such as for example the receptor 
binding site, are very conserved across all subtypes, considerable differences are 
reported along the entire structure. HA1 and HA2 have different degrees of 
conservation, with HA1 presenting higher variation than HA2. The conservation 
degree across all the subtypes, calculated by comparing aligned amino acid 
sequences, is approximately 12% for HA1 and 30% for HA2. Strains classified within 
the same subtype instead, show an overall conservation degree of HA between 80% 
and 100% (Nobusawa et al., 1991). Based on sequence homology, then, the 16 
subtypes are classified in two groups and four clades. Group 1 includes H1, H2, H5, 
H6, H11, H13 and H16 in the first clade, and H8, H9, and H12 in the second. Group 
2 is represented by H3, H4, and H14 that cluster in the first clade, and H7, H10, and 
H15 in the second (Nobusawa et al., 1991, Russell et al., 2004)  (Fig. 1.11).   
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Figure 1.11. Phylogenetic tree of the hemagglutinin subtypes.  
The hemagglutinin amino acid sequence separated into different branches during the evolution. The 
subtypes circulating nowadays (16) are grouped into four clades, termed H9, H1, H3, and H7. One 
subtype, H16 is not shown in this image. Image modified from (Russell et al., 2004). Reproduced with 
permission from Elsevier.  
 
The localization of the antigenic sites along the HA sequences have been studied by 
many investigators by using escape mutants and by observing the cross-reaction to 
anti-HA mAbs raised against defined subtypes. The epitope maps for H1, H2, H3, 
and H5 were investigated in this way (Wiley et al., 1981, Tsuchiya et al., 2001, 
Kaverin et al., 2007, Philpott et al., 1989). For H3, the first subtype to be antigenically 
characterized, 5 regions were identified that contain the majority of amino acid 
substitutions that produce new epidemic strains. The sites, nominated A, B, C, D, 
and E, are localized along the stalk of the protein. The majority of them are 
positioned on surface loops and bulges (A-D) (Wiley et al., 1981). Similarly, five 
antigenic sites were identified on H1, namely Sa, Sb, Ca1, Ca2, and Cb (Deem and 
Pan, 2009, Caton et al., 1982), and six sites on H2, nominated I-A, I-B, I-C, I-D, II-A, 
and II-B (Tsuchiya et al., 2001). The antigenicity of H5 hemagglutinin was also 
investigated (Kaverin et al., 2007), however not identified precisely. 
 42 
1.2.3.4 The neuraminidase 
The neuraminidase (NA) is a glycoside hydrolyse enzyme that cleaves the alpha-
ketosidic linkage between the terminal neuraminic acid and the adjacent 
oligosaccharide moiety of glycoproteins. The cleavage of this link is essential to 
permit release of the progeny virions and spread of the infection. NA is a homo-
tetrameric glycoprotein with a total mass of 240 kDa; it is composed of a head 
domain (200kDa) and a membrane-anchored stalk region. The head, sized 90Å x 
90Å x 60Å, is composed of six 4-stranded anti-parallel beta-sheets whose 
organisation has been described as a ‘propeller-like’ shape (Fig 1.12 a and b). Each 
of the four subunits of the tetramer contains one active site in a deep pocket located 
in central position with residues that are very conserved among all NA varieties, 
likely optimised during evolution to bind the sialic acid. Two types of calcium binding 
sites have been described; one lies along the 4-fold axis of the tetramer, the second 
is present in each unit of the tetramer in proximity of the active site (Burmeister et al., 
1993, Colman, 1994).  
 
Figure 1.12. Structure of the Neuraminidase tetramer (a) and a monomer (b).  Panel (a): figure 
reproduced with permission from Macmillan Publishers Ltd: Nature, 2006 (Russell et al., 2006). Panel 
(b): figure reproduced with permission from John Wiley and Sons (Colman, 1994).  
 
 
As for the hemagglutinin A, also the neuraminidase A is classified in subtypes. Nine 
have been isolated thus far (designated N1 to N9). The three-dimensional structures 
of N1, N2, N4, N5, N6, N8, and N9 have been solved by X-ray analysis (Russell et 
al., 2006, Taylor et al., 1993, Tulip et al., 1991, Varghese et al., 1992). Overall, the 
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amino acid variation between different subtypes is higher than 50%, while the 
variation among strains of the same subtype is up to 30% (Colman, 1994, Russell et 
al., 2006). Based on amino acid sequences, the NA subtypes cluster in two groups 
(Fig. 1.13). Group 1 includes N1, N4, N5, and N8, and group 2 includes N2, N3, N6 
and N9 (Wang et al., 2011). Recently, a structural component has been 
demonstrated to be group-specific, a region in the active site called ‘150-loop’ found 
in strains of the group 1 subtypes, but not in those from group 2 (Wang et al. 2011).  
The neuraminidase of influenza B has also undergone sequence variation over time, 
however no different subtypes have been reported so far. The three-dimensional 
structure was determined by Burmeister (Burmeister et al., 1993). 
The epitope mapping of the neuraminidase has been predominantly focused on the 
N2 and N9 subtypes. Numerous studies showed that the majority of the antibody 
binding regions are located between amino acids 329 and 403, corresponding to the 
top of the proteins (Air et al., 1985, Air et al., 1990, Gulati et al., 2002). 
 
 
 
 
Figure 1.13. Phylogenetic relationships between the neuraminidase subtypes.  
The neuraminidase, similarly to the hemagglutinin differentiated during evolution and branched into 
two groups. The subtypes of the neuraminidase of influenza A circulating nowadays are 
phyogenetically divided into two groups. Figure reproduced by permission from Macmillan Publishers 
Ltd: Nature, 2006 (Russell et al., 2006).  
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Genetic and antigenic diversity of influenza 
 
The molecular mechanisms by which genetic and antigenic diversity between 
influenza viruses arise have not been completely elucidated yet. Nevertheless, two 
main models, termed “antigenic drift” and “antigenic shift”, are postulated, as 
reviewed by van den Berg (van den Berg et al., 2008). 
 Antigenic drift refers to the gradual and progressive accumulation of point mutations 
in the viral genes coding for HA and NA, and is caused by the lack of proofreading 
activity of the RdRp. Non-deleterious mutations can result in changes in the amino 
acidic composition of those epitopes of the HA and NA that are targeted by the 
neutralizing antibodies; HA, especially, has five such epitopes and, following 
progressive life cycles, their diversity increases, thereby determining a decreased 
efficiency of the correspondent neutralizing antibodies (Schweiger et al., 2002). 
Novel HA and NA variants, therefore, can undergo selective pressure caused by the 
activity of antibodies generated against previously circulated strains and as a 
consequence the new surface antigens may render the pathogen resistant to the 
immune defence.    
Antigenic shift indicates the replacement of an entire HA or NA determinant with one 
from a different subtype. The change results either from genetic reassortment and 
recombination between RNA segments of two subtypes (Fig. 1.14).  
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Figure 1.14. Antigenic shift.  
A new antigenic asset is acquired after RNA segments of two different subtypes are combined in the 
viral progeny. Such mixing happens during co-infection of hosts that are susceptible of infection with a 
variety of strains, such as for example the pig. Figure reproduced from http://employees.csbsju.edu. 
 
This molecular recombination may occur during co-infection carried by two viruses 
towards an intermediate host, for which both pathogens are infective. One such 
candidate is the pig, as the epithelial cells in the respiratory tract of this animal 
display both the !-2,3 and the !-2,6 linked sialic acids, An alternative mechanism is 
represented by the occasionally successful direct infection carried by a species-
specific virus towards a different species such as, for example, avian to man. 
Adaptation to the new host may be gradual and include one or more intermediate 
hosts, although mechanisms for such viral cross-species spread have never been 
formally demonstrated.  Following adaptation to the new host, the virus will represent 
an antigenic “novelty” against which the human population has no immunity. 
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While the antigenic shift is believed to have caused the abrupt emergence of the last 
pandemic viral subtypes by endowing them with surface receptors that had never 
circulated in man, the antigenic drift is believed to be responsible of the recurrent 
epidemics that periodically occur in different locations worldwide.   
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1.3 Epidemiology of influenza 
 
 
1.3.1 Impact of influenza on the population  
 
The epidemiology of influenza is characterized by periodic, local epidemics and, 
occasionally, of worldwide pandemics.  
Epidemics occur in a seasonal pattern, and in young individuals they cause febrile 
illness that lasts 1-2 weeks. In patients with pre-existing cardio-vascular or 
respiratory diseases instead, and in the elders, influenza-associated infections and 
diseases often occur. Among these pneumonia, and other secondary respiratory 
infections can be exacerbated by influenza and result in death. Due to the 
concomitant infections it is difficult to estimate the precise impact of seasonal 
influenza on the population in terms of mortality. Death certificates then often don’t 
include influenza as a concomitant cause. Calculations are normally based on the 
excess mortality from pneumonia and other infective causes. Figures calculated for 
the USA for example indicate that 25,000-50,000 cases of influenza occur every 
year, and these result in 150,000 hospitalisations (Boullata et al., 2004). In a study 
conducted by Molinari and colleagues relatively to the year 2003, also relative to the 
USA, it was estimated that influenza caused a total of 3.1 million hospitalized days 
and 31.4 millions outpatients visits (Molinari et al., 2007). 
Outbreaks of influenza normally peak in the months between November and March 
in the Northern Hemisphere, and April to September in the Southern Hemisphere. In 
the tropical regions instead outbreak occurs through the year.  
Influenza spreads through small virus-laden droplets emitted by infected individuals. 
Droplets with diameter larger than 10-20 #m can be inhaled by people nearby and 
deposit in the upper respiratory tract. Droplets with diameter lower than 5-6 #m, 
instead, typically exhibit aerosol behaviour and, as such, they remain airborne for 
prolonged periods of time and float over long distances (Bell et al., 2006). Although 
diffusion through large droplets is considered to be the predominant way of spread, 
hypothesis have been formulated for the aerosol as an important mean of 
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transmission (Moser et al., 1979). The epidemic strains normally replace the pre-
existing epidemic virus, and co-circulation of the two only occurs for a limited period 
of time. 
Pandemics are caused by strains that adapt to humans following infection from other 
species. The most devastating of these tragic events, commonly referred to as 
‘Spanish influenza’, occurred in 1918-1919. The causative agent was an avian virus 
later classified as subtype H1N1, which, after a two years pandemic period, 
continued to circulate in the human population for approximately 3 decades causing 
milder, recurring epidemics. A new pandemic, termed ‘Asian influenza’ then arose in 
1957. The causative pathogen, this time, was the subtype H2N2, which displaced 
the previously circulating H1N1 from the human population. In 1968, a third 
pandemic, named ‘Hong Kong influenza’ resulted from the transmission and 
adaptation to man of the H3N2 avian virus. Subsequently, infections with H1N1 virus 
reoccurred in 1977, when the so-called ‘Russian pandemic’ spread. However, 
mortality during this event was restricted to young people who were born after the 
late 1950s and, hence, hadn’t been exposed to the H1N1 pathogen during the 
previous transmission. Since 1977, the H3N2 and the H1N1 co-circulate in the 
human population and, along with B viruses, are responsible for the current periodic 
epidemics (Figure 1.15). 
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Figure 1.15. Spread of influenza viruses in the 20th century. 
Three influenza subtypes, H1N1, H2N2, and H3N2 infected man causing word-wide mortality in the 
last century, and then remained circulating in the population causing yearly epidemics. These 
pandemic strains transmitted to man from avian species upon decisive antigenic changes. Figure 
reprinted by permission from Macmillan Publishers Ltd: Nature reviews Microbiology, 2005, (Horimoto 
et al. 2005).  
 
While the pandemics that took place in the last century where caused by 
transmission from birds, the latest influenza threat, the S-OIV, generated genetic re-
arrangement of two viruses: a triple reassortant virus circulating in North American 
swine, and a Eurasian avian-like swine A (H1N1) strain. The first S-OIV, firstly 
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isolated in North American pigs in 1998, arose from genetic reassortment of North 
American avian, classic swine A (H1N1), and human adapted A (H3N2) viruses 
(Zhou et al., 1999). In undefined circumstances, the triple-reassortant had its NA and 
M1 components replaced with those of a Eurasian influenza A (H1N1) swine virus 
(Michaelis et al., 2009). The resulting antigenic composition of the new threat then 
includes the NA and M1 protein from the Eurasian avian-like swine virus A (H1N1) 
and the other genes from the triple-reassortant. Precisely, the PB2 and PA genes 
derive from the North American Avian, the PB1 segment from the human A (H3N2), 
and HA, NP, and NS, from the classical swine A (H1N1) virus.  
Although the first wave of the 2009 pandemic has been milder compared to the 
pandemics of the last century, a great source of concern is represented by the 
similar ‘mildness’ of the first wave of the Spanish 1918-1919 influenza pandemic, 
which then struck with dramatic mortality in its second wave, a few months later. 
Healthcare officials, and influenza virologists, therefore, fear that also the current 
pandemic may develop in a consistently more violent global threat. 
The ability of the virus to infect man depends on the degree of cross-protection 
provided by antibodies acquired during previous, seasonal epidemics. Those strains 
that have undergone antigenic modifications in surface antigens have higher 
chances to overcome immune defences. However, the impact of the infecting virus 
on the organism and, ultimately, on the population, depends on two factors. 
 
1) Infectivity 
The infectivity of the virus towards the host is restricted by the species- and tissue- 
specific distribution of the receptors that mediate the entry inside the cell. The key 
receptors for influenza, the sialic acids, possess different conformations, as 
described in paragraph 1.2.2.1. Tropism of different strains depends on their ability 
to recognise either linkage type. Those viruses that recognize the !-2,6 sialic acids 
are potentially infective to man, as the epithelial cells lining the respiratory tract of 
humans are populated with sialic acids linked with this particular conformation. 
Viruses that recognise the !-2,3 linkage tend to be infective towards birds.  
 
2) Virulence  
Measured in laboratory with the intravenous pathogenicity index, virulence classifies 
the influenza viruses in two pathotypes, the high-pathogenic avian influenza (HPAI) 
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or low-pathogenic avian influenza (LPAI) (Shankar et al., 2009). Various viral 
components determine the degree of pathogenicity, however a predominant role is 
played by the type of proteolytic cleavage site present in the HA protein. The 
proteolytic cleavage of the HA precursor HA0 is a post-translational modification 
essential to activate the hemagglutinin to its fusogenic activity and to allow the initial 
phase of the infection (paragraph 1.2.3.3). The cleavage is catalyzed by host 
enzymes present in the infected tissue. Low-pathogenic influenza viruses normally 
posses trypsin-like protease cleavage sites and, hence, they can only propagate in 
those tissues where this class of enzymes is distributed, mainly along the respiratory 
tract. HAs of high-pathogenic viruses, instead, are endowed with multi-basic 
cleavage sites which can be cleaved by more widespread and ubiquitous proteases 
such as, for example, the subtilisin-like serine endoprotease Furin. Other 
determinants of virulence include the viral protein NS1, which is involved in inhibition 
of the host-interferon response, the PB1, PB2, and PA subunits, and the NA.  
 
 
 
1.3.2 Means of influenza control 
 
Influenza control relies on two measures, preventive vaccination and administration 
of antiviral drugs. For these measures to be effective, prompt and detailed 
information about the circulating strains is essential.  
The administration of vaccines reduces the risk of infection by eliciting an immune 
response against the pathogen. Normally, however, the immune response is directed 
against the HA and NA. As these proteins possess high antigenic variability, 
continuous surveillance is required to identify the novel strains.   
Vaccination can be administered with either virus or antigen preparations that closely 
resemble the antigenic asset of the strain that is predicted to circulate, and they are 
broadly distinguished in two categories, the inactivated virus vaccine and the live 
attenuated vaccines (LAIV). 
The inactivated virus vaccines consist of HA and NA protein preparations with 
different degree of purity. The initial version, developed in 1940, consisted of whole 
inactivated virions. These preparations showed a considerable immunogenicity but 
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also excessive reactogenicity (Gross et al., 1977) and where replaced by the split 
vaccines. This second category consists of HA and NA proteins extracted from 
virions by use of detergents (Treanor et al., 2006). When the extracted proteins are 
purified, then the preparation is referred to as subunit vaccine. The split and subunit 
vaccines have been for many years the predominant form of vaccine administration 
because of their proven safety (Keitel et al., 2008, Treanor et al., 2006, Atmar et al., 
2006). However, importantly, they have lower immunogenicity of the whole-virion 
preparations, and thus they have to be administered in double doses in order to 
confer protective immunity. The need of double doses poses practical problems 
when millions of vaccines have to be administered worldwide, as in the case of a 
pandemic. Indeed, vaccines are mainly produced using embryonated chicken eggs. 
And thus the time needed for the production of an immunogenic compound, following 
the prediction of the next circulating viral strains constitutes a major bottleneck of the 
vaccination strategy (Gerdil, 2003). Another concern is related to the fact that the 
viruses that constitute the vaccine must be grown in bulk before they are inactivated, 
with considerable health and safety problems and logistic limitations. 
The live attenuated influenza vaccines (LAIVs) consist of licensed, cold-adapted 
viruses endowed with wanted HA and NA subtypes. These vaccines induce both the 
neutralising antibody response and the cell-mediated immunity. The latter could 
target conserved residues and provide a more cross-reactive vaccine (Thomas et al., 
2006). These advantages however are only theoretical, and further investigation is 
needed to prove the feasibility. Despite of the promise of broad protection, the LAIVs 
are affected by the same problems as the inactivated vaccines. Additionally, not all 
HA and NA subunits are compatible with the genetic backbone of the licensed strain.  
Both the inactivated vaccines and the LAIVs should contain antigenically equivalent 
HA and NA combinations, normally two A subtypes, H1N1 and H3N2, and one B 
subtype (He et al., 2006).  
Decision about the strains to include in a vaccine preparation relies on continuous 
surveillance for prompt detection of viral variants generated upon antigenic drift. 
Global surveillance is conducted by WHO and the Global Influenza Surveillance 
Systems, and the strain selection is conducted between February and April each 
year to allow enough time to produce and deliver the vaccine by September-October 
in the same year. Novel viral variants however can emerge and spread faster than 
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vaccines are selected, produced, and delivered; thus vaccination programs cannot 
be coordinated without detailed information on the circulating strains. 
The administration of antiviral drugs can reduce the severity of the symptoms and 
contribute to decrease the risk of infection. However, antivirals must be administered 
24-48 hours after infection onset to be effective; and they should be chosen on the 
base of specific subtype information, as shown by documented resistance that 
specific influenza strains present for various antiviral classes. For instance, the 
seasonal human H1N1 that circulated during the 2008-2009 influenza season was 
resistant to Oseltamivir, instead the seasonal H3N2 subtype and the S-OIV strains 
were sensitive to Oseltamivir and resistant to adamantines (Chen et al., 2009, Hauge 
et al., 2009, Ginocchio, 2011). Furthermore, multiple strains with different antigenic 
properties and with a spectrum of antiviral resistance can co-circulate in the same 
period and in the same area, as demonstrated in the initial period of the 2009 
pandemic outbreak (Ginocchio, 2011).  
 
 
 
1.3.3 Influenza in birds 
 
In the picture of global influenza control it is also very important to monitor the 
infection among species others than humans. Birds are an important reservoir for a 
number of different influenza strains. Infection in water birds often remains 
undetected because it not always causes visible symptoms; and yet, asymptomatic 
waterfowls can shed viral titres as high as 108 EID50/ml (He et al., 2010). On the 
other hand, both low and high pathogenic avian viruses can cause considerable 
economic burden, especially in those countries where the poultry industry represents 
an important segment of the national economy. For example, strains of the H6 
subtype cause infection in domestic poultry in Asia, Africa, and America and, 
although they are classified as low pathogenic virus, they caused drastically reduced 
rates of eggs deposition in poultry (Chen et al., 2012). The H5 and H7 high 
pathogenic strains instead are a reason of concern among the veterinary community 
due to the high mortality rate they cause in birds. The culling of large numbers of 
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birds is necessary to contain zoonotic transmission in these instances, and a prompt 
diagnosis would help to reduce the birds’ slaughters. 
These facts illustrate the importance of detecting influenza and identifying the type, 
subtype, and oftentimes also the strain of the infecting virus. Ideally the detection 
method should give a positive result for all the infected samples and a negative 
result for all the non-infected samples. In practise, however, the majority of the 
diagnostic strategies are far from infallible, and the goodness of each technique is 
evaluated and quantified using two clinical parameters, the clinical sensitivity and the 
clinical specificity.  
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1.4 Diagnosis of influenza 
 
 
1.4.1 Importance of a prompt diagnosis  
 
The symptomatology of influenza is indistinguishable from that caused by a broad 
range of pathogens, including other viruses (e.g. rhinovirus, adenovirus) and 
bacterial strains, such as Chlamidia pneumoniae, Mycoplasma pneumoniae, and 
Streptococcus pneumonia. Patients presenting fever, headache, cough, and other 
influenza-like illness, especially the children, are typically administered anti-bacterial 
drugs. While effective against a broad range of microbiological pathogens, their 
administration is often empirical and leads to potential side-effects. When viral 
infection is suspected then, anti-viral drugs are prescribed. However, these 
medications are expensive, and therefore they are not feasible for use on large 
numbers of patients. Over the time, then, the excessive usage of anti-bacterial and 
anti-viral agents can lead to the development of resistance against these drugs, and 
thus, they become less effective in future use.  
Laboratory-based diagnostics is essential for a more precise identification of the 
pathogen. Although several diagnostic methods have been developed over the last 
40 years, each of them carries advantages and disadvantages with regard to their 
sensitivity, specificity, costs, time required to obtain a result, and the quality of the 
information produced. An ideal diagnostic methodology has the following 
characteristics. 
 
Rapidity  
The capability to provide diagnostic information in a clinically-useful timeframe is 
extremely important in the context of pandemic prevention. Indeed, a prompt 
identification of infected individuals can guide the implementation of counter-
measures such as their temporary isolation from the community or a targeted 
administration of anti-viral drugs. In an ideal situation, the screening is actuated at 
the Point-Of-Care (POC), represented for example by border posts, airports, police 
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stations, and schools. The screening should identify individuals infected with those 
viruses that could generate high mortality among people in case of spread. 
Rapidity also translates into a better management of hospitalised patients. Several 
studies have indicated that the availability of the diagnostic information in a useful 
timeframe leads to a number of advantages, such as for example a reduced length 
of stay in the hospitals, a reduction of the inappropriate use of anti-bacterial and anti-
viral drugs and a decrease in ancillary tests (Barenfanger et al., 2000, Sharma et al., 
2002, Esposito et al., 2003, Falsey et al., 2007, Woo et al., 1997). 
 
Analytical Sensitivity  
The analytical sensitivity, also indicated as detection limit indicates the lowest 
amount of viruses that a diagnostic test can detect. The test should be capable of 
detecting influenza at an early stage of infection. However the amount of virus likely 
to be found in a human/animal sample depends on a number of factors, such as for 
example the stage and severity of the infection, the susceptibility of the host, the 
pathogenicity of the virus.  
The analytical sensitivity is reported in literature using different units of measure, and 
therefore it is somewhat difficult to compare the minimal analytical sensitivities 
needed to detect an infection. Often, the viral concentration is measured based on 
the effect that the virus has on the biological system used to grow it. Influenza 
viruses are normally grown in either chicken embryo or in cell lines. The sensitivity is 
respectively reported in terms of Chicken Embryo Infective dose 50% (EID50), or the 
Tissue Culture Infective Dose 50% (TCID50). When the virus is grown in cells then, 
its concentration can also be indicated in PFU/ml (Plaque Forming Units/ml). 
Oftentimes then a viral preparation is evaluated using the hemagglutination inhibition 
assay. In this case the concentration is reported in terms of HA units (hemagglutinin 
units). Alternatively, the viral concentration is measured in terms of protein 
concentration, reported as mg/ml of total protein or, more rarely, one specific protein. 
Finally, viral preparations are often analysed with techniques that rely on the 
amplification of viral sequences. In this case, the viral load is reported in terms of 
genome copies detected per reaction.  
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Clinical sensitivity 
The clinical sensitivity indicates the ability of the test to identify the infected samples, 
and it is mathematically represented by the ratio between the truly positive results of 
the test and the total of the truly positive samples (including the false negatives). The 
truly positives are determined with an alternative ‘gold standard’ technique. Those 
tests that perform with good clinical sensitivity can typically exclude false negatives. 
Instead, for tests that perform with poor clinical sensitivity a negative result must be 
confirmed with an alternative diagnostic technique. 
 
Clinical specificity 
The clinical specificity indicates the ability of the test to identify the non-infected 
samples, and it is represented by the ratio between the truly negative results of the 
test and the total of the truly negative samples (including the false positives), as 
determined by the alternative gold standard technique.  
 
Subtype detection 
As indicated by the different anti-viral resistance developed by strains of different 
subtypes (see paragraph 1.3.2), it is important to differentiate viruses that will have 
different responses to different treatments.  
 
Ease of use and portability 
Ideally, diagnostic procedures should be performed outside of a laboratory context. 
For this reason, the mobility of the diagnostic instrumentation is a major issue, and 
bulky diagnostic systems need transport of samples to the laboratory, with a 
consequent elongation of the diagnostic times.  
 
Scalability 
An ideal test should be feasible with different sizes of sample batches.  The 
scalability depends on the number of tests included in the commercial presentation 
of the kit, the size of each testing run, the number of negative and positive controls 
required for each run, the requirement of additional laboratory procedures and 
reagents that are not included in the diagnostic kit (i.e. the extraction procedure for 
the nucleic acids in PCR-based tests). In general, a cost- and time-effective way to 
organise the diagnostic procedures consist in batch-testing a suitable number of 
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samples. However, batching is not always suitable, for example when a limited 
number of samples need testing, or when samples come at time intervals that do not 
allow efficient batching. 
 
 
Diagnostic techniques can be classified in two groups. 
1) The techniques that involve the amplification of the virus or viral sequences. 
These include the classic diagnostic procedures based on egg or cell 
culturing, and the Nucleic Acid Amplification Tests (NAATs) that amplify 
specific portions of the viral genome. 
2) The techniques that reveal viral proteins without an amplification step. These 
include the Enzyme-Linked Immunosorbent Assay (ELISA), the Rapid 
Influenza Diagnostic Tests (RIDTs), and the protein microarray. 
Combinations of these methods are often practised to achieve better detection limits.   
 
 59 
1.4.2 Diagnostic techniques based on amplification 
 
Viral culture 
For decades, the demonstration of an influenza infection has relied on the viral 
culture. This method amplifies the infective viruses to a sufficient titre for the 
following detection and analysis of the type, subtype, and pathogenicity. Normally, 
nasal and pharyngeal swabs, nasal washes and sputum, are collected in appropriate 
viral medium and transported to the laboratory facilities. There, the samples are 
inoculated into the amniotic or allantoic cavity of embryonated chicken eggs in order 
to generate high viral titres for the analysis (Manual on Animal Influenza Diagnosis 
and Surveillance, 2002, WHO). The length of the incubation needed to obtain 
enough virus for the following detection technique depends on the pathogenicity of 
the strain; HPAI strains normally produce a considerable titre after 24-to-48 hours 
incubation; LPAI strains require several passages and a total incubation up to three 
weeks. Alternatively, cell cultures susceptible of influenza infection cells are used. 
The most common cell lines employed to this scope include the cynomolgus monkey 
kidney, rhesus monkey kidney, or Madin Darby canine kidney (MDCK). Cell cultures 
are normally propagated for 1-to-5 days, depending on the cell strain and the 
susceptibility to the pathogen, and the viral infection is inferred by observation of a 
cytopatic effect.   
Following viral amplification the HA subtype is identified using the hemagglutination 
inhibition assay (HI). This test exploits the ability of the influenza hemagglutinin to 
bind the erythrocytes through their sialic acid receptors, and to link them in a latex-
like network. When anti-HA neutralizing antibodies bind the antigenic sites of the 
hemagglutinin, the binding to the erythrocytes is inhibited. Occurrence of the 
hemagglutination effect can be screened visually in the wells of a microplate. While 
the hemagglutinated preparations form a latex around the walls of the wells, in those 
where the hemagglutination is inhibited the erytrocytes fall at the bottom forming a 
defined red button. In the test reference anti-sera or monoclonal antibodies are used. 
These reagents react monospecifically against the sixteen HA subtypes and possess 
a broad reactivity for the strains of the same subtype. The anti-sera/antibodies are 
incubated together with the viral preparation and the erythrocytes in different wells of 
the plate. If the hemagglutination is inhibited, this indicates a specific reactivity of the 
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hemagglutinin with the antibody. The HA subtype then is identified by the reference 
antisera/antibody that causes the inhibition. The length of the assay is typically 30-60 
minutes depending on the type of erythrocytes employed (WHO 2002).  
Similarly, the NA subtype is identified with the neuraminidase inhibition assay (NI). 
This test relies on the spectrophotometric quantification of a colorimetric substrate 
generated upon a neuraminidase-catalysed reaction (Aymar-Henry et al. 1973). Anti-
NA antibodies cause a measurable inhibition of the activity of the neuraminidase if 
they bind in proximity of the active site. Anti-NA anti-sera or antibodies are 
introduced in the assay; these are chosen on the base of their monospecific 
reactivity for the nine NA subtypes. The antiserum that causes inhibition of the 
neuraminidase activity identifies the NA subtype (WHO 2002). 
The viral culture approach, associated to the HI and NI assays was for decades the 
most sensitive mean to detect very low viral titres, and it is still considered by many 
authors the gold standard technique in viral identification. However, all culturing-
based techniques require a high level of expertise and laboratory facilities suitable to 
the culture of chicken eggs or mammalian cells, that diagnostic laboratories do not 
usually posses. Due to the time required to detect the virus and to define the subtype 
the results obtained in this way don’t impact the management of hospitalised 
patients, and have little or no diagnostic value. Nowadays, therefore, virus culture is 
mainly employed as a confirmatory analysis to validate the results of alternative 
tests.  
 
Nucleic Acid Amplification Tests (NAAT) 
The NAAT tests detect very minute viral concentrations by amplifying selected 
regions of one or more genes. The amplified sequence is then recognised by use of 
different strategies. The two most investigated NAAT techniques, the reverse-
transcription PCR (RT-PCR), and the real-time PCR, also called quantitative-PCR 
(Q-PCR), are employed in routine laboratory diagnostics.  
In a typical RT-PCR, the viral RNA is isolated, retro-transcribed in cDNA, and then 
amplified with optimised primers. The PCR product can be sequenced and identified 
with a BLAST analysis against known sequences. The DNA amplification normally 
relies on primers that match conserved sequences on the M1 or the HA and NA 
sequences. For example, the 12, 3’-terminal and the 13, 5’-terminal nucleotides, 
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conserved in all the influenza genes across the known subtypes, allow amplification 
of the entire length of all 8 RNA segments (Hoffmann et al., 2001). Degenerate 
primers instead (i.e. primers mixes that present single base differences), have been 
employed to amplify highly conserved sequences on the HA (Phipps et al., 2004, 
Wang et al., 2008) and the NA genes and (Qiu et al., 2009, Alvarez et al., 2008).   
The Q-PCR approach represents an improvement of the RT-PCR in that it amplifies 
and simultaneously quantifies the target DNA by use of fluorescent reagents that 
bind to it during the amplification cycles. In the TaqMan version of the assay, the 
probe is labelled with a reporter dye at the 5’-end and a quencher dye at the 3’-end. 
During amplification, the exonuclease activity of the Taq polymerase cleaves the 
reported dye, thereby separating it from the quencher. At each cycle of amplification, 
fluorescence is produced in response to a laser source, and the recorded signal 
associated to the number of amplification cycles. A number of TaqMan protocols 
have been developed over the last 10 years; in the majority, conserved sequences 
on the M1, HA, and NA genes are targeted (Di Trani et al., 2006, Ng et al., 2005, van 
Elden et al., 2001). Results, including type-and subtype-identification are normally 
produced in 4-5 hours hands-on time, and as little as 0.006 TCID50 has been 
detected ((van Elden et al., 2001).  
In the last decade TaqMan assays were adopted in surveillance studies of live-bird 
markets and waterfowl stocks (Bokma et al., 2006, Runstadler et al., 2007) and in 
monitoring programs of avian H5N1 strains and pandemic 2009 H1N1 swine flu 
((Das et al., 2008, Carr et al., 2009, Whiley et al., 2009). Despite of the promising 
analytical and clinical performance, the fluorescent probes used in these tests are 
expensive, and thus the method is impractical for large-scale surveillance programs. 
The issue has been partially addressed in the protocols that use the SYBR green 
reagent; this compound replaces the fluorescent probes and allows cheaper, 
however less sensitive, protocols. The SYBR green Q-PCR technique, indicated as a 
more practical option for routine analysis of high volumes of samples (Giglio et al., 
2003) (Whiley et al., 2009), was applied to the identification of seasonal H1N1 and 
H3N2 as well as swine H1N1 strain (Krafft et al., 2005) and, and it proved capable of 
detecting all 16 HA and 9 NA of avian influenza ((Tsukamoto et al., 2012).  
The PCR amplification was employed in association with the DNA microarray 
technology. In this technique short nucleotide sequences are spotted in a defined 
pattern on a solid support from where they capture the amplified viral sequences. 
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These are labelled with fluorescent probes and their identity determined on the basis 
of the localised fluorescence on known positions of the array. Hundreds of different 
sequences can be spotted on a surface smaller than 1cm2, and the result is easily 
read with a scanner and evaluated with automated algorithms.  
DNA microarrays have been demonstrated for the detection of a number of 
pathogens, including influenza (Li et al. 2001, Sengupta et al. 2003, Kessler et al. 
2004, (Dawson et al., 2006, Townsend et al., 2006, Huang et al., 2009). For 
example, in the Mchip, developed by Dawson and colleagues, influenza was 
subtyped by targeting the M1 gene. A combination of oligonucleotide pairs, 16-25 nt 
in length, was optimised to bind sequences unique to the M1 genes of different 
subtypes and to guarantee coverage across known clades. The array correctly 
differentiated H1N1, H3N2, and H5N1 strains with a clinical sensitivity of 95%. The 
assay was then tested against a panel of 16 historic subtypes, including the 
influenza virus that caused the 1918-pandemic, and it confirmed a robust detection 
and subtype-identification method with a hands-on time of 7 hours (Moore et al., 
2007).  
The DNA microarray developed by Townsend and co-workers, included 5 
probe/label pairs designed to capture a panel of influenza A and influenza B 
sequences (Townsend et al., 2006).The system was evaluated in a blind study 
where it discriminated influenza A from B, and performed with a clinical sensitivity of 
95%. The test required 11 hours to be completed. 
Nowadays, the multiplexing side of the DNA microarray is represented very well in 
the TessArray RPM-Flu 3.1 (TessArae LLC), capable of detecting 86 different 
pathogens; about one third of the probes in the assay are optimised to reveal the 16 
HA and 9 NA sequences of recent avian influenza strains, as well as a set of M1, 
NS1, and PB2 sequences. The performance of the assay was evaluated using 
artificial genes that mimicked the 16HA and 9NA genes (Lin et al., 2009); as little as 
1,000 viral genome copies could be detected. The assay was then demonstrated 
against 37 cultured influenza specimens of different clades, mostly H5 and H7 
subtypes, and a good agreement was reported with results obtained with HI tests. 
Importantly, the test also gave information about sequence markers that may help to 
differentiate high-pathogenic and low-pathogenic strains. 
DNA-microarrays have also been developed using the electronic microarray 
platform. In this case, capture sequences are positioned on microelectrodes spots. 
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By controlling the charge on the electrodes it is possible to adjust stringency of the 
DNA hybridisation. Using this technique, Huang and co-workers detected and 
discriminated H1N1, H3N2, H5N1, and influenza B strains (Huang et al. 2008). The 
test was evaluated on 146 human clinical samples and performed with a sensitivity 
of 93% for the detection of influenza A, and 91% for influenza B. 
 
 
 
1.4.3 Non amplification techniques 
 
The ELISA tests 
The ELISA test is a solid-phase assay where chosen antibodies or antigens are 
immobilised in the wells of a microtiter plate and employed as capture agents for 
target molecules. There exist two formats of ELISA immunoassay (Figure 1.16). In 
the direct format, also referred to as antigen-capture ELISA (AC-ELISA), a target 
analyte is captured in a ‘sandwich’ conformation between two antibodies; one is 
bound to the support, and the second is incubated with or after the analyte. In the 
indirect format, instead, a chosen antigen is deposited in the well where it interacts 
with the antibodies contained in the sample. In both formats, an additional 
monoclonal or polyclonal antibody and downstream reagents are added that 
generate colorimetric, chemiluminescent, or fluorescent signal. The intensity is 
measured with a proper reader and then related to presence/absence of the target 
analyte. However, the indirect format can only be applied to reveal antibody titres 
that arise days to months after the infection, and therefore it is only employed for 
retrospective analysis or in epidemiological studies. The AC-ELISA, instead, is better 
suited for the detection of a virus, and it has been largely assessed as a front-line 
diagnostic approach. 
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Figure 1.16. Different ELISA formats. 
In the direct ELISA (antigen-capture), the analyte is captured by two antibodies in a sandwich 
conformation, and the second antibody (detector) is conjugated to reagents that generate a 
recordable signal. In the indirect ELISA the sample is displayed on a solid support and then probed 
with antibodies with known specificity. This primary interaction is then revealed with a secondary 
antibody that cross-reacts with the primary antibodies.  
 
The typical workflow of the AC-ELISA assays consists in the following sequential 
phases. Firstly, the coating antibodies or anti-sera are incubated in the wells of the 
plate in appropriate buffers. The unbound antibodies are washed away and the wells 
are treated with a blocking solution in order to avoid non-specific interactions 
between the downstream reagents and uncoated areas of the surface. Secondly, the 
sample is added to the well for minimum 30 minutes up to one night; dilution of the 
sample is achieved in optimized buffers that help the solubilisation of the target 
protein as well as the interaction with the capture antibodies. Unbound antigens are 
washed away and then a detector antibody is incubated in the well for 30-to-60 
minutes. The following steps then vary according to the chosen detection strategy. 
The most utilized options include: a) direct conjugation of the detector antibody with 
fluorophore molecules; b) direct conjugation of the detector antibody with enzymes 
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for the generation of recordable signal; c) biotin-conjugation of the detector antibody 
and its detection with streptavidin- or avidin-conjugated enzyme particles; d) 
detection of the detector antibody with a secondary polyclonal reagent and detection 
of the latter using either of the above-mentioned strategies. The most common 
enzymes employed in the ELISA tests are the horseradish peroxidase (HRP) and the 
alkaline phosphatase.  
The majority of the diagnostic AC-ELISAs developed so far focus on the capture of 
the influenza NP. Being one of the most abundant components of the virions, and 
given the conservation of its amino acid sequence among different subtypes, this 
antigen was considered by a number of investigators the most reliable option for the 
antigen-detection of influenza, as well as for the type-differentiation. The lowest 
concentration detected with the technique was reported the low ng/ml range of total 
viral protein (Grandien et al., 1985). Siebinga and co-workers on the other hand, 
reported that the detection limit varies with different viral strains, and they detected 
as little as 8 ng/ml for a H3N2 virus, but not less than 143 ng/ml for a H1N1 
(Siebinga and Deboer, 1988). Lee and colleagues revealed 1 ng/ml using the biotin-
avidin strategy, with viral strains quantified as 104 EID50/ml. Also the length of the 
test is very variable; however a typical processing time for an AC-ELISA on a pre-
coated and pre-blocked plate is of about two hours. 
The influenza M1 protein was also targeted for diagnostic proposes. For example, 
Bucher and colleagues developed an ELISA test where a monoclonal anti-M1 and 
polyclonal anti-M1 antibodies were employed in the detection of H1N1 and H3N2 
strains.  While the assay detected 10 ng of purified virus, the sensitivity achieved 
was not enough to reveal influenza in nasal and throat specimens.  
Recently then (Jian-Umpunkul et al., 2012), a triple-antigen ELISA assay was 
developed that captures the NP, the M1, and the NS1 proteins simultaneously. In the 
study, three antibody pairs were optimized for a simultaneous sandwich assay, and 
the signal generated by the combined detection proved higher than that generated 
from the single detection of each antigen.  
While the NP- and the M1- based ELISA tests cannot differentiate among subtypes, 
several groups constructed AC-ELISA tests focused on the detection of the HA 
antigens. The tests were developed in both microplate and lateral-flow device 
formats. For example He and colleagues developed an ELISA procedure using 
monoclonal antibodies generated against the recombinant HA1 of a H5 subtype (He 
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et al., 2007). The assay could identify H5N1, H5N2 and H5N3 with detection limits of 
124, 62, and 31 TCID50 respectively. The analytical sensitivity, tested against 
tracheal samples, measured between 105 and 107 EID50/ml, and no cross-reactivity 
was detected against H9 subtypes (He et al., 2007). Yi-Tung and colleagues 
developed a microtiter-based ELISA using mAbs raised against the H6 HA, validated 
it against tracheal samples (Chen et al., 2012), and they recorded no cross-reactivity 
against H1N1 and the H3N2 strains. 
 
 
 
Rapid diagnostic influenza tests 
In recent years, a class of “rapid” influenza diagnostic tests (RIDT) also called rapid 
antigen diagnostic tests (RADT) have been increasingly developed and introduced 
into the market. Similarly to the AC-ELISA, the RIDTs are typically sandwich assays 
with one or more anti-NP reagents embedded into a membrane that is pre-cast in a 
plastic pouch. The most promising features of these tests are the short time needed 
to produce results, typically less than 20 minutes, and the simplicity and applicability 
outside of a laboratory setting. The clinical parameters are variable, depending on 
the type and conservation state of the sample, and the gold-standard technique used 
for the comparison. While the clinical specificity approaches 100%, the clinical 
sensitivity varies between 20% and 70%.  
The Centers for Disease Control and Prevention (CDC) indicates a list of RIDTs that 
can be used to help the diagnosis. The analytical sensitivities of some of the most 
common RIDTs, BinaxNOW Influenza A&B (Emergo Europe, The Netherlands), 
QuickVue Influenza A+B (Quidel Corporation, CA, USA), Directigen Flu A+B/ EZ Flu 
A+B (Becton Dickinson and Company, MD, USA), Poctem Influenza A/B (Sysmex, 
Japan) and Rapid Testa Flu II (Genzyme Diagnostic, Japan) were compared using 
viral culture as a reference method, and were shown to be up to 1000-fold less 
sensitive than the techniques based on virus isolation. A direct comparison of 
different RIDTs then was conducted by Taylor and co-workers who compared twenty 
rapid antigen assays using dilutions of virus culture supernatants from human 
isolates of influenza A H5N1, H3N2, H1N1, and influenza B (Taylor et al. 2009). A 
significant variability was found amongst the clinical sensitivities of the different tests.  
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Besides the low sensitivity, the second important limit of currently available RIDTs, is 
represented by the impossibility to discriminate the subtypes. Only the types, A and 
B, can be distinguished by the antibodies casted into these diagnostic kits, as 
subtype identification would require inclusion of a number of HA and NA specific 
capture substrates difficult to introduce in the small sized membrane of the devices.    
Given the limitation of the diagnostic methodologies, there exists a clear unmet 
clinical need for more powerful rapid diagnostic assays at the POC capable of robust 
identification of virus variants at the subtype level within a very short time frame.  
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1.4.4 The protein microarray 
 
The protein microarray is a technique for the screening of protein-protein interactions 
in a high-throughput format. Selected proteins are displayed on a solid support from 
where they interact with their molecular targets, if present in a sample, and this 
primary interaction is revealed using an appropriate detection protocol. Crucially, the 
proteins are immobilized in micro-spots of the size 100-500 µm each, distributed 
across a miniaturised area, typically 1-2 cm2. The reduced dimensions determine 
several advantages as compared to non-miniaturized protein screening assays. 
In a microarray experiment a sample is simultaneously exposed to a matrix of many 
capture elements, thus enabling the screening of hundreds/thousands of discrete 
binding events in parallel. Thus, true parallelism and multi-analyte analysis are 
achieved with the technique. The volumes needed a microarray experiment are 
typically less than 100 µl, and this allows analysis with samples and reagents for 
which there is limited availability.  
The multiplexing properties of the microarray technology contrast with non-
miniaturized assays normally performed using microplates. Here, each interaction is 
screened by applying the sample in different wells. 
Miniaturisation then, opens up possibilities for introduction of microarray components 
into portable devices that can potentially fulfil the needs of the Point-of-Care 
analysis. 
Microarrays can achieve higher theoretical sensitivity as compared to the non-
miniaturized formats as explained in the next section. 
 
1.4.4.1 Theoretical base of the protein microarray technology 
The theoretical principles of the microarray technology lay in the ‘ambient analyte’ 
theory, developed by Ekins and colleagues in the eighties to describe the ligand-
receptor interactions that occur on a micro-spot (Ekins, 1989). The concepts are 
applicable to any miniaturized solid-phase assay that measures the interaction 
between a capture agent and an analyte.  
The theory predicts that the capture process of an analyte on a miniaturized surface 
doesn’t significantly change the concentration of analyte in the sample, provided that 
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the concentration of the capture agent is low enough.  The theory is valid for those 
systems where the concentration of capture agent is lower than 0.01/Ka, with Ka, 
being the affinity constant of the capture-analyte reaction. If the ambient analyte 
condition is respected, the signal recorded on the spots is directly related to the 
concentration of the analyte, and is independent from both its total mass and 
volume. 
One crucial outcome of the theory is that the analytical sensitivity of a miniaturized 
assay is higher than that of a non-miniaturised system. One principle is assumed in 
the formulation: the signal recorded on the micro-spots depends on the fraction of 
the binding sites that are occupied by the analyte, defined as fractional occupancy. 
Tthe fractional occupancy achieved in a micro-spot is higher than that achieved for a 
spot with a larger area. Figure 1.17 (Templin et al., 2002b, Ekins and Chu, 1991) 
shows the principle. Spots of increasing size are generated with an antibody. The 
total amount of antibody (white blocks in the figure) increases with increasing spot 
size. The total signal recorded on the spot also increases and it reaches a maximum 
in correspondence of the total amount of antibody that captures all the analyte 
molecules. However, if the concentration of the analyte is a limiting factor, the signal 
density from any single point in the spots (red blocks) decreases. Instead, when the 
spot is miniaturised, the signal density increases, while the total signal drops. The 
signal density reaches a maximum when concentration of antibody is less than 
0.01K. The concentration of the signal in a miniaturise area gives the technique a 
significtive theoretical advantage over non miniaturized assays.  
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Figure 1.17. Total signal and signal density of the capture spots. 
Antibodies are spotted with constant density on all spots. As the spots increase in size so does the 
total amount of antibody. For each amount of antibody, the signal density (red blocks) and total signal 
(white blocks) are illustrated. The signal density increases with smaller spots and it reaches a 
maximum when the total amount of antibody is 0.01/K. Conversely, the total signal increases with 
bigger spots and reaches a maximum when all the analytes are captured. Reprinted from Trends in 
Biotechnology, Vol. 20, 160-166, reproduced with permission from John Libbey Eurotext and Elsevier 
(Ekins and Chu, 1992, Templin et al., 2002a).  
 
 
1.4.4.2 Chemistry of protein immobilization in the microarray technology  
The generation of a protein microarray consists in the ordered deposition of droplets 
of protein solutions on a chemically modified slide surface. The chemistry of the 
protein-surface interaction is an essential element in the final performance of the 
microarray, and its selection is guided by a number of considerations.  
Firstly, the surface should bind the capture agent without interfering with its 
biochemical activity. Secondly, the immobilisation should be reasonably stable and 
resist to downstream addition of reagents and washing procedures. Thirdly, non-
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specific interactions need to be acceptably low in order to avoid any interference 
during the assay. 
The chemical strategies to immobilise a protein can be categories in four classes.  
1) Physical adsorption. Proteins can bind a chemically active surface via 
electrostatic interactions, represented by ionic bonds and polar or hydrophobic 
forces. This method employs materials such as, for example nitrocellulose and poly-
lysine membranes (Joos et al., 2000, Ge, 2000, Haab et al., 2001, Reck et al., 2007). 
These materials are relatively inexpensive, and their interaction with proteins is well 
known based on their popular use in other biochemical techniques, for example 
nitrocellulose membranes are routinely employed in the western-blot technique. 
However, several problems are normally associated with the physical adsorption. 
The adsorbed proteins assume orientations that minimise repulsive forces with the 
surface or with neighbour proteins and, as a consequence, they bind a surface with 
random orientations. Additionally, the nature of the physical interaction is weak, and 
therefore proteins can be easily removed by the reagents used in the downstream 
processing. The resulting protein-surface interaction is non-specific, and protein 
binding on areas outside the microspots causes potential high background noise, 
with consequent reduction of the signal/noise.   
2) Covalent binding. Proteins can be attached to a support via covalent bonds 
between molecular groups on the amino acid side chains and selected active groups 
on the support. A variety of functional groups found along the protein can be targeted 
with different immobilisation strategies.  
The most popular method exploits the amine groups present on the side chains of 
lysine and arginine. The amine groups can be used as anchor points on slides 
derivatised with chemical groups such as for example the aldehydes, the carboxylic 
acid, the epoxy group, or active esters. One of the first studies on covalent-binding 
protein microarrays was conducted by Macbeth and Schreiber (MacBeath and 
Schreiber, 2000) who demonstrated  attachment of the proteins to aldehyde-
derivatized slide. Other groups investigated the technique further and applied it to a 
variety of studies involving protein-protein interactions (MacBeath and Schreiber, 
2000, Zhu et al., 2001, Di Cristina et al., 2010, Kusnezow et al., 2003).  
However, as the lysin resides are very abundant on the surface of the proteins, this 
strategy leads to a multi-point attachment, with random orientation.  
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The carboxyl group of the aspartic and glutamic acid represents a second option for 
protein immobilisation. The two amino acids are a consistent fraction of the surface 
protein amino acids and therefore constitute a reliable choice for protein attachment, 
however they present the same issue with multi-point attachment as the amine group 
(Fernandezlafuente et al., 1993). The same logic and issues relate to the 
immobilisation via the hydroxyl groups or Serin and Threonin. These have been 
exploited by a number of authors, who immobilised proteins on slides derivatised 
with epoxi-linkers  (Zhu et al., 2000, Haab et al., 2001, Kusnezow et al., 2003).  
Imobilisation via the thiol group of the cysteine residues has also been exploited. 
Cysteines are less abundant than the Lysine and aspartic and glutamic acid 
residues, and thus they offer a better control over protein orientation. They are 
normally exploited to bind the protein via maleimide linkers to form thioether bonds 
(Viitala et al., 2000).  
3) Gel entrapment. Proteins are physically trapped in a gel-like structure, for 
example agarose or polyacrylamide. The main advantage of this strategy is 
represented by the three dimensional shape of the immobilization matrix. This 
increases the surface available for the immobilisation and permits higher loading 
capacity. Also due to the acqueous environment of the gel, protein conformation is 
normally retained (Afanassiev et al., 2000, Charles et al., 2004) (Arenkov et al., 
2000).  
4) Bioaffinity immobilization. The immobilisations achieved by physiosorption, 
covalent binding and gel entrapment result in random orientation of the capture 
agent. Therefore, alternative immobilization strategies have been developed that 
employ modification of the protein with affinity molecular partners. Examples include 
the employment of nickel-coated slides along with capture proteins engineered with 
histidine tags. In this case the affinity of short histidine tails for nickel is exploited as 
a tool for the immobilisation of recombinant proteins. Similarly, the biotin-avidin and 
biotin-streptavidin affinity couples can be exploited, as the interaction of these two 
partners then permits robust, oriented, protein immobilization (Rowe et al., 1999). 
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1.4.4.3 Different protein-microarray formats 
Similarly to the ELISA tests, two different formats of protein microarray immunoassay 
can be distinguished (Figure 1.18).  
1) The forward-phase microarray. Similarly to the antigen capture-ELISA, antibodies 
are spotted on the array and capture analytes in the sample.  
2) The reverse phase microarray. Similarly to the indirect ELISA tests, the sample 
solution is spotted on a slide and then probed with selected labelled antibodies to 
detect a protein of interest.  
 
 
Figure 1.18. Forward and Reverse-phase microarray immunoassay. In the forward-phase format, 
the analyte is captured by two antibodies in a sandwich conformation, where the second antibody 
(detector is conjugated to reagents that generate a recordable signal. In the reverse-phase format the 
sample is displayed on a solid support and then probed with antibodies with known specificity. This 
primary interaction is then revealed with a secondary antibody that cross-reacts with the primary 
antibodies.  
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For diagnostic proposes, the forward-phase microarray represents the best option. 
The arrayed capture agents, (probes) on the slide are represented either by simple 
proteins (i.e. antigens, cytokines) or, more frequently, by polyclonal and monoclonal 
antibodies. The probe must be specific enough to bind its target among thousands 
different molecules present in the sample. For this reason, the probes are selected 
on the base of their specificity and affinity for the target analyte and then purified 
using high affinity and low cross-reactivity resins. Specific probes include polyclonal 
and monoclonal antibodies.  
The protein microarray technique has been successfully used for a number of 
different applications, for instance the detection of specific diseases’ biomarkers (i.e. 
pathogen-derived antigens or antibodies raised by the organism in response to a 
pathogen). An early microarray immunoassay, developed with this aim, is 
represented by that produced by Mezzasoma and colleagues (Mezzasoma et al., 
2002). Microbial antigens printed on amino-silane-activated glass slides were 
successfully employed to determine, in human sera, several antibodies directed 
against Toxoplasma gondii, Rubella virus, Cytomegalovirus, and Herpes simplex 
virus simultaneously, and the detection limit calculated for the system was of 0.5 
picograms of IgG or IgM. Steller and co-workers employed nitrocellulose-coated 
slides to print recombinant proteins of Neisseria meningitides (Steller et al., 2005). 
Upon incubation of the microarray with sera of meningitis patients, the authors were 
able to identify 47 immunogenic proteins, thereby contributing to the identification of 
diagnostic markers of the infection. A more sophisticated array, for the simultaneous 
detection of both antibodies and antigens, was investigated by Xu and colleagues 
(Xu et al., 2007). In this case, an integrated protein microarray was generated that 
could simultaneously determine two antigens and seven antibodies against human 
hepatitis virus in human sera, with a detection limit of 0.1 ng/ml.   
One particular type of protein microarray, the antibody microarray, has proved a very 
powerful tool for the detection of analytes associated with pathogenic conditions. For 
instance, Sreekumar and colleagues successfully spotted 146 distinct antibodies on 
superaldehyde coated glass slides and they measured the level and activity of 
proteins in LoVo colon carcinomal cells. In a different application, developed by Gao 
and colleagues, a microarray displaying 84 antibodies was used along with the 
rolling circle amplification (RCA) methodology to analyze the relative abundance of 
proteins in sera from patients with lung cancer. As a result, a specific protein profile 
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was described for patients with lung cancer, thus providing valuable information for 
the identification of diagnostic biomarkers (Sreekumar et al., 2001, Gao et al., 2005). 
The antibody microarray strategy was also investigated in a proof-of-concept study 
for its capability to identify biomarkers for metastatic breast cancer (Carlsson et al., 
2008).  
These reported examples show how the antibody microarray represents a promising 
technology that can be further developed for a number of applications. 
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1.4.5 Bottleneck of current diagnostic methods 
 
From the practical point of view, there are two major problems associated to modern 
laboratory diagnostics: the time needed to obtain results, and the costs associated to 
the testing. Both issues are related not only to the procedure for the single tests, but 
also to the scalability of the test. For example, the number of the tests included in the 
commercial version of an immunoassay, the size of each testing run, the number of 
negative and positive controls required for each run, the requirement of additional 
laboratory procedures and reagents that are not included in the diagnostic kit (i.e. the 
extraction procedure for the nucleic acids in PCR-based tests). In general, a cost- 
and time-effective way to organise the diagnostic procedures consists in batch-
testing a suitable number of samples. However, batching is not always suitable, for 
example when a limited number of samples need testing, or when samples come at 
time intervals that do not allow efficient batching. Also, diagnostic instrumentation 
has considerable costs (i.e. $35,000-$85,000 per instrument in the case of real-time 
machines), which add to the costs associated to the technical personnel, and those 
for the quality control procedures. 
The majority of current diagnostic methods then are not feasible outside of a 
laboratory contest. FDA-approved systems for automated real-time PCR constitute a 
considerable step forward in terms of automation and simplicity; however they 
cannot presently be used at the point-of-care. The RIDT represent the only option 
that is available at the moment of writing for use at the point-of-care. These tests can 
aid GPs and health authorities to identify infected patients. However, given their poor 
clinical sensitivity, the negative results must be confirmed with laboratory analysis, 
and therefore their diagnostic potential is still limited. 
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1.5 Project outline  
 
 
This PhD project focused on the development of an antibody microarray 
immunoassay for the rapid detection of influenza viruses in biological specimens. 
The designed assay aimed to differentiate both types and subtypes (for type A) of 
influenza viruses currently circulating in humans (H1N1, H1N2, H3N2), as well as 
avian subtypes H5N1, H7N2, H7N3, H7N7, and H9N2 that might, as a consequence 
of genetic changes, acquire infectivity for man. Several European partners, each with 
specific tasks and responsibilities, contributed to project, termed ‘Fluarray’. The 
project aimed at transferring the developed microarray immunoassay onto a newly-
developed diagnostic instrument targeted at the point-of-care setting. The European 
consortium was formed by three academic partners (the Italian Istituto Superiore di 
Sanita’ (ISS), the University of Perugia (UNIPG) and the UK Health Protection 
Agency (HPA) and three industrial partners (SEAC Ltd. (Italy), Protein Therapeutics 
(PX’) (France) and Microtest Matrices (MtM) (UK). During the course of the project 
the University of Bologna (UNIBO) joined the project.  
 
 
 
1.5.1 Rationale 
 
The decision to exploit an antibody microarray format relies upon the necessity, to 
detect and differentiate tens (if not eventually hundreds) of different variants of 
influenza surface antigens (HA and NA) as well as the two main types (A and B) of 
the internal nucleoprotein (NP) antigen. In contrast, current RADTs employ one or 
two antibodies specific for the nucleoprotein antigen and are thus unable to perform 
tasks beyond basic virus detection and, in some cases, virus typing (see section 
1.4). Due to the technical and spatial difficulties associated with integrating a number 
of different anti-HA and anti-NA antibodies with visualizing many different Ab/Ag 
reactions at the same time, existing rapid test technologies do not lend themselves 
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to more complex diagnostic tasks. The microarray approach was chosen due to 
several reasons. First, they are an excellent means for displaying a complete panel 
of capture antibodies that includes specificities for all possible target HA and NA 
variants, as well as the A and B nucleoproteins. Second, antibody microarrays lend 
themselves to the rapid diagnostic analysis of biological samples, as favourable 
kinetics mean that antibody/antigen interactions can occur rapidly within a few 
minutes. Finally, given the small size of a microarray (up to 500 discrete interactions 
within an area less than 1 cm2), the small sample/reagent volumes needed to 
perform an assay, and the advantages, in terms of scarce matrix effects, high 
sensitivity and rapid kinetics, afforded by the miniaturized nature of the assay, 
antibody microarrays represent a formidable tool for both diagnostic and research 
purposes. Adding to this, due to their miniaturized format, microarrays can be easily 
housed within a compact device for easy transfer between different locations, both 
inside and outside of laboratory and hospital facilities.  
 
 
1.5.2 Experimental outline 
 
 
The assay format that was first investigated was the competition immunoassay. Here 
two variants of the same antigen, the sample-derived viral antigen and a 
recombinant, 6xHis-tagged form representing a “tracer” compete for a limited 
number of binding sites on capture antibodies. The assay was therefore initially 
designed to comprise the following components: a) a microarray made of 
monoclonal antibodies specific for nucleoproteins (NP), selected haemagglutinins 
(HA) and selected neuraminidases (NA); b) a panel of recombinant, 6xHis-tagged 
tracer proteins corresponding to each of the selected NP, HA and NA proteins; and 
c) a monoclonal antibody specific for the 6xHis tag for use in detecting tagged 
tracers captured by the arrayed antibodies. These three components interact in a 
“sandwich type” conformation. The presence of viral antigens (NPs, HAs and NAs) in 
the sample competes with the tracers for antibody capture, thus causing a 
measurable decrease in the level of fluorescent signal recorded at the corresponding 
microarray spot.  
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As the work progressed then, the non-competitive, sandwich format was evaluated 
as a better option. In this format, the antigens, not the traces, are captured directly 
on the microarray and an increasing signal is recorded from the spot in presence of 
increasing concentration of target antigen. 
The microarray-based immunoassay used reagents produced by the other partners 
of the consortium; initially, while monoclonal antibodies against the selected panel of 
NP, HA and NA proteins were produced, a feasibility study was performed using 
commercial antibodies and nucleoprotein antigens provided by Protein Therapeutics 
to assess the feasibility of employing a competition immunoassay format. The assay 
developed using the recombinant proteins was then evaluated introducing spiked 
samples (containing known viral titres of specific influenza strains) provided by the 
HPA, and egg/cell-grown viruses provided by ISS and UNIBO.   
This study focused on ensuring that the developed immunoassay is compatible with 
a prototype automated diagnostic instrument that is being developed by Microtest 
Matrices and SEAC. And, once the immunoassay and instrument are completed, 
work will be performed to evaluate the resulting rapid test for both clinical and 
analytical sensitivity and specificity.   
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Figure 1.18. Outline of the PhD project.
My PhD project was developed in the frame of a European joint effort. The project, termed Fluarray, 
aimed at generating a new diagnostic platform based on the antibody microarray. Monoclonal 
antibodies developed at UNIPG were sent to Imperial College. Following purification and 
characterisation, I integrated them in a microarray application. Two immunoassay formats, the 
competitive assay and the non-competitive assay were evaluated to detect recombinant viral antigens 
produced by PX. The assay was then demonstrated with viral samples kindly provided by UNIBP, ISS 
and HPA. The test is designed for integration in the Automated Diagnostic Analyser for Microarrays 
developed by MtM in collaboration with SEAC. 
.  
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2 Materials and methods 
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2.1 List of key reagents and instrumentation 
employed in the study 
 
 
The experiments carried out in the course of this PhD employed reagents produced 
by the collaborating institutions of the European consortium as well as commercial 
reagents.  
Five recombinant nucleoproteins (NPs) were synthesised at PX’: the human NPA, 
the avian NPA, and three variants of NPB, indicated as NPB, NPB3 and NPB4.  
The NPs were made available in three different forms; a) conjugated to a short 
amino-terminal molecular tag constituted of the amino acids HHHHHHGS (referred 
to as ‘6xHis-tag’, or simply ‘6xHis’, in this thesis); b) conjugated to Gluthatione S-
transferase (referred to as ‘GST-tag’ or simply GST); and c) untagged (referred to as 
‘untagged’). A list of the nucleoproteins used in the project is illustrated in table 2.1. 
The amino acid sequences of the nucleoproteins, communicated by PX’ for the 
6xHis-tagged nucleoprotein are as follows.  
 
Sequence of 6xHis-tagged human influenza A nucleoprotein (human 6xHis-NPA): 
MHHHHHHGSIEGRASQGTKRSYEQMETDGDRQNATEIRASVGKMIDGIGRFYIQMCTELKLSDHEGRLIQNSLTI
EKMVLSAFDERRNKYLEEHPSAGKDPKKTGGPIYRRVDGKWMRELVLYDKEEIRRIWRQANNGEDATAGLTHIMI
WRSNLNDATYQRTRALVRTGMDPRMCSLMQGSTLPRRSGAAGAAVKGIGTMVMELIRMVKRGINDRNFWRGENGR
KTRSAYERMCNILKGKIQTAAQRAMVDQVRESRNPGNAEIEDLIFLARSALILRGSVAHKSCLPACAYGPAVSSG
YDFEKEGYSLVGIDPFKLLQNSQIYSLIRPNENPAHKSQLVWMACHSAAFEDLRLLSFIRGTKVSPRGKLSTRGV
QIASNENMDNMGSSTLELRSGYWAIRTRSGGNTNQQRASAGQTSVQPTFSVQRNLPFEKSTIMAAFTGNTEGRIS
DMRAEIIRMMEGAKPEEVSFRGRGVFELSDEKAANPIVPSFDMSNEGSYFFGDNAEEYDN 
 
Sequence of 6xHis-tagged avian influenza A nucleoprotein (avian 6xHis-NPA): 
MHHHHHHGSIEGRASQGTKRSYEQMETGGERQNATEIRASVGRMVSGIGRFYIQMCTELKLSDYEGRLIQNSITI
ERMVLSAFDERRNRYLEEHPSAGKDPKKTGGPIYRRRDGKWVRELILYDKEEIRRIWRQANNGEDATAGLTHLMI
WHSNLNDATYQRTRALVRTGMDPRMCSLMQGSTLPRRSGAAGAAVKGVGTMVMELIRMIKRGINDRNFWRGENGR
RTRIAYERMCNILKGKFQTAAQRAMMDQVRESRNPGNAEIEDLIFLARSALILRGSVAHKSCLPACVYGLAVASG
YDFEREGYSLVGIDPFRLLQNSQVFSLIRPNENPAHKSQLVWMACHSAAFEDLRVSSFIRGTRVVPRGQLSTRGV
QIASNENMEAMDSNTLELRSRYWAIRTRSGGNTNQQRASAGQISVQPTFSVQRNLPFERATIMAAFTGNTEGRTS
DMRTEIIRMMESARPEDVSFQGRGVFELSDEKATNPIVPSFDMNNEGSYFFGDNAEEYDN 
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Sequence of 6xHis-tagged influenza B nucleoprotein (6xHis-NPB): 
MHHHHHHGSIEGRSNMDIDGINTGTIDKTPEEITSGTSGTTRPIIRPATLAPPSNKRTRNPSPERATTSSEADVG
RKTQKKQTPTEIKKSVYNMVVKLGEFYNQMMVKAGLNDDMERNLIQNAHAVERILLAATDDKKTEFQKKKNARDV
KEGKEEIDHNKTGGTFYKMVRDDKTIYFSPIRITFLKEEVKTMYKTTMGSDGFSGLNHIMIGHSQMNDVCFQRSK
ALKRVGLDPSLISTFAGSTIPRRSGATGVAIKGGGTLVAEAIRFIGRAMADRGLLRDIKAKTAYEKILLNLKNKC
SAPQQKALVDQVIGSRNPGIADIEDLTLLARSMVVVRPSVASKVVLPISIYAKIPQLGFNVEEYSMVGYEAMALY
NMATPVSILRMGDDAKDKSQLFFMSCFGAAYEDLRVLSALTGTEFKPRSALKCKGFHVPAKEQVEGMGAALMSIK
LQFWAPMTRSGGNEVGGDGGSGQISCSPVFAVERPIALSKQAVRRMLSMNIEGRDADVKGNLLKMMNDSMAKKTS
GNAFIGKKMFQISDKNKTNPVEIPIKQTIPNFFFGRDTAEDYDDLDY 
 
Sequence of 6xHis-tagged influenza B3, Yamagata line, nucleoprotein (6xHis-
NPB3): 
MHHHHHHGSIEGRSNMDIDGINTGTIDKTPEEITSGTSGTTRPIIRPATLAPPSNKRTRNPSPERATTSSEADVG
RKTQKKQTPTEIKKSVYNMVVKLGEFYNQMMVKAGLNDDMERNLIQNAHAVERILLAATDDKKTEFQKKKNARDV
KEGKEEIDHNKTGGTFYKMVRDDKTIYFSPIRITFLKEEVKTMYKTTMGSDGFSGLNHIMIGHSQMNDVCFQRSK
ALKRVGLDPSLISTFAGSTIPRRSGATGVAIKGGGTLVAEAIRFIGRAMADRGLLRDIKAKTAYEKILLNLKNKC
SAPQQKALVDQVIGSRNPGIADIEDLTLLARSMVVVRPSVASKVVLPISIYAKIPQLGFNVEEYSMVGYEAMALY
NMATPVSILRMGDDAKDKSQLFFMSCFGAAYEDLRVLSALTGTEFKPRSALKCKGFHVPAKEQVEGMGAALMSIK
LQFWAPMTRSGGNEVGGDGGSGQISCSPVFAVERPIALSKQAVRRMLSMNIEGRDADVKGNLLKMMNDSMAKKTS
GNAFIGKKMFQISDKNKTNPVEIPIKQTIPNFFFGRDTAEDYDDLDY 
 
Sequence of 6xHis-tagged influenza B4, Victoria line, nucleoprotein (6xHis-NPB4): 
MHHHHHHGSIEGRSNMDIDGINTGTIDKAPEEITSGTSGTTRPIIRPATLAPPSNKRTRNPSPERATTISEADVG
RKTQKKQTPTEIKKSVYNMVVKLGEFYNQMMVKAGLNDDMERNLIQNAHAVERILLAATDDKKTEFQKKKNARDV
KEGKEEIDHNKTGGTFYKMVRDDKTIYFSPIRVTFLKEEVKTMYKTTMGSDGFSGLNHIMIGHSQMNDVCFQRSK
ALKRVGLDPSLISTFAGSTLPRRSGATGVAIKGGGTLVAEAIRFIGRAMADRGLLRDIKAKTAYEKILLNLKNKC
SAPQQKALVDQVIGSRNPGIADIEDLTLLARSMVVVRPSVASKVVLPISIYAKIPQLGFNVEEYSMVGYEAMALY
NMATPVSILRVGDDAKDKSQLFFMSCFGAAYEDLRVLSALTGTEFKPRSALKCKGFHVPAKEQVEGMGAALMSIK
LQFWAPMTRSGGNEVGGDGGSGQISCSPVFAVERPIALSKQAVRRMLSMNIEGRDADVKGNLLKMMNDSMAKKTN
GNAFIGKKMFQISDKNKTNPVEIPIKQTIPNFFFGRDTAEDYDDLDY 
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Nucleoprotein (NP) Molecular Tag Molecular weight 
(kDa) 
Theoretical pI (pH) 
6xHis tagged 57.3 9.3 
Human NPA 
Untagged 57.3 9.3 
6xHis tagged 57.7 9.47 
Avian NPA 
Untagged 57.7 9.47 
6xHis tagged 62.9 9.57 
NPB 
Untagged 62.9 9.57 
6xHis tagged 63 9.43 NPB Yamagata line 
(NPB3) 
GST tagged 88.7 8.94 
6xHis tagged 62.9 9.4 NPB Victoria line 
(NPB4) 
GST tagged 88.7 8.94 
Table 2.1. List of the recombinant nucleoproteins received from PX’ and employed in the 
project. 
 
 
A panel of antibodies were kindly provided by UNIPG. These were utilised in the 
project along with commercial antibodies. Additionally, one key reagent, antibody 
4D11, was kindly provided by Professor Crisanti. A list of these reagents is 
presented in table 2.2. 
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Antibody Specificity Provenance 
4D11 HHHHHHGS tag Courtesy of Crisanti  
AA5H NPA  Serotec 
MAB8258B NPA Millipore 
C01321M NPA Meridian Lifescience 
C01323M NPA Meridian Lifescience 
10-I55G NPB Fitzergald 
7G11 NPA UNIPG 
11B11 NPA UNIPG 
21H8 NPA UNIPG 
109 NPA UNIPG 
105 NPA UNIPG 
4A11 NPB UNIPG 
5D12 NPB UNIPG 
2B4 NPB UNIPG 
3F6 NPB UNIPG 
Table 2.2. List of antibodies employed in the study.  
The details about the specificity were either indicated by the manufacturer (in the case of the 
commercial antibodies) or expected on the base of preliminary characterisation done by the other 
members of the consortium. I the table, the NPA indicate both the human and the avian NPA. The 
antibodies anti-NPB indicate potential reactivity against the NPB3 and the NPB4.  
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Viral samples of different influenza strains were kindly provided by the HPA, the ISS, 
and UNIBO. A list of the viruses is presented in table 2.3. The viral load of the 
samples was communicated by the providing partners in three different units of 
measure, the HA (hemagglutination) units, the EID50 (Embryo Infective Dose, 50%), 
and the PFU/ml (Plaque Forming Units/ml).  
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Virus Subtype or lineage HA EID50 PFU/ml 
A/NewCaledonia/20/1999  H1N1   10 7 
A/Wisconsin/67/2005 H3N2   10 7 
B/Malaysia/5606/2004 B virus   10 7 
A/Parma/8/2007 
H3N2 
(A/Wisconsin/67/2005-
like) 
1:  512    
 
A/Perugia/1/2008 
H1N1 (A/Solomon 
Islands/3/2006-like) 
1:  32    
 
A/Parma/26/2009 
H1N1 
(A/Brisbane/59/2007-like) 
1:  128    
 
A/Perugia/23/2011 
H1N1 (pandemic 2009-
like) 
1:  64    
 
B/Milano/5/2011 B/Victoria/2/87- lineage 1:  512    
B/Milano/10/2011 
B/Yamagata/16/88-
lineage 
1:  512   
 
A/Mallard/Italy/Unibo/433/06 H9N?   10 9.8  
A/Mallard/Italy/Unibo/196/07 H4N?   10 9.2  
A/Mallard/Italy/Unibo/249/06 H11N6 1:  512     
A/Mallard/Italy/228090/05 H5N1 1:  128     
A/Mallard/Italy/Unibo/167/07 H5N8   10 7.7  
A/Mallard/Italy/23/95 H1N1 1:  64     
A/Mallard/Italy/Unibo/168/07 H3N8 1:  64     
A/Mallard/Italy/Unibo/399/06 H8N4 1:  128     
A/Mallard/Italy/43/01 H7N3 1:  256     
Table 2.3. List of virus samples sent from HPA, ISS, and UNIBO.  
Yellow cells indicate human strains, provided by HPA and ISS. Red cells indicate avian strains 
provided by UNIBO. The viral load is indicated in terms of HA (hemagglutination) units, the EID50 
(Embryo Infective Dose, 50%), and the PFU/ml (Plaque Forming Units/ml).  
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Microarrays were generated with the Nano-Plotter NP2.1 (GeSim) with a spotting 
volume of 1.25 nl unless differently specified.  
The instrument allows spotting of droplets of various types of solution on precise 
locations on different surface materials. The core of the instrument is the piezo-
electric tip. Through the tip, an electric pulse is applied to the solution thereby 
causing a controlled dispensing.  
The spotting procedure is a cycle composed of the following steps (Fig. 2.1).  First, 
the sample is aspired inside the pipette with a micro-pipetting system connected to a 
syringe. Secondly, the electrical parameters of the spotting procedure are adjusted 
with a ‘spotting test’. For this, the solution is dispensed in front of a camera, and the 
voltage and the pulse are modified manually. Then, the solution is dispensed with 
the optimised parameters on the surface of the slide. The volume of each droplet is 
250 pL, the number of droplets dispensed on each spot in the arrays presented in 
this thesis is 5, unless differently specified. After the solution has been dispensed on 
all slides, the pipette is thoroughly washed both inside and outside with system 
liquid.  
 
 
Figure 2.1. Spotting cycle of the Nano-Plotter NP2.1 (adapted from GeSim, Nano-Plotter NP 2.1 
users manual). 
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The microarrays were visualised using GenePix 4100 Microarray Scanner. The 
instrument was utilised at an excitation wavelenght of 532 nm and filter set at 575 
nm. The reading output was provided in PMC (Photo Multiplier Counts) and 
visualised as a coloured image. The scale of the colours is related to the PMC 
reading as in illustrated in figure 2.2. 
 
 
Figure 2.2. Scale of colours visualised with the Genepiz 4100 
White indicates the highest detectable signal (65,535 PMC), black indicates the lowest detectable 
signal (0 PMC). 
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2.2 Procedures for protein characterization 
 
 
2.2.1  SDS-PAGE 
 
To characterise the proteins employed in the assay, these were separated by one-
dimensional sodium-dodecyl sulphate-polyacrilamide gel electrophoresis (SDS-
PAGE) (8-12% pre-cast gels, Invitrogen). Proteins were denatured in 1x sample 
buffer (Invitrogen) implemented with DTT (25 mM), boiled for 5 minutes, and loaded 
on the gel. Proteins were then separated at 150 V in SDS running buffer (Invitrogen). 
Two alternative molecular weight standards purchased from Invitrogen were used 
alongside protein samples to estimate the size of separated polypeptides: SeeBlue® 
Plus2 Pre-Stained Standard (10-190 kDa (Invitrogen) and Invitrogen or Precision 
Plus Protein Kaleidoscope Standard, 10-250kDa, Bio-Rad. Finally, gels were either 
used for immunoblot analysis or stained. 
 
 
 
2.2.2 Protein staining 
 
Proteins separated by SDS-PAGE were visualised using coomassie brilliant-blue. 
Polyacrylamide gels containing separated proteins were incubated with coomassie 
brilliant-blue stain (0.05% w/v coomassie brilliant blue R-250 in 50% methanol, 10% 
glacial acetic acid (v/v)) for 45 minutes. Gels were then de-stained with a  solution of 
30% methanol and 10% acetic acid (v/v) prepared in ddH2O for 1 hr, left O/N in 
ddH2O and then photographed digitally. Nitrocellulose membranes were incubated 
with Ponceau S stain (0.2% Ponceau S (3-hydroxy-4-[2-sulfo-4-(sulfo-
phenylazo)phenylazo]-2,7-naphtalene disulfonic acid) in 3%  trichloroacetic acid, 3% 
sulfosalicylic acid) for 1 minute and then de-stained with 2xTBST for 30 min. 
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2.2.3 Immunoblot analysis 
 
After separation by SDS-PAGE, proteins were electroblotted onto a nitrocellulose 
membrane using a semi-dry transfer unit run for 30-40 minutes at 20 V. The blotting 
buffer (250 mM Tris-HCl, 1.92 M Glycine, 0.1% SDS) was diluted 1:10 in ddH2O 
containing 20% (v/v) methanol.  Transfer was confirmed using a reversible protein 
stain before membranes were blocked for 1 hr at RT or overnight at 4 °C in 2xTBS-T 
(Tris-buffered saline Tween-20) (20 mM Tris-HCl pH 8.0, 300 mM NaCl, 0.1% Tween 
20 (v/v)) containing 2% BSA (w/v) and 3% dry milk (w/v). Membranes were then 
probed using the appropriate primary antibody (anti-nucleoprotein, anti-6xHis tag, or 
anti-IgG/anti-IgM monoclonal antibodies) diluted in the same blocking solution for 1 
hour at RT.  
To analyse the purification of the antibodies, one of the following reagents were 
incubated on the membrane for 1 hour at RT: a) anti-mouse IgG antibody conjugated 
to Horseradish Peroxidase (HRP) (Jackson Immunoresearch), or c) anti-mouse IgM 
conjugated to HRP (Sigma), or d) anti-mouse immunoglobulin antibody conjugated 
to HRP (Dako).  
To analyse the anti-NP reactivity pattern of the antibodies, the anti-6xHis tag mAb 
(clone 4D11) and the anti-nucleoprotein mAbs were incubated on the membrane for 
1 hour at RT at a final concentration of 1 µg/ml. After washing with 2xTBS-T, bound 
antibodies were detected using one of the following secondary antibodies as 
indicated along the text: a) anti-mouse IgG antibody conjugated to alkaline-
phosphatase (AP) (Promega), or b) anti-mouse IgG antibody conjugated to 
Horseradish Peroxidase (HRP) (Jackson Immunoresearch). Secondary antibodies 
were used at concentrations according to the manufacturer’s instructions and 
incubated for 45 minutes at RT.  
Membranes were washed with 2xTBS-T before proceeding to visualisation of the 
results. 
Alkaline Phosphatase activity was detected by incubating the membrane with 3 
#g/ml NBT (Nitro-blue Tetrazolium) and 3 #g/ml BCIP (5-Bromo-4-Chloro-3-Inolyl 
Phospate) in 100 mM Tris-HCl pH 9.5, 100mM NaCl, 5 mM MgCl2. After 1-2 minutes, 
phophatase activity was stopped by immersion of the membrane in ddH20. 
Membranes were then dried at RT and finally photographed digitally. 
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Horseradish Peroxidase acitivty was detected by incubating the membranes with 
ECL substrates (Pierce). 
 
 
 
2.2.4 Isotype determination of the antibodies 
 
Hybridoma supernatants provided by UNIPG were analysed using Rapid Isotyping 
kit-Mouse (Pierce). The test is composed of two cassettes for each sample. The 
supernatants were tested following the manufacturer instructions. Each supernatant 
was diluted 1:100 in Sample Diluent provided with the kit. After mixing, the sample 
was loaded in the cassette, and this was incubated at room temperature. After 10 
minutes, the cassette was visually checked for presence of coloured bands. The 
isotype was identified by the pattern of coloured bands that appeared at specific 
locations in the kit. Each location identifies one isotype as indicated by the 
manufacturer. Additionally, the device produced two positive control bands that 
indicated the validity of the result. Tests that did not produce the positive control 
bands were discarded. Bands that appeared in the cassette after the 10 minutes 
incubation time were not considered. 
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2.3 Dialysis of the proteins 
Dialysis was carried out overnight at 4 °C using Slide-A-Lyzer Dialysis Cassette 
(7kDa MWCO) (Pierce) according to manufacturer’s instructions. The exchanged 
buffer was 1xPBS (pH 7.4). First the dialysis membrane was immerged in 500 ml 
buffer for approximately 2 hours at +4 °C. Then, the PBS solution was replaced with 
1 L of new PBS and incubated overnight at +4 °C. The buffer was kept in constant 
stirring during the procedure.  
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2.4 Production and purification of the anti-
6xHis antibody, clone 4D11 
 
 
Mouse monoclonal antibody, 4D11 anti-mouse (IgG2a), recognises N- and C- 
terminal HHHHHHGS (6xHis) epitopes encoded by the polylinker of several 
expression vectors ((Robson et al., 1995). In order to generate large quantities of 
purified anti-6xHis monoclonal antibody, murine 4D11 hybridoma cells were acquired 
(a gift from A. Crisanti) and cultured. 
4D11 hybridoma B cells were cultured in IMDM (Invitrogen) containing 10% Foetal 
Calf Serum (FCS) at 37 °C, 5% CO2. 500 ml of medium were supplemented with 5 
ml Penicillin (5000 units/ml)/streptomycin (5000 ?g/ml solution, 5ml of L-glutamine 
(200mM), 5 ml of MEM non-essential amino acid solution (1x), 5 ml Sodium Pyruvate 
(100 mM) and 5 ml of MEM vitamins solution (1x) Invitrogen. To maintain cell lines, 
the cells were split when attached cells reached confluence. 
To purify the 4D11, a protein A column (HiTRAP rProtein A FF 5 ml Column) (GE 
Healthcare) was employed. In preparation for purification, tissue cultures were grown 
past confluence and culture supernatant was harvested when hybridoma cell death 
was observed. Cell debris was removed by centrifugation at 1,000 x g for 10 min and 
the decanted supernatant buffered with 50 mM Tris-HCl, pH 8.0. Antibody was then 
filtered (0.22 µm) under sterile conditions and applied to the column. Following an 
equilibration step with binding buffer (50 mM Tris-HCl, pH 8.0), antibody was eluted 
by addition of 100 mM glycine, pH 3.0 to the column.  Eluted fractions were collected 
in 1/20 volume 1M Tris-HCl, pH 9.0, placed immediately on ice and checked for the 
presence of antibody by A 280 absorbance. Fractions containing eluted antibody 
were pooled and dialysed against 1L of PBS. Dialysis was carried out with the 
procedure described in 2.3. Purified antibody was filtered (0.22 µm) under sterile 
conditions and the concentration of purified antibody was determined by A 280 
absorbance. 
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2.5 Purification of the antibodies 4A11, 2B4, 
3F6 and 21H8 
 
 
 
 
Hybridoma supernatants were received from the UNIPG and stored at +4 °C until the 
purification procedure started. Protein chromatographic columns (Pierce) were 
purchased on the base of their affinity for isotype of the antibody. The column was 
connected to a AKTA peristaltic pump (Pharmacia). 
The columns were equilibrated with binding buffer. The sample was diluted 1:1 with 
binding buffer and then it was applied to the column at the flow rate indicated by the 
manufacturer (typically 1-2 ml/min). The column was washed with binding buffer with 
a volume corresponding to 5 to 10 column volumes. Afterwards, elution buffer was 
applied through the column at the flow rate indicated by the manufacturer and the 
eluted fractions were collected in 1M Tris-HCl (pH 9.0) and placed in ice.   
For the purification of 4A11 chromatography cartridge Protein A (Pierce) was utilized. 
The binding and the elution buffer were constituted of 100 mM sodium phosphate, 
150 mM sodium chloride (pH 7.2), and 0.1 M glycine, pH 2.5 respectively. 
For the purification of 2B4 chromatography cartridge Protein G (Pierce) was utilized. 
The binding buffer was constituted of 50 mM sodium acetate (pH 5.0) and 0.1 M 
glycine, (pH 2.4), respectively. 
For the purification of 3F6 chromatography cartridge Protein L (Pierce) was utilized. 
The binding and the elution buffers were constituted of 100 mM sodium phosphate, 
150 mM sodium chloride (pH 7.2), and 0.1 M glycine (pH 2-3), respectively. 
For the purification of the 21H8, HiTrap IgM Purification HP, 1ml, from GE healthcare 
was utilized. The binding buffer and the elution buffer were constituted of 20 mM 
sodium phosphate, 0.8 M (NH4)2SO4 (pH 7.5) and 20 mM sodium phosphate (pH 
7.5) respectively.  
After the elution step, the presence of the antibody was checked by A 280 
absorbance. The fractions that gave absorbance higher than 0.5 were pooled 
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together and dialysed overnight as described in paragraph 2.3. Concentration of the 
purified antibody was again determined by A 280 absorbance reading.  
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2.6 Protein modifications applied to the 
antibodies 
 
 
 
Protein modifications protocols were carried out using the following three protein-
conjugation protocols. 
Alexa 555 labelling. 4D11 antibody was labelled with Alexa 555 using Alexa Fluor 
555 protein labelling kit (Promega). 
Direct HRP conjugation. 4D11 antibody was conjugated with HRP using a 
commercial kit purchased from Serotec (Lynx Rapid HRP antibody conjugation), and 
the instructions were followed for the conjugation of approximately 400 #g of the 
antibody.  
Biotin-conjugation. EZ-Link Sulfo-NHS-LC-LC-Biotin (Pierce) was utilised in the 
biotin-conjugation procedures. The instructions were followed for the conjugation of 
approximately 500 µg of antibody. The protein was incubated with the biotin reagent 
at 15 biotin:antibody molar excess. The incubation was carried out for 3 hours in ice.  
After the three protocols were accomplished, the antibody was dialysed against PBS 
as described in 2.3. 
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2.7 Generation of the microarrays  
 
 
 
Microarrays were generated by automated deposition of 1.25 nl of protein solution, 
arrayed in a “n x n” matrix, in discrete spots with an approximate diameter of 300 µm, 
separated by a pitch of 600 #m. Antibodies were diluted in 30 #l final volume of 
borate (pH 9.4), PBS (pH 7.4), glycine (pH 2.4), or glycerol (2.5%, v/v, in water), as 
specified in the thesis in the presence of Tween 20 (0.02% (v/v) final concentration). 
Samples were loaded into 384-well plates and microarrays were printed onto 
aldheyde-activated glass microscope slides (Cell associates) using (Nano-Plotter 
NP2.1, GeSim). In order to minimize carry over effects, the printing was performed 
beginning from the lowest dilutions towards the highest ones, with the negative 
controls (i.e. the spotting solution without the antibody, BSA solutions, or just H20) 
printed first. Between the spotting of each component, the piezoelectric tip was 
automatically washed with Ultra-Pure water. Different types of microarray were 
generated by arraying solutions in different patterns. Printed slides were always 
stored overnight inside the printing cabinet and were then removed for storage in the 
dark in boxes containing silica bags. 
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2.8 Generation of a ‘universal buffer’ 
(Teorell & Stenhagen) 
 
 
 
A multi-component buffer system was prepared according to the Teorell-Stenhagen 
recipe (Bisswanger Hans, 2012). The buffer, referred to as ‘Universal buffer’, is 
composed of citric acid, phosphoric acid, boric acid, and NaOH. The citric acid 
solution, 100 ml 0.33 M, was prepared by solubilising 7 g in 100 ml ddH2O, while for 
the phosphoric acid, 100 ml 0.33 M, 2.2 ml (85% stock) were mixed in 100 ml 
ddH2O. 3.54 g of boric acid were solubilised in 343 ml of 1N NaOH. The three 
components were then mixed and brought to a final volume of 900 ml with ddH2O. 
The solution was then divided in 90 ml aliquots, and these were brought to the 
desired pH value. The volume was finally adjusted at 100 ml with ddH2O.  
The universal buffer was then implemented with BSA (20% w/v) before being used in 
the experiments.  The BSA-implemented buffer is referred to as ‘NP diluent’ in this 
thesis. 
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2.9 Processing of microarrays generated 
with the nucleoproteins 
 
 
 
Prior to processing, printed slides were incubated in a blocking solution (1xPBS 
containing 2% BSA (w/v) and 0.01% (v/v) Tween 20) for 1 hour at room temperature 
to block non-specific binding to the activated slide surface. After blocking, the slides 
were rinsed for 3 minutes with 1xPBS containing 0.01% (v/v) Tween 20. This buffer 
mix is referred to as ‘rinse buffer’. 
Arrays generated with nucleoproteins were processed with two alternative protocols. 
- Non amplified protocol. The arrays were incubated for 30 minutes with the anti-
NP antibody at the concentration of 20 µg/ml. The dilution was achieved diluted in 
2xPBS, containing 0.01% (v/v) Tween 20 and 2% (w/v) BSA. This buffer mix is 
referred to in the text as ‘antibody diluent’.  After a 3 minute wash, the arrays were 
incubated for 15 minutes with anti-mouse IgG Alexa-546 conjugated antibody 
(Invitrogen). As an alternative to these two antibodies, the microarray was incubated 
for 15 minutes with an Alexa-555 conjugated anti-6xHis tag (clone 4D11) at a final 
concentration of 20 µg/ml. Each slide underwent two final 3 minute washes with rinse 
buffer and was then dried at 37 °C for 20 minutes. 
- Amplified protocol. The arrays were incubated for 20 minutes with the anti-NP 
antibody at the concentration of 20 µg/ml. The dilution was achieved in antibody 
diluent as described above. After a 3 minutes wash, the arrays were incubated for 10 
minutes with HRP-conjugated anti-mouse immunoglobulin antibody (Dako). 
Following a second 3 minutes wash, fluorescent substrates for the HRP (TSA kit, 
Invitrogen) were added for 5 minutes. Each slide underwent two final 3 minute 
washes with rinse buffer and was then dried in at 37 °C for 20 minutes.   
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2.10 Processing of microarrays generated 
with the antibodies 
 
 
 
Prior to processing, printed slides were incubated in a blocking solution (1xPBS 
containing 2% BSA (w/v) and 0.01% (v/v) Tween 20) for 1 hour at room temperature 
to block non-specific binding to the activated slide surface. After blocking, the slides 
were rinsed for 3 minutes with 1xPBS containing 0.01% (v/v) Tween 20. 
The subsequent processing protocol depended on the specific aim of the experiment 
and was developed and improved during the project. Three experimental 
configurations can be classified. 
Protocol 1 (Fig 2.2 A). Microarrays were incubated with 10 #g/ml of 6xHis-tagged 
nucleoproteins diluted in the NP diluent defined in 2.8 (adjusted to pH 2, 3, 4, 5, 6, 7, 
8, 9, 10, 11, and 12), with 0.01% (v/v) Tween 20 and 2% (w/v) BSA. After 30 minutes 
of incubation each array underwent a second 3 minute wash with the rinse buffer 
and was then incubated for 10 minutes with 17 #g/ml 4D11-Alexa 555 antibody 
diluted in the antibody diluent defined in paragraph 2.9. Slides then underwent one 
last 3 minute wash and were dried in at 37 °C for 20 minutes. 
Protocol 2 (Fig. 2.2 B). Microarrays were incubated with 10 #g/ml of 6xHis-tagged 
nucleoproteins as indicated in the text, diluted in NP diluent. After 20 minutes of 
incubation each array underwent a 3 minute wash with the rinse buffer and was then 
incubated for 10 minutes with 17 #g/ml 4D11-HRP diluted in the antibody diluent. 
After a third 3 minutes washing step, Alexa-555 Tyramide (TSA kit, Invitrogen) was 
diluted 1:200 in Amplification Buffer containing 0.0015% H202 was incubated on the 
array for 15 minutes. The slides were washed twice for 3 minutes each and were 
dried at 37 °C for 20 minutes. 
Protocol 3 (Fig. 2.2 C). Microarrays were incubated with the 6xHis-tagged NPA or 
NPB diluted in the NP diluent adjusted at pH 4 or pH 8 as indicated in the text. After 
10 minutes of incubation at room temperature, each array was washed for 3 minutes 
with rinse buffer and was then was incubated with 20 #g/ml biotin-4D11 antibody 
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diluted in the antibody diluent. After 5 minutes incubation the slides were washed for 
3 minutes and then incubated for 5 minutes with 2 #g/ml streptavidin-HRP. Slides 
were again washed for 3 minutes, then incubated for 5 minutes with Alexa-555 
Tyramide diluted 1:50 in Amplification Buffer containing 0.0015% H202, (TSA kit, 
Invitrogen). 
Protocol 4. To develop sandwich immunoassays with the biotin-conjugates of 4A11, 
2B4 and C01321M, the same scheme as for protocol 3 was used, but the incubation 
times were modified. Microarrays of antibodies were incubated with different 
concentrations of NPs diluted in NP diluent at pH 8. After 20 minutes incubation at 
room temperature, each array was washed for 3 minutes and was then incubated for 
5 minutes with 10 #g/ml biotinilated antibody (biotin-4A11, biotin-C01323M or biotin-
2B4) prepared in antibody diluent. Following a second 3 minutes wash, slides were 
incubated for 5 minutes with 2 #g/ml streptavidin-HRP. Slides were again washed for 
3 minutes, then incubated for 5 minutes with Alexa-555 Tyramide diluted 1:200 in 
Amplification Buffer containing 0.0015% H202, (TSA kit, Invitrogen). 
Protocol 5. To test the viral samples, the same scheme as for protocol 3 was used, 
but the incubation times were modified. Microarrays of antibodies were incubated 
with different dilutions of the virus. The dilutions were achieved with NP diluent (pH 
8). Alternatively, and where indicated in the text, the dilution was achieved using the 
dilution buffer contained in the commercial test Directigen EZ Flu A/B (BD). The 
arrays were incubated for 40 minutes at room temperature. Each array was washed 
for 3 minutes and was then incubated for 5 minutes with 10 #g/ml biotinilated 
antibody (biotin-4A11, biotin-C01323M or biotin-2B4 indicated along the text).  
Following a second 3 minutes wash, slides were incubated for 10 minutes with 2 
#g/ml streptavidin-HRP. Slides were again washed for 3 minutes, then incubated for 
10 minutes with Alexa-555 Tyramide diluted 1:200 in Amplification Buffer containing 
0.0015% H202, (TSA kit, Invitrogen). 
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Figure 2.3. Scheme of the assay configurations used in the project. 
Three protocols were employed with different types of detector antibody. One used the Alexa 555-
conjugated detector (a). The second used the HRP-conjugated detector antibody along with 
fluorescent tyramide (b). The third used the biotin-conjugated detector antibodies along with a 
Streptavidin-HRP reagent and fluorescent tyramide (c) 
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3 Results 
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3.1 Overview of the experimental activity 
 
 
 
During the course of this PhD a microarray immunoassay was studied to detect 
human and avian influenza viruses.  
The first phase of the study focused on the proof-of-principle demonstration that 
influenza nucleoproteins (NPs) can be detected using an antibody microarray 
platform. Essential components of the microarray were the monoclonal antibodies, 
developed at UNIPG (Italy) as part of the European collaboration, or purchased from 
commercial sources. The UNIPG antibodies were purified and then characterised for 
their immunogenic properties before being employed in the microarray. Using these 
reagents, experiments were carried out to investigate two alternative immunoassay 
formats, the competitive immunoassay, and the non-competitive (‘sandwich’) set up.  
In the second phase of the study, the performance of the assay was tested using a 
panel of viral samples provided by the HPA, ISS and the UNIBO. This validation 
phase included a preliminary comparison of the analytical power of the microarray 
assay against the performance of Rapid Influenza Diagnostic Tests available on the 
market. 
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3.2 Selection and Characterization of the 
monoclonal antibodies 
 
 
 
3.2.1 Isotype determination of the hybridoma supernatants 
 
The isotype analysis of hybridoma supernatants containing the antibodies 4A11, 
5D12, 7G11, 11B11 and 21H8 was conducted using a commercial isotyping kit, as 
described in paragraph 2.2.4.  
Figure 3.1 shows an illustrative example, the isotype determination of antibody 4A11. 
The photo was taken at the end of the incubation time indicated by the manufacturer. 
Two bands corresponding to the positive controls were apparent. Additionally, two 
isotype bands were observed. One corresponded to isotype IgG2a, and the second 
indicated an isotype IgG3. The band localised at the location indicating IgG2a was 
darker than the band at the IgG3 location. Also, the band indicating the IgG2a 
appeared earlier during the test. No band was visualised in the positions indicating 
the other isotypes. Based on this banding pattern, 4A11 was classified isotype IgG2a.  
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Figure 3.1. Isotype determination of antibody 4A11.  
Each isotyping experiment is performed in a kit composed of two plastic cassettes. Inside each 
cassette sits a membrane that is embedded with isotype-specific reagents located in positions 
indicated by the manufacturer. Two positive control bands are clearly visible on the top position in 
each cassette, thereby indicating proper handling of the test. Additionally, one band corresponding to 
isotype IgG2a, was clearly visible, as illustrated in the cassette on the right-hand side. Also, one band 
corresponding to isotype IgG3 was visible, as illustrated in the cassette to the left. This latter band was 
very light and it was observed later in the test, at the end of the testing time indicated by the 
manufacturer (10 minutes).  
 
The same procedure was followed for the supernatants of the other antibodies. 
Clones 5D12, 11B11, and 21H8 were identified as IgM isotype. Clone 7D12, 
produced two bands in correspondence of the IgM and IgG3 isotype locations. The 
two bands were of similar intensity and they appeared in the kit at the same time. 
The isotype for 7D12 therefore could not be identified with certainty.  
The results were compared with the analysis performed by PX’ on the same 
supernatants using a different, ELISA-based, kit. A good correlation was observed 
with the results obtained at Imperial College, as shown in table 3.1. Antibody 4A11 
was indicated by PX’ as isotype IgG2a. The other candidates were reported as IgMs.  
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Antibody 
Isotype determination 
(Imperial College) 
Isotype determination 
(Protein Therapeutics) 
4A11 IgG2a IgG2a 
5D12 IgM IgM 
7G11 IgM/IgG3 IgM 
11B11 IgM IgM 
21H8 IgM IgM 
Table 3.1. Isotype determination of the monoclonal antibodies developed at UNIPG. Five 
monoclonal antibodies are listed in the left column. The central column indicates the isotypes 
determined at Imperial College. These were compared with the results determined by PX’, listed in 
the right-hand column. The results obtained at Imperial College agree with the isotype analysis 
performed by PX’. The analysis conducted at Imperial College obtained one unclear result, for 
antibody 7G11, as two isotypes were indicated for this antibody. The analysis performed at Protein 
Therapeutics indicated 7G11 was an IgM. 
 
3.2.2 Purification of the monoclonal antibodies 
 
Antibodies 4D11 (gift from Professor Crisanti), 4A11, 2B4, 21H8, and 3F6 (UNIPG) 
were purified, and the quality of the purified product carefully evaluated.  
The quality of the purification was analysed with SDS-PAGE in reducing conditions 
as described in paragraph 2.2.1. The results were visualised by staining the 
polyacrilamide gel with Coomassie dye as described in paragraph 2.2.2. When 
indicated, the proteins were electroblotted onto nitrocellulose membrane and probed 
with isotype-specific reagents as described in paragraph 2.2.3.  
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3.2.2.1 Purification of the IgG2a 4D11 
 
The 4D11 antibody was purified using the HighTrap Protein A FF column following 
the procedure described in paragraph 2.4. 
Purified 4D11 was tested by SDS-PAGE and produced two bands (Figure 3.2): one 
at about 50 kDa, and the other at about 25 kDa. These two bands correspond to the 
expected bands indicating the heavy and the light chain of the IgG antibodies, 
respectively. No different sized bands were visualized in the lane, thus indicating 
absence of degradation products and a good quality of the purification. One other 
IgG antibody was run as positive control in the gel and produced two bands of the 
same molecular weights as the 4D11.  
 
 
Figure 3.2. SDS-PAGE evaluation of the purified 4D11 antibody.  
The 4D11 antibody was run on a polyacrylamide gel alongside with a second IgG antibody. 
Equivalent amounts of the two antibodies were loaded. The proteins were visualised with Coomassie 
staining. The molecular size of the bands was determined by comparing them to the bands visualised 
in the marker lane. The numbers indicated on the left side of the gel indicate the molecular size 
(expressed in kDa) for each of the marker bands. Antibody 4D11 segregated in two bands. One 
migrated at 25 kDa, and the other at 50 kDa. The banding pattern of the 4D11 was identical to that of 
the positive control IgG. No other bands were observed. 
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3.2.2.2 Purification of the IgG2a 4A11 
 
The 4A11 antibody was purified using a protein A packed column following the 
procedure described in paragraph 2.5. 
The SDS-PAGE evaluation indicated a good quality of the purification. As shown in 
figure 3.3, the purified 4A11 separated in two bands: one at about 50 kDa (the heavy 
chain of the IgG), and the other at about 25 kDa, (the light chain). No other bands 
were visualised along the lane, thus indicating a good quality of the purification and 
absence of degradation products. One other IgG antibody was run as positive 
controls in the gel and produced an identical banding pattern. 
 
 
Figure 3.3. SDS-PAGE evaluation of the purified 4A11 antibody.  
The 4A11 antibody was run on a polyacrylamide gel alongside with an equivalent amount of a second 
IgG antibody. The gel was then stained with the Coomassie protocol. The molecular size of the bands 
was determined by comparing them to the bands visualised in the marker lane. The numbers 
indicated on the left side of the gel indicate the molecular size (expressed in kDa) for each of the 
marker bands. Antibody 4A11 segregated in two bands, one sized 25 kDa, and the other sized 50 
kDa. The banding pattern of the 4A11 was identical to that of the positive control IgG. No other bands 
were visualised on the two lanes. 
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3.2.2.3 Purification of the IgM 21H8 
 
Antibody 21H8 was purified using a chromatography column packed with 2-
mercaptopyridine following the method described in paragraph 2.5.  
When analysed by SDS-PAGE (figure 3.4, panel A), 21H8 separated in three bands 
that migrated at approximately 25, 50, and 75 kDa. While the bands sized 25 and 75 
kDa correspond to the light and the heavy chain of the the IgM antibodies, 
respectively, the origin of the intermediate sized band was unclear. 
The supernatant and the flow through produced two intense bands at around 60 kDa 
as well as a banding patter migrating 10 kDa higher and 10 kDa lower. Additionally, 
two small bands were observed in both lanes at approximately 100 kDa and 25 kDa. 
One post-elution fraction produced a banding pattern very similar to that of the 
purified 21H8, with two bands at 25 and 75 kDa. However, no other band was 
observed along the lane. 
One lane loaded with the IgG control antibody (purified 4D11) produced the typical 
banding pattern of an IgG, instead the lane loaded with BSA indicated protein 
migration at approximately 60 and 100 kDa.  
The proteins where electroblotted and revealed with the HRP-conjugated anti-IgM 
antibody following the protocol described in paragraph 2.2.3. The anti-IgM revealed 
two main bands along the purified 21H8-lane, at the molecular size of 50 and 70-80 
kDa. Additionally, one band was revealed at 25 kDa and two bands localised at 
approximately 200 kDa. No bands were revealed along the lane loaded with the 
4D11 antibody and with the BSA. 
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Figure 3.4. SDS-PAGE and Western-blot evaluation of the purification the antibody 21H8.  
The banding pattern of purified 21H8 was analysed by SDS-PAGE separation followed by Coomassie 
staining of the gel (a) and by western-blot analysis using an anti-IgM antibody (b). The molecular size 
of the bands was determined by comparing them to the bands visualised in the marker lane, 
indicating the molecular sizes (in kDa).  The banding pattern of 21H8, as seen on the gel includes two 
bands at approximately 25 kDa and 75-80 kDa, corresponding to the light and the heavy chains of the 
IgM isotype, and a third band sized 50 kDa is visible in the 21H8 lane. These three bands are 
recognised by the anti-IgM antibody utilised to develop the western-blot experiment, thus indicating 
they are components of the purified 21H8 antibody.  
 
 
3.2.2.4 Purification of the IgG2a 2B4 
 
Antibody 2B4 (isotype determination carried out at UNIPG) was purified using the 
protein G purification method as described in section 2.5.  
When evaluated by SDS-PAGE (figure 3.5, panel A), 2B4 produced the typical 
banding pattern of an IgG antibody, with two bands migrating at 25 and 50 kDa. One 
third band was noted at approximately 150 kDa, that corresponds to the size of an 
IgG fraction whose chains didn’t separate properly during the SDS-PAGE run. No 
other bands were seen on the lane, thus indicating absence of degradation products 
and overall good quality of the purification.  
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The banding pattern observed for 2B4 was similar to that generated by the IgG 
positive control (antibody 4D11), however bands in the control lane resulted weaker.  
In the lanes loaded with the supernatant and the flow-through protein accumulation 
was observed between 50 and 70 kDa, and additional bands were observed above 
100 kDa. 
The western-blot analysis (figure 3.5, panel B) was conducted with anti-mouse IgG 
HRP (Dako) as described in paragraph 2.2.3. The analysis confirmed the presence 
of the IgG antibody in the purified preparation, and no other bands were produced by 
2B4, thus confirming good quality of the purification. The same banding pattern was 
revealed in the post-elution fraction. 
 
 
Figure 3.5. SDS-PAGE and Western-blot evaluation of the purified of 2B4 antibody.  
The banding pattern of purified 2B4 was analysed by SDS-PAGE separation followed by Coomassie 
staining of the gel (a). The separation of the bands in the 2B4-lane indicate the typical banding pattern 
of a pure IgG anitbody, with the light chain migrating at 25 kDa and the heavy chain migrating at 50 
kDa. One additional band is visible at aorund 150 kDa, and probably indicates a fraction of 2B4 did 
not separated properly during the run. The banding pattern is very similar to that of the 4D11 IgG, 
used as positive control in this experiment. In the western-blot analysis (b) an HRP-conjugated anti-
mouse antibody revels the light and the heavy chain of the 2B4. No other band is visualised in the 
2B4-lane, thus confirming good quality of the purification. 
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3.2.2.5 Purification of the IgA 3F6 
 
Antibody 3F6 (Isotype determination carried out at HPA) was purified using the 
protein L purification method as described in paragraph 2.5. The banding produced 
by the SDS-PAGE separation is illustrated in figure 3.6. 
The lanes corresponding to the supernatant and the flow-through produced bands 
between 50 and 60 kDa, as well as fainter bands at approximately 100kDa. The 
supernatant lane then showed one additional band at 20-25 kDa.  
The banding pattern produced by the purified 3F6 included two bands that migrated 
at 25kDa and 50kDa. No bands were visualised in the post-elution fraction. 
Electroblotted proteins were detected with HRP-conjugated anti-IgG antibody (Dako) 
as described in paragraph 2.2.3. In the lane run with purified 3F6 one band was 
produced at 25 kDa corresponding to the light chain of the IgA. No other bands were 
detected in the 3F6 preparation. Also, no bands were revealed inthe post-elution 
fraction, thus indicating that likely all antibody had been purified.  
 
Figure 3.6. SDS-PAGE and Western-blot evaluation of the purified 3F6 antibody.  
The banding pattern of purified 3F6 was analysed by SDS-PAGE separation followed by Coomassie 
staining (a). The molecular size of the bands was identified by comparing them to the bands of the 
molecular marker, whose size is indicated in kDa by the number on the left. The two bands visualised 
at 20-25 kDa and 50 kDa in the lane of the 3F6 represent the light and the heavy chains of the IgA 
antibody. No other bands are visible. The proteins were analysed by Western-blot (b) with an anti-
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mouse antibody (DAKO). This reagent revealed the light chain of the IgA. No other band was 
evidenced in the analysis of 3F6. 
 
 
 
3.2.3 Characterization of the anti-NP reactivity pattern using 
the Western Blot technique 
 
To evaluate the pattern of reactivity against the NPs, nucleoproteins were separated 
by SDS-PAGE as described in paragraph 2.2.1 and electroblotted. The antibodies 
under investigation were then used as probes against the nucleoproteins using the 
protocol described in paragraph 2.2.3. Object of this analysis where the three 
commercial antibodies used in the initial phase of the project, clones 10-I55 
(Serotec), AA5H (Fitzgerald), and MAB8258B (Millipore), and antibodies 4D11 
(Crisanti lab) and 2B4 (from UNIPG).  
The nucleoproteins employed in the experiments described in this section are the 
6xHis-tagged and untagged variants of the human NPA, with an expected migration 
in SDS-PAGE at approximately 57 kDa, the 6xHis-tagged and untagged variants of 
the NPB, with an expected migration at 62 kDa, and the 6xHis-tagged avian NPA, 
with expected migration at 57 kDa. Additionally, the NPB3 (Yamagata line) and the 
NPB4 (Victoria line) were tested. The 6xHis-tagged NPB3 and NPB4 are expected to 
migrate at 63 kDa, the GST-tagged variants have an expected size of 88 kDa. 
 
 
 
 
 
 
 
 
  117 
3.2.3.1 Reactivity of monoclonal antibodies 10-I55G, AA5H, MAB8258B 
and 4D11 against the recombinant nucleoproteins 
 
Antibodies AA5H, 10-I55G, MAB8258B, and 4D11 were tested as probes against the 
human 6xHis-tagged/untagged NPA, the 6xHis-tagged/untagged NPB and the avian 
6xHis-tagged NPA. The proteins were loaded in equal amounts. 
When separated by SDS-PAGE the proteins migrated at the expected molecular size 
(Figure 3.7, panel a). One exception was constituted of the untagged NPB, that 
produced a doublet band in between 55 and 62 kDa. 
When the antibodies were probed against the nucleoproteins, results were observed 
as follows. 
Clone AA5H (an anti-NPA) produced one band at approximately 55 kDa in the lanes 
corresponding to the two tagged/untagged NPAs, and in the lane corresponding to 
the avian NPA. No bands were observed in the lanes containing the NPB (Figure 
3.7, panel b). 
Clone 10-I55G (an anti-NPB) produced a double band at 50-62 kDa in the lane 
loaded with the untagged NPB and one band at 62 kDa in the lane corresponding to 
the 6xHis-tagged NPB (Figure 3.7, panel c). No bands were observed in the lanes 
containing the NPA. 
Clone MAB8258B (an anti-NPA) produced a band at approximately 55 kDa in the 
lanes corresponding to the two human NPAs and in the lane corresponding to the 
avian NPA (Figure 3.7, panel d). No bands were observed in the lanes loaded with 
the NPB. 
4D11 produced one band at 55 kDa in the lanes run with the 6xHis Avian NPA and 
the 6xHis-Human NPA, one main band at 62 kDa in the lane with the 6xHis-tagged 
NPB, and one second band of lesser intensity about 5 kDa below (Figure 3.7, panel 
e). No bands were seen against the untagged NPs. 
In all tests BSA was loaded as a negative control of reactivity and was not detected 
by any of the probes. 
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Figure 3.7. Evaluation of the reactivity of the antibodies AA5H, 10-I55G, MAB8258B, and 4D11 
against the human NPA, NPB and the avian NPA.  
The proteins were loaded in equal amounts on a polyacrilamide gel, separated by SDS-PAGE and 
visualised with Coomassie staining (a). Then, they were electroblotted and probed with the antibodies 
anti-NPA AA5H (b), anti-NPB 10-I55G (c), anti-NPA MAB8258B (d) and anti-6xHis 4D11 (e). The 
antibodies were then revealed using an alkaline phospatase-conjugated anti-mouse IgG. The size of 
the bands was evaluated by comparing them to the bands of the protein marker indicated on the right 
side of the gel and the membranes. 
  119 
The commercial anti-NPB antibody 10-I55G and the anti-6xHis tag antibody 4D11 
were next probed against the nucleoproteins NPB3 and NPB4.  
Equal amounts of the 6xHis-tagged and the GST-tagged NPB3 and NPB4 were 
separated by SDS-PAGE. The banding pattern confirmed with Coomassie staining 
(Figure 3.8, panel a) indicated that the protein preparations were pure, and produced 
the separated at the expected size. 
The proteins were electroblotted and probed with the two antibodies, and these were 
then revealed with an Alkaline Phospatase mouse anti-IgG antibody as described in 
paragraph 2.2.3. Anti-NPB 10-I55G detected both the GST-tagged and the 6xHis-
tagged forms of NPB3 and NPB4 (Figure 3.8, panel b). No other bands were 
produced in the test. Antibody detected the 6xHis-tagged NPB3 and NPB4 (Figure 
3.8, panel c) and showed no reaction against the GST-tagged proteins.  
 
 
Figure 3.8. Evaluation of the reactivity of the antibodies 10-I55G and 4D11 against the NPB3 
and the NPB4.  
The proteins were loaded in equal amounts on a polyacrilamide gel, separated by SDS-PAGE and 
visualised with Coomassie staining (a). Then, they were electroblotted and probed with the antibodies 
anti-NPB 10-I55G (b) and anti-6xHis 4D11 (c). The antibodies were then revealed using an alkaline 
phosphatase-conjugated anti-mouse IgG. The size of the bands was evaluated by comparing them to 
the bands of the protein marker indicated on the left side of each panel. 
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3.2.3.2 Reactivity of monoclonal antibody 2B4 against the recombinant 
nucleoproteins 
 
Antibody 2B4 was tested for its specificity against the human and avian NPA, and 
the NPB4. The proteins were separated on polyacrilamide gel and electroblotted as 
for the previous characterization experiments. Antibody 2B4 showed very good 
specificity for the NPB4, as it produced only one band in the lane loaded with this 
protein (figure 3.9, panel b). No bands were produced against the human and avian 
NPA. One lane loaded with an IgG control antibody produced diffuse 
chemiluminescence, however this didn’t affect the overall results of the experiment. 
 
 
 
 
Figure 3.9. Reactivity of 2B4 antibody against the human/avian NPA and the NPB. 
The proteins were loaded in equal amounts on a polyacrilamide gel, separated by SDS-PAGE and 
visualised with Coomassie staining (a). Then, they were electroblotted and probed with the antibody 
2B4 (b). 2B4 was then revealed using an HRP-conjugated anti-mouse IgG. The size of the bands was 
evaluated by comparing them to the bands of the protein marker loaded on the right side of the gel 
and the membrane. 
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3.2.4 Characterization of the anti-NP reactivity pattern using 
the protein microarray technique 
 
The pattern of anti-NP reactivity was next evaluated with the protein microarray 
technique.  
Protein microarrays were generated as described in paragraph 2.7 by spotting 
different combinations of human and avian A, an B nucleoproteins at the 
concentration of 100 #g/ml (unless specified differently). The arrays were processed 
with the anti-NP antibodies under evaluation following the protocol described in 
paragraph 2.9. The results were evaluated on the base of visual observation of the 
fluorescence on selected spots. 
 
 
 
3.2.4.1 Reactivity of monoclonal antibodies 10-I55G, AA5H, MAB 8258B 
and 4D11 against arrayed nucleoproteins 
Three commercial antibodies, clones AA5H (anti-NPA), 10-I55G (anti-NPB), and 
MAB8258B (anti-avian NPA), along with one aliquot of 4D11 (anti-6xHis tag) labelled 
with fluorophore Alexa-555 were tested against the 6xHis-tagged human and avian 
NPA and against the NPB3 (NPB from the Yamagata line) and NPB4 (NPB from the 
Victoria line). Results are illustrated in figure 3.10. 
Antibody AA5H produced homogenous fluorescence localised on the spots 
generated with the human and avian NPA. Weak fluorescence, very similar in 
intensity to the background fluorescence was observed on the spots generated with 
the nucleoproteins B. 
A very similar pattern of fluorescence was produced by antibody MAB8258B. 
Antibody 10-I55G produced fluorescence on the spots generated with the NPB3 and 
the NPB4. Particularly, the spots containing the NPB4 resulted more reactive than 
those with the NPB3. A weak fluorescence, close to background level was seen on 
the spots containing the human and avian NPA 
Antibody 4D11 reacted with all the arrayed nucleoproteins. The spots generated with 
the NPB4-spots was brighter than that observed on the other spots of the array. 
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The negative control array was processed identically to the other arrays, however 
the antibody diluent (described in paragraph 2.9) replaced the anti-NP antibodies. 
On this array, the signal observed on the spots was close to background level. 
On all slides, the background remained close to zero. 
 
    
 
Figure 3.10. Reactivity of AA5H, MAB8258B and 10-I55G against arrayed nucleoproteins.  
The human NPA, NPB3 (Yamagata line), NPB4 (Victoria line) and the avian NPA were arrayed as 
illustrated in the array scheme (a). The arrays were processed with the antibodies as listed on top of 
each array-image (b). In each array, the NPs are boxed with the same colour as the spots in the array 
scheme.  
 
 
Antibody 4A11 was tested against the 6xHis-tagged and the GST-tagged human 
NPA and the NPB4. The proteins were spotted at the concentration of 100 #g/ml and 
10 #g/ml. Spots with only printing buffer were included in the array as control for non-
specific interactions of the antibodies. The antibodies were incubated on the arrays 
and then revealed with an Alexa-546 anti-mouse IgG. 
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Antibody 4A11 produced saturated (i.e. highest detectable) fluorescence on the 
spots generated with 100 #g/ml of 6xHis-NPB4 and GST-NPB4. Fluorescence 
remained close to background level on all the NPA-spots as well as on the spots 
generated with the printing buffer alone.  
The array processed with the commercial antibody 10-I55G showed a very similar 
pattern of fluorescence. However, it was noted that the fluorescence observed on the 
spots containing the GST-NPB4 was visibly lower as compared to the spots with 
6xHis-NPB4. Fluorescence recorded on all the other spots remained close to 
background level. 
On the negative control-array weak fluorescence was observed on the locations 
generated with the 6xHis-NPB4, and no fluorescence was observed on the rest of 
the array. 
 
 
Figure 3.11. Reactivity of 4A11 and 10-I55G against arrayed nucleoproteins.  
The human NPA and NPB4 were arrayed as illustrated in the array scheme in (a). 6xHis-tagged and 
the GST-tagged nucleoproteins were included in the array, spotted at two different concentrations, 
100 and 10 #g/ml. The arrays were processed with the antibodies as listed on top of each array-
image (b). In each array, the NPs are boxed with the same colour as the spots in the array scheme. 
The 4A11 antibody shows a clear anti-NPB specificity. 
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3.2.4.2 Reactivity of antibodies 2B4 and 3F6 against arrayed 
nucleoproteins 
 
Antibodies 2B4 and 3F6 (supposedly anti-NPB reagents) were tested against the 
6xHis-tagged human NPA and NPB4 spotted in different conditions as illustrated in 
figure 3.12.  
The pattern of fluorescence of antibody 2B4 indicated a marked reactivity against the 
NPB4. No fluorescence was observed on the area of the array containing the NPA-
spots. 
Antibody 3F6 produced very low fluorescence on the spots generated with the 
NPB4, and no fluorescence was observed on the other NPs. 
The fluorescence observed on the two arrays was compared to the fluorescence 
observed on one array that was processed with the 4A11 antibody. The reactivity 
pattern of 2B4 proved very similar to that caused by 4A11, thus indicating a similar 
immunogenicity.  
One negative control array, processed identically to the other arrays but with 
antibody diluent instead of the anti-NP antibodies, produced no specific 
fluorescence.  
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Figure 3.12. Reactivity of 2B4 and 3F6 antibodies against arrayed nucleoproteins.  
The recombinant human NPA and NPB4 (Victoria line) were arrayed as illustrated in the array 
scheme (a). The arrays were generated with different volumes of solution, thereby the different 
diameters of the spots in the image. In row 1 spots are generated with 1.25 nl of spotting solution. 
Rows 2 and 3 are generated with 2.5 and 5 nl of spotting solutions, respectively. The last raw of the 
array contains negative and positive control spots. The arrays were processed with the antibodies as 
listed on top of each array-image (b). In each array, the NPs are boxed with the same colour as the 
spots in the array scheme.  
 
3.2.4.3 Reactivity of antibodies 105 and 109 on microarray 
 
Antibodies 105 and 109 were tested against the 6xHis-tagged human and avian 
NPA, NPB3 and NPB4 spotted at the concentration of 100 #g/ml.  The arrays were 
processed as described in paragraph 2.9.   
Both antibodies 105 and 109 produced fluorescence on the spots generated with the 
human and avian NPAs. They produced no fluorescence on the NPB3 and the 
NPB4; this indicates good specificity for the NPA (Figure 3.13). 
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Figure 3.13. Reactivity of antibodies 105, and109 against arrayed nucleoproteins.  
The human NPA, NPB3, NPB4 and avian NPA were arrayed as illustrated in the array scheme (a). 
Positive control spots are located at the corners of each array. The arrays were processed with the 
antibodies as listed on top of each array-image (b). One array was processed with 4A11 as a control 
for the presence of the NPB3/NPB4. In each array, the NPs are boxed with the same colors as in the 
array scheme.  
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3.3 A competitive microarray immunoassay 
for the detection of the influenza 
nucleoproteins  
 
 
 
3.3.1 Set up of a sandwich immunoassay for the detection of 
the tracer (6xHis-tagged) nucleoproteins 
 
Experiments were carried out to investigate the feasibility of detecting 6xHis-tagged 
nucleoproteins (the ‘tracers’) using an antibody microarray. The aim of the study 
described in this section was to demonstrate: 
a) Appropriate physiochemical conditions for the spotting of the antibodies; 
b) Appropriate physiochemical conditions for the incubation of the tracers on the 
array. 
Anti-NPA AA5H (Serotec) and anti-NPB 10-I55G (Fitzgerald) were arrayed at 
different concentrations in four buffers: glycine (pH 2.4) PBS (pH 7.4), borate (pH 
9.4) and glycerol (2.5% v/v in H20) following the procedure described in paragraph 
2.7. Arrays were incubated with the tracers at the concentration of 10 µg/ml and 
processed with ‘protocol 1’ described in paragraph 2.10. Briefly, the tracers were 
incubated at pH 2, pH 3, pH 4, pH 5, pH 6, pH 7, pH 8, pH 9, pH 10 and pH 12 in the 
‘Universal buffer’ buffer described in paragraph 2.8. The captured proteins were then 
revealed using the Alexa 555-conjugated anti-6xHis tag antibody, clone 4D11.  
Figure 3.14 illustrates the scheme of the processing (panel A) and the scheme of the 
array (panel B). The slides were scanned after the processing, as shown in panel C. 
The fluorescence signal was measured on the spots generated with each spotting 
condition and then divided by the signal recorded from the spots generated with only 
printing buffer. These signal:noise values (S/N) were plotted against the pH values of 
incubation of the nucleoproteins.  
  128 
As shown in the graph in figure 3.14, panel C, the highest S/N ratio for the detection 
of the NPA tracer was obtained when the capture antibodies were printed in borate 
(pH 9.4) and when the tracer was incubated onto the microarray diluted at pH 4. At 
pH values above 5 instead, the S/N ratios tended towards zero. When the capture 
antibody was printed in PBS and glycine, S/N ratios were very low across the whole 
pH range. The spots generated with glycerol resulted in intermediate S/N values 
however, importantly, showed very good, rounded spot morphology.  
The pH 4 also proved to be the best condition for the dilution and incubation of the 
NPB tracer. Indeed, at this pH, both PBS and borate buffers delivered promising S/N 
ratios (Fig 3.15 panels B and C).  
Following the experimental results, it was decided to spot the anti-NPA antibody in 
borate (pH 9.4) and the anti-NPB in PBS (pH 7.4). The spotting buffers were 
implemented with 0.01% (v/v) Tween 20.  
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Figure 3.14. Evaluation of critical parameters for the set up of a microarray immmunoassay for 
the detection of the NPA.  
The physiochemical conditions were tested with the assay format shown in (a). The anti-NPA and 
anti-NPB antibodies were spotted in duplicate at decreasing concentration in printing buffers 
composed of PBS, borate, glycine or glycerol, as shown in (b). Spots containing only printing buffer 
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were also included as controls for the non-specific signal. Spots generated with the same buffer are 
boxed within the same colour. Spots containing 6xHis-tagged proteins at different concentrations 
were included and are indicated in the printing scheme with a ‘+’. These spots are positive controls for 
the interaction of the 4D11 on the slide during the assay. Additionally, spots generated with IgG-Alexa 
555 were included as positive controls of fluorescence. Each array was incubated with 10 #g/ml of 
6xHis-NPA diluted at the pH reported on top of the arrays (c), and the captured NPAs were revealed 
with an Alexa 555-4D11 antibody. S/N values were calculated relatively to the spots generated with 
each spotting condition. For each condition (spotting concentration of the antibody and spotting 
buffer) the fluorescence was measured and averaged across the two replicate spots. This value was 
divided by the fluorescence measured on the replicate spots generated with the corresponding 
spotting buffer alone. These S/N values were plotted across the pH of NP incubation as shown in (d). 
Only the S/N values generated with the highest spotting concentration (1 mg/ml) were quantified. 
These spots are boxed in panel c. 
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Figure 3.15. Evaluation of critical immunoassay parameters for the microarray detection of the 
NPB.  
The immunoassay conditions were tested with the assay format and scheme shown in the previous 
figure (figure 3.14, panels a and b). Each array was incubated with 10 #g/ml of NPB diluted at the pH 
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reported on top of the arrays (a) and then the captured NPBs were detected with Alexa 555-4D11. 
S/N values were calculated for each printing buffer and concentration of antibody as described in the 
previous figure. The S/N values were plotted against the pH of incubation as shown in (b). 
 
 
3.3.2  Assessment of a signal amplification system based on 
the HRP amplification  
 
Next, two different detection strategies were compared for the ability to generate 
specific fluorescent signal: (1) a direct immuno-fluorescence method - Alexa 555-
labelled anti-6xHis antibody (4D11-Alexa 555) and (2) a non-linear amplification 
system - Horseradish Peroxidase (HRP) labelled anti-6xHis antibody (4D11-HRP) in 
conjunction with TSA (Tyramide Signal Amplification) Alexa 555. With the latter, the 
HRP enzyme catalyzes the activation and deposition of a number of highly-reactive 
fluorescent tyramide radicals onto tyrosine residues in the close vicinity of the 
enzyme/antibody, and this can potentially lead to a significant boost in the signal 
generated when compared to a directly labelled antibody, such as 4D11-Alexa 555.  
The Alexa 555 labelling and the HRP conjugation of 4D11 were carried out as 
described in paragraph 2.6. 
To compare the two methods, arrays displaying the anti-NPA AA5H (Serotec) and 
anti-NPB 10-I55G (Fitzgerald), generated as in 2.7, were incubated with the NPB 
tracer at the concentration of 10 µg/ml. Captured tracers were then revealed using 
equal concentrations (20 µg/ml) of the 4D11-Alexa 555 or the 4D11-Alexa 555, 
following ‘protocol 1’ an ‘protocol 2’ described in 2.10. 
Figure 3.16 illustrates the arrays processed with the two protocols. Fluorescence 
was observed on the spots generated with the anti-NPB in both arrays. However, the 
fluorescence observed in the slide processed with the amplified HRP-protocol was 
saturated, whilst the non-amplification protocol produced fluorescence below 
saturation. No fluorescence was observed on the negative control arrays, with any of 
the two 4D11 preparations. The result indicates that, while both methods generate 
specific fluorescence localised to the 4D11 antibody, the HRP-conjugation method 
determines a boost of signal that can be exploited for detection purposes.  
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Figure 3.16. Comparison of the Alexa 555 direct-labelling (4D11-Alexa 555) with the HRP-based 
protocol (4D11-HRP). 
Anti-NPA and anti-NPB antibodies were arrayed as shown in (a). The 6xHis-NPB was incubated on 
the array and then revealed with the 4D11-Alexa 555 and the 4D11-HRP alternatively (b). For each 
test, a negative control array was processed with the same protocol, but without the tracer. The NP 
diluent was incubated instead. The four corner spots, containing Alexa 555-IgG antibodies are 
positive controls for the fluorescence. 
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3.3.3  Evaluation of the competition effect on a microarray 
Using the optimized conditions for antibody spotting and for antigen incubation, as 
well as the HRP amplified detection protocol, a preliminary evaluation of the principle 
of the tracer/antigen competition was carried out. The aim of this phase of the study 
was to investigate whether a competition-based assay was feasible, and to evaluate 
what concentration of untagged nucleoproteins could be detected.  
Identical microarrays constructed with the anti-NPA (AA5H) and anti-NPB (10-I55G) 
antibodies were processed using ‘protocol 2’ described in 2.10. Briefly, the 
microarrays were incubated with 10 #g/ml 6xHis-tagged NPA and NPB tracer 
alternatively, and different concentrations of untagged nucleoproteins were co-
incubated with the tracer. Three different concentrations of untagged nucleoprotein 
were tested (1 #g/ml, 10 #g/ml, and 100 #g/ml), and one control slide, in which no 
untagged nucleoprotein was added, was processed in parallel. Captured tracers 
were then revealed with the 4D11-HRP antibody. 
Results obtained with NPA (figure 3.17), indicated that the co-incubation of the tracer 
and the antigen resulted in an effective competition for the capture sites. The 
addition of increasing concentration of untagged nucleoprotein caused a decrease of 
the signal generated on the anti-NPA spots.  A similar outcome was observed for the 
NPB completion assay. The anti-NPB array showed a drop in the signal, when the 
tagged/untagged NPBs were co-incubated (Figure 3.18). However, it was noted that 
a significant signal drop was measured only when 100 #g/ml of competitor were 
added.  
A quantitative analysis of the arrays confirmed the visual result. For the analysis, in 
the case of NPA, the mean signal collected from the anti-NPA spots was calculated 
and then divided by the mean of the blank spots printed with the spotting buffer. The 
same procedure was used for the anti-NPB. Values were then plotted against the 
concentration of competitor (untagged) antigen as shown in the graphs in Figure 
3.17 and 3.18 (panels d). 
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Figure 3.17. Detection of the NPA with a competitive-format assay.  
The principle of the competition was tested with the experimental format scheme presented in panel 
(a). Microarrays were generated with anti-NPA antibodies and then processed with 10 µg/ml 6xHis-
tagged nucleoprotein A (tracer) either alone or mixed with 1, 10, or 100µg/ml untagged NPA. 
Captured tracers were then revealed with the 4D11-HRP. Results shown in panel (b) indicated 
striking competition of the untagged NPA against the tracers. A scheme of the array is presented in 
panel (c). The signals measured on the six anti-NP spots were averaged and then divided by the 
mean signal measured on the spots generated with the printing buffer alone. These S/N values were 
then plotted against the concentration of competitor to generate a competition curve (shown in panel 
d). 
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Figure 3.18. Detection of the NPB with a competitive-format assay.  
The principle of the competition was tested with the same scheme as shown in previous figure (3.17, 
panel a). Microarrays were generated with an anti-NPAB antibody and then processed with 10 µg/ml 
6xHis-tagged nucleoprotein B (tracer) either alone or mixed with 1, 10, or 100 µg/ml untagged NPB. 
Captured tracers were then revealed with the 4D11-HRP. Results shown in panel (a) indicated clear 
competition of the untagged NPB against the tracers. A scheme of the array is presented in panel (b). 
The signals measured on the six anti-NP spots were averaged and then divided by the mean signal 
measured on the spots generated with the printing buffer alone. These S/N values were then plotted 
against the concentration of competitor to generate a competition curve (panel c). 
 
 
The competition immunoassay was evaluated further in a second round of 
experiments aimed at generating a curve containing more concentration points. For 
these experiments, the B nucleoprotein representative of the Victoria viral line 
(NPB4) was used along with the GST-tagged form of the nucleoprotein as competitor 
against the corresponding 6xHis-tagged tracer nucleoprotein. Figure 3.19 (panel b) 
shows the results obtained when the arrays were co-incubated with 10 #g/ml of 
tracer (6xHis-tagged NPB4) along with increasing concentrations of GST-competitor 
(GST-tagged NPB4). The captured tracers were then revealed with the 4D11-HRP 
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with the protocol described in paragraph 2.10 (‘protocol 2’). While the observed trend 
was not very regular, competition was again observed with registered signals 
dropping most quickly when between 50 and 75 #g/ml of competitor was added. 
However, no significant difference in the fluorescence level was observed between 
lower concentrations of competitor (i.e. 1 and 10 #g/ml).   
A normalisation of the fluorescent signal was calculated by subtracting the 
fluorescence signal averaged across the spots printed with printing buffer alone. The 
quantification of the competition effect confirmed the result concluded with the visual 
observation.  
 
 
Figure 3.19. Detection of the NPB4 (Victoria line) with a competitive-format assay using GST-
tagged proteins as competitors.  
The principle of the competition was re-evaluated using the GST-tagged nucleoprotein B. The 
experimental scheme is the same illustrated in figure 3.17. Microarrays were generated with an anti-
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NPAB antibody as shown in panel (a) and then processed with 10 µg/ml 6xHis-tagged NPB4 (tracer) 
either alone or mixed with 1, 5, 10, 25, 50, 75 or 100 µg/ml of GST-tagged NPB4. Captured tracers 
were then revealed with the 4D11-HRP. Results shown in panel (b) indicated a signal drop when 
GST-tagged NPB was added at the concentration of 25-50 µg/ml, and an even more dramatic drop 
when 75 µg/ml were added. The signals measured on the six anti-NPB spots were averaged and then 
they were normalized by subtracting the mean signal measured on the spots generated with the 
printing buffer alone (indicated as ‘noise’). These S-N values were then plotted against the 
concentration of competitor to generate a competition curve (panel c). 
 
 
3.3.4 A new signal amplification system based on the biotin-
streptavidin affinity  
 
An alternative strategy to exploit the HRP amplification was investigated next. In this 
case, the 4D11 antibody was conjugated to biotin and employed along with a 
streptavidin-HRP reagent (Pierce) to generate signal. A biotin conjugation of the 
4D11 was performed with EZ-Link Sulfo-NHS-LC-LC-Biotin as described in 
paragraph 2.6 and, after dialysis overnight, the biotinilated conjugate was tested. 
Arrays displaying 6xHis- and GST-tagged NPA were sequentially incubated with the 
biotinilated 4D11 and a streptavidin-HRP reagent (Pierce, High Sensitivity 
Streptavidin-HRP) . Although a weak fluorescence was visualised on the non-spotted 
surface of the array, and non-specific fluorescence of the same level was also 
observed on the some of the spots generated with the GST-tagged NPA, the pattern 
of fluorescence indicates the biotin-conjugated 4D11 retains its 6xHis tag specificity 
(Figure 3.20). The background fluorescence could be caused by either a suboptimal 
washing step or by a suboptimal blocking step. Strong fluorescence instead was 
emitted from the spots containing the 6xHis-NPA, as expected.  
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Figure 3.20. Biotinilation of 4D11 antibody.  
6xHis-tagged and GST-tagged NPAs were arrayed as show in (a). The proteins were detected with 
the biotin-4D11 and then with a streptavidin-HRP reagent to evaluate the reactivity pattern of the 
conjugate.  Panel (b) indicates tha the 4D11-biotin reacts with the spots containing the 6xHis-NPA 
spotted at 100 #g/ml (boxed in red). Lower fluorescence is recorded from the spots containing the 
same protein at the concentration of 10 #g/ml. The negative control array was processed with only 
streptavidin-HRP and HRP substrates in order to evaluate potential non-specific signal derived from 
the streptavidn-HRP reagent. The streptavidin-HRP instead, proved a very specific reagent. 
 
 
 
Subsequent work focused on evaluating the feasibility of employing the biotin-
streptavidin protocol to detect the tracer nucleoprotein in a sandwich immunoassay. 
Arrays were generated as described in 2.7 with commercial anti-NPA and anti-NPB 
antibodies, and then processed following the protocol described in 2.10 (protocol 3). 
Briefly, the arrays were processed with the serial addition of the 6xHis-tagged NPA, 
the biotinilated 4D11, streptavidin-HRP reagent and the fluorescent HRP substrates. 
Identical arrays were processed following the 4D11-HRP based procedure (protocol 
2 in 2.10). The two protocols were compared in the detection of the 6xHis-tagged 
NPA incubated at two concentrations, 10 #g/ml and 1#g/ml.  
As shown in figure 3.21, the protocol exploiting the biotin-4D11 generated higher 
specific fluorescence as compared to that generated by the 4D11-HRP. It was 
observed that two slides processed with the biotin-4D11 showed diffused 
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fluorescence on the non-spotted area. This high background however was 
occasional, and likely due to a non-optimal washing or blocking step of the slide. The 
pattern of fluorescence clearly demonstrated that the biotin-4D11 not only retained 
its capacity to specifically bind the 6xHis tagged proteins, but also it could be 
successfully employed in a sandwich format assay. The based on the pattern of 
fluorescence observed from this test then, the protocol based on the biotin-4D11 and 
streptavidin produced stronger specific signal than that achieved by the 4D11-HRP. 
Decision was therefore taken to replace the 4D11-HRP antibody with the biotin-4D11 
in the following experiments. 
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Figure 3.21. Comparison of the performance achieved by the 4D11-HRP protocol with that of 
the new biotin-4D11 conjugate.  
Arrays were generated with commercial anti-NPA (AA82H) and anti-NPB (10-I55G), as shown in 
panel (a). 6xHis-tagged NPA was incubated at the concentration of 10 µg/ml and 1 µg/ml, then 
revealed using the two alternative detector antibody-conjugates: the standard 4D11-HRP and the new 
biotin-4D11. The latter was applied along with the streptavidin-HRP reagent. Comparison of the 
fluorescence pattern indicates that, for each concentration of the nucleoproteins, the biotin-4D11 
protocol produces stronger localized fluorescence.   
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3.3.5 Demonstration of the detection limit of the sandwich 
assay using the biotin-conjugated 4D11 antibody.  
 
The following experiments aimed at evaluating the detection limit that the new biotin-
4D11 conjugate permitted to achieve. For this, a titration of the 6xHis-tagged 
nucleoproteins was carried out. Arrays displaying the commercial anti-NPA and anti-
NPB antibodies were printed from solutions prepared at two different concentrations 
each (500 #g/ml, and 50 #g/ml) as described in 2.7. Identical arrays were incubated 
with 0.1, 0.01, and 0.001 #g/ml of 6xHis-tagged NPA diluted in NP diluent at pH 4. 
Then, each array was sequentially incubated with the biotin-4D11, the streptavidin-
HRP reagent, and the fluorescently labelled tyramide as described in 2.10, protocol 
3. One negative control array was processed with the same protocol but with the NP 
diluent instead of nucleoproteins.  
Fuorescence on the anti-NPA spots (printed at  500 #g/ml) was produced in 
presence of the 6xHis-NPA at the concentration of 0.1 and 0.01 #g/ml (Figure 3.22, 
panel b). When the tracer was incubated at 0.001 #g/ml, the fluorescence produced 
on the anti-NPA spots was very low, and close to background level. Low 
fluorescence was also observed on the spots printed with the anti-NPB antibody in 
one slide (processed with 0.01 #g/ml NPA), however the same spots remained black 
in the other arrays. 
Two arrays were processed with the 6xHis-NPB4 at 0.1 and 0.01#g/ml.  In these two 
arrays the anti-NPB spots produced sustained fluorescence (Figure 3.22, panel c). 
No cross-specific fluorescence on the anti-NPA spots was observed.  
Importantly, in the negative control array, processed without the nucleoproteins, no 
fluorescence was observed on any of the anti-NPA/anti-NPB spots.  
The result of the experiment indicated that the protocol developed using the biotin-
4D11 conjugate and the streptavidin reagent is capable to reveal the tracer 
nucleoproteins at concentrations in the low ng/ml range. Although the detection limit 
was not determined precisely, it was demonstrated that the developed microarray 
protocol allows detection of 10 ng/ml of 6xHis-NPA and 6xHis-NPB. Importantly, the 
processing time (not including the washing steps) is 25 minutes.  
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Figure 3.22. Detection limit achieved with the biotin-4D11 conjugated.   
Anti-NPA (AA82H) and anti-NPB (10-IggG) antibodies were arrayed as shown in panel (a). The 
6xHis-NPA was added for 10 minutes at three concentrations, 0.1, 0.01, and 0.001 #g/ml. Then, the 
streptavidin-HRP reagent was added for 5 minutes, followed by addition of the fluorescence HRP 
substrate for 5 minutes. The pattern of fluorescence shown in panel (b) illustrates that the developed 
protocol can reveal 0.01 #g/ml of 6xHis-NPA. A titration with 6xHis-NPB4 was carried out in parallel in 
the same experiment, however only 0.1 and 0.01 #g/ml were tested. The pattern of fluorescence 
shown in panel (c) demonstrates the detection of  0.01 #g/ml of 6xHis-NPB4. 
 
 
 
 
 
 
 
 
  144 
3.3.6 pH titration of the 6xHis-NPA using the biotin- protocol 
 
A second pH titration study for the dilution of the nucleoproteins was carried out next 
with the aim to evaluate whether varying pHs of incubation of the nucleoproteins 
affected the performance of the new protocol. The set up of the experiment was 
similar to that described in paragraph 3.3.1. Arrays generated with anti-NPA and 
anti-NPB were incubated with 10 ng/ml 6xHis-tagged NPA diluted at six pH values 
following protocol 3 (2.10). As shown in figure 3.23, when the NP was incubated at 
pH 8, it produced stronger signal as compared to lower or higher pHs. While 
incubation of 10 ng/ml at pH 6 and pH 10 also generated detectable signal, other pH 
conditions produced fluorescence comparable with background level (Figure. 3.23, 
panel C). 
 
 
Figure 3.23. pH titration of the 6xHis-NPA using the biotin protocol.  
Anti-NPA and anti-NPB antibodies are printed as shown in (a). 10 ng/ml 6xHis NPA is incubated on 
the slides at the pH values shown above each array (b). The mean signal from the spots generated 
with printing buffer alone was subtracted to the mean signal of the antibody-spots, and the resulting 
values plotted against the pH of incubation of the NPs.  
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3.3.7 Employment of 4A11 antibody as capture agent 
 
The 4A11 antibody was spotted as described in 2.7. The spotting buffer was 
selected by testing the following: borate (pH 9.4), PBS (pH 7.4), and in a mixture of 
borate with 2.5% (v/v) glycerol. 4A11 antibody was printed using solutions at 1 
mg/ml, 250 #g/ml and 100 #g/ml prepared with each of the mentioned buffers. Spots 
with the commercial anti-NPB 10-I55 antibody were also included to compare the 
performance of the 4A11 candidate. The array was processed with 100 and 10 ng/ml 
6xHis-NPB4 diluted in the NP diluent at pH 8. The assay protocol was as described 
in paragraph 2.10 (‘protocol 3’). Briefly, the 6xHis-NPB4 were incubated on the array 
for 10 minutes, and then detected by serial addition of the biotin-4D11 (5 minutes), 
streptavidin-HRP (5 minutes) and fluorescent substrates (5 minutes) 
Based on the pattern of fluorescence it was observed (Figure 3.24) that the spots 
generated with the 4A11 antibody diluted in PBS (pH 7.4) produced stronger 
fluorescence than those obtained with dilution in the other printing buffers. 
Particularly, the addition of glycerol seemed to cause a dramatic drop of the 
fluorescence. The result indicates that 4A11 antibody can capture the 6xHis-tagged 
NPB4 with similar performance as the commercial candidate. This lead to the 
decision to replace the commercial candidate with the 4A11 in the following 
experiments.  
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Figure 3.24. Evaluation of the spotting conditions of the 4A11 antibody.  
4A11 was printed in three different buffers (borate, borate/glycerol, and PBS) at three different 
concentrations (panel a). Row 1 contains spots generated with the antibodies at 1 mg/ml. Rows 2 and 
3 are generated with 250 #g/ml and 100 #g/ml respectively. The arrays were processed with 100 
ng/ml and 10 ng/ml 6xHis-tagged NPB4. Captured proteins were revealed with the biotin-4D11, 
streptavidn-HRP and fluorescent substrates.  One negative control array was obtained by processing 
the same array without NPB4. The pattern of fluorescence indicated that the 4A11 antibody could 
capture the NPB4 with a performance similar to that of the commercial anti-NPB. This conclusion can 
be withdrawn by looking at the antibody spots on the row n.1 of the array, were the antibodies are 
printed at the concentration of 1 mg/ml. Spots generated with lower antibody concentrations show 
very high morphological variability (panel b).  
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3.3.8 Biotin-conjugation of 4A11 and 2B4 
 
Antibodies 4A11 and 2B4 were biotin conjugated in order to asses their use as 
detector antibodies. 
Biotinilation was performed with EZ-Link Sulfo-NHS-LC-LC as described in 2.6 and, 
after dialysis overnight, biotinilated products were tested. Arrays displaying human 
NPA and NPB4 and avian NPA were sequentially incubated with the biotin-2B4 or 
biotinilated 4A11, the streptavidin-HRP reagent, and the fluorescent HRP substrates.  
The pattern of fluorescence (FIgure 3.25) indicates that both the biotin-2B4 and the 
biotin-4A11 retain their specificity for the nucleoprotein NPB4. Occasional 
fluorescence on the NPA spots was detected.  
 
 
 
Figure 3.25. Biotin-conjugation of 2B4 and 4A11 antibodies.  
Nucleoproteins were arrayed as shown in the scheme (a). They were then detected using the biotin-
conjugates of 2B4 and 4A11 and with the streptavidin-HRP reagent (b). 
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3.3.9 Titration of the 6xHis-tagged NPB4 using 4A11 as capture 
substrate 
 
Titration curves were set up for the detection of the 6xHis-NPB4. The curves were 
generated by combining the 4A11 anti-NPB antibody as capture agent on the array 
and the biotin-4D11/streptavidin-HRP protocol. Three parallel titration experiments 
were performed using identical arrays prepared with two solutions of 4A11 antibody, 
1 mg/ml, and 200 #g/ml. For the titrations, the arrays were incubated with the 6xHis-
NPB4 at 40, 20, 10, 5, 2.5, 1.25, and 0.6 ng/ml diluted in the NP diluent (pH 8). 
Captured proteins were revealed by adding the biotin-4D11 antibody, the 
streptavidin-HRP and the fluorescent HRP substrates (paragraph 2.10, ‘protocol 3’). 
The trend of the three curves was very similar (figure 3.26), and resembled a 
sigmoid (Figure 3.26, panel C). Background fluorescence was variable, with no 
defined distribution among different slides. One of the negative control array instead 
produced fluorescence on the 4A11 spots. 
The detection limit observed for the developed assay lies between 2.5 and 5ng/ml.  
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Figure 3.26. The 6xHis-tagged NPB4 is titrated using 4A11 as capture agent and the biotin- 
4D11 as detector.  
The 4A11 antibody was printed at two concentrations, 1 mg/ml and 200 µg/ml. Spots generated with 
printing buffer-only as well as BSA were included in the array as negative controls. Spots generated 
with an Alexa 555-IgG and with a 6xHis-NPB4 were included in the array as positive controls of 
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fluorescence (panel a). The arrays were incubated for 10 minutes with the 6xHis-NPB4 serially diluted 
from 40 ng/ml to 0.6 ng/ml. Then 4D11-HRP antibody was added for 5 minutes, followed by addition 
of the streptavidin-HRP and the fluorescent HRP-substrate for 5 minutes each. Three titration 
experiments were performed in parallel (panel b). One negative control array for each curve was 
obtained by processing the array with the same protocol as the other arrays but with the NP diluent 
instead of the 6xhis-NPB4. In the titration n.2, fluorescence is visible on the 4A11-spot on the 
negative control experiment. For the quantifications, the signal measured on the 4 spots of each array 
printed with 4A11 (at 1 mg/ml) was measured and averaged. The signal measured on the spots with 
printing buffer alone was measured and averaged, and then subtracted to the mean signal of the 
4A11 spots. The resulting S-N values were plotted against the concentrations of 6xHis-NPB4 (panel 
c).  
 
 
3.3.10 Assessment of competition using the improved 
detection protocol 
 
Using the 4A11 antibody as capture agent, and the biotin-4D11/streptavidin-HRP 
protocol a competitive assay was set up to re-evaluate the principle of the 
tracer/antigen competition.  
Three groups of arrays were constructed (Figure 3.27). The first group was 
generated with the 4A11 antibody printed at 800 #g/ml. The second group with 4A11 
printed at 400 #g/ml. The third group with 4A11 printed at 200 #g/ml. The arrays 
were processed using ‘protocol 3’ described in 2.10. Briefly, the microarrays were 
incubated with 40 ng/ml 6xHis-tagged NPB4 and two concentrations of GST-NPB4 
were co-incubated together with the tracers. One control slide, in which no untagged 
nucleoprotein was added, was processed in parallel. The biotin-4D11 was added for 
5 minutes, followed by streptavidin-HRP and fluorescent HRP-substrates for 5 
minutes each. 
Visual analysis of the results (Figure 3.27) showed no significant difference in the 
fluorescence pattern when arrays of the same printing group (printed with the same 
concentration of capture antibody) were processed with and without the GST-tagged 
antigen. One array, processed with the GST-NPB4 at 80 ng/ml produced lower 
fluorescence than the two 10 ng/ml and zero GST-NPB4. However, it was expected 
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that a more dramatic difference be seen when 80 ng/ml of competitor compete 
against 40 ng/ml of tracer. 
When the arrays of different printing groups were analysed, the fluorescence was 
observed to drop with the decreasing concentration of capture antibodies.  
All spots produced an external halo with brighter fluorescence compared to the inner 
area of the spot. Although the halo is observed on all spots, it was much more 
evident on those with lower antibody concentrations (400 and 200 #g/ml). 
 
 
Figure 3.27. Assessment of the competition with 4A11 and the biotin-4D11/streptavidin-HRP 
protocol.  
Microarrays were generated by printing the 4A11 antibody. Spots with the printing buffer or BSA were 
included in the array as negative controls. Spots with the Alexa 555-IgG and with a 6xHis-tag protein 
were included as positive controls of fluorescence (panel a). Three groups of array were generated. 
Antibody 4A11 was printed at 800 µg/ml in the first group of arrays, 400 #g/ml in the second, and 200 
#g/ml in the third group, as indicated in the arrows (panel b). One array with each concentration of 
printed antibody was processed with 40 ng/ml 6xHis-NPB4 either alone or mixed with two 
concentrations of GST- tagged NPB4: 10 ng/ml and 80 ng/ml (panel b). Negative control slides 
underwent the same protocol, but the NP diluent instead of NPs was incubated. 
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3.4 A non-competitive microarray immuno-
assay for the detection of the nucleo-
proteins.  
 
 
3.4.1 Setup of a sandwich assay for the non-competitive 
detection of the recombinant NPA and NPB4. 
 
A non-competitive, sandwich assay was constructed using the anti-NPA antibody 
pair C01321M (capture) and biotin-C01323M (detector) (both purchased from 
Meridian Lifescience). Arrays were generated with C01321M and two anti-NPB 
antibodies, 4A11 and 2B4. The antibodies were spotted at 1mg/ml, 500 µg/ml, and 
250 µg/ml (Figure 3.28 A).  
Two arrays were processed. One array was incubated for 20 minutes with the 
human NPA at the concentration of 100 ng/ml in NP diluents (pH 8). Then, biotin-
C01323M was added to the array for 5 minutes followed by the streptavidin-HRP 
reagent and the fluorescence HRP substrates, for 10 minutes each (as described in 
paragraph 2.10, ‘protocol 4’). A second array (negative control) was processed in the 
same way but NP diluent was incubated instead of the human NPA. 
The pattern of fluorescence indicated that the NPA was detected on the spots 
printed with the anti-NPA (C01321M). No cross-reactivity was visualised on the anti-
NPB spots (figure 3.28, panel b). Fluorescence was measured on the spots 
containing the antibodies and then normalised by subtracting the mean fluorescence 
of the spots with the printing buffer alone. The normalised values were plotted 
against the concentration of the three capture antibodies. The graph in figure 3.28 
(panel c) confirms the visual result. The signal generated on the anti-NPA spots 
indicates detection of the NPA. The signal of the anti-NPB is very close to zero.  
The negative control array showed fluorescence in correspondence of two anti-NPA 
spots. This non-specific signal seemed to be localised on the right side of the array, 
while the left side produced lower non-specific reactivity.  
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On both arrays, several spots showed a comet-like morphology, particularly those 
printed with the human and avian NPAs at the highest printing concentration (200 
µg/ml). The comets seem to diffuse in different directions towards the outside of the 
arrays. 
 
 
Figure 3.28. Detection of the human NPA using anti-NPA antibodies C01321M and biotin-
C01323M in sandwich conformation (follows from figure at previous page).  
Anti-NPA commercial antibody (C01321) and anti-NPB 4A11 and 2B4 were printed at three 
concentrations each, 1 mg/ml, 0.5 mg/ml, and 0.25 mg/ml in the rows indicated by the arrows (panel 
a).  The human and avian NPA and the NPB4 were included in the array as controls for the detector 
antibody. Spots with printing buffer were included as negative control spots. In the processing, the 
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NPA (non-tagged form) was incubated on the array at the concentration of 100 ng/ml for 20 minutes 
and then detected with the biotin-C01323M for 5 minutes. Then, streptavidin-HRP and the HRP 
substrates were incubated for 10 minutes each. The observed pattern of fluorescence (panel b) 
indicated specific detection on the spots printed with the anti-NPA antibody. No fluorescence, as 
expected, was detected on the anti-NPB spots. On the negative control array, two of the spot 
generated with the anti-NPA generate considerable fluorescence, while the other two showed close-
to-background signal. Fluorescence levels were quantified and normalised by subtracting the signal of 
the spots containing the printing buffer. Signal was then plotted against the concentration of capture 
antibodies. In the graph (panel c) the blue blocks represent the signal recoded on the antibody spots 
of the array incubated with 100 ng/ml NPA. The red blocks represent the signal recorded on the same 
antibody spots of the negative control array. 
 
In the second experiment, one array was incubated with the NPB4 at the 
concentration of 100 ng/ml for 20 minutes. Then, biotin-4A11 was added to the array 
for 5 minutes followed by the streptavidin-HRP reagent and the fluorescence HRP 
substrates, for 10 minutes each. A second array (negative control) was processed in 
the same way but NP diluent was incubated instead of the NPB4. 
The pattern of fluorescence indicated that the NPB4 was detected on the spots 
printed with the anti-NPB antibodies. No cross-reactivity was visualised on the anti-
NPA spots (figure 3.29, panel a). Fluorescence was measured and then normalised 
by subtracting the mean fluorescence of the spots with the printing buffer alone. The 
normalised values were plotted against the concentration of the three capture 
antibodies. The graph in figure 3.29 (panel b) confirms the visual result. The signal 
generated on the anti-NPB spots is indicates detection of the NPB4. Although the 
signal for the 4A11 and 2B4 spots oscillates at different concentrations, no real 
difference could be seen between the detection achieved on the spots with 4A11 that 
on the spots with 2B4. The signal on the anti-NPA was close to zero, thus indicating 
that no cross-reactivity was generated.  
In the negative control array no fluorescence was visualised. When quantified, 
fluorescence remained close to zero on all anti-NA and anti-NPB spots.  
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Figure 3.29. Detection of the human NPB4 using anti-NPB antibodies 4A11/2B4 and biotin-2B4 
in sandwich conformation.  
The same array as for the previous experiment was used. In the processing, the NPB4 (non-tagged 
form) was incubated on the array at the concentration of 100 ng/ml for 20 minutes and then detected 
with the biotin-2B4 for 5 minutes. Then, streptavidin-HRP and substrates for the HRP were incubated 
for 10 minutes each. The observed pattern of fluorescence (panel a) indicated specific detection on 
the spots printed with the anti-NPB antibodies. No fluorescence, as expected, was detected on the 
anti-NPA spots. On the negative control array, all the antibody spot produced zero fluorescence. 
Fluorescence levels were quantified and normalised by subtracting the signal of the spots containing 
the printing buffer. Signal was then plotted against the concentration of capture antibodies. In the 
graph (panel b) the blue blocks represent the signal recorded on the antibody-spots in the array 
incubated with 100 ng/ml NPB4. The red blocks represent the signal recorded on the same antibody 
spots in the negative control array. 
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3.4.2 Introduction of UNIPG-antibodies 105 and 109, in the non-
competitive assay  
 
Clones 105 and 109 were biotin-conjugated as previously described (paragraph 2.6) 
and then the two biotin-conjugates were employed in a sandwich immunoassay for 
the detection of the human NPA. Arrays were constructed with antibodies 105, 109 
and C01321M and one anti-NPB antibody, clone 2B4. 
Three arrays were incubated for 20 minutes with the human NPA at the 
concentration of 20 ng/ml, 4 ng/ml and 0.8 ng/ml. One array (negative control) was 
incubated with the NP diluent alone. Afterwards, the arrays were incubated for 5 
minutes with the biotin-conjugated 109, and then with the streptavidin-HRP and the 
HRP-fluorescent substrates for 10 minutes each (as described in paragraph 2.10, 
‘protocol 4’). 
Arrays were analysed visually. The arrays were 20 ng/ml NPA had been incubated 
showed fluorescence on the spots generated with the anti-NPA antibodies. No 
fluorescence was visualised on the 2B4-spots. The array where 4 ng/ml NPA had 
been incubated had the same pattern, however the fluorescence was lower (as 
expected). In the array incubated with 0.8 ng/ml, as well as the negative control 
array, no fluorescence was visualised on the 105- and 109-spots. Instead 
fluorescence was present on the spots with the C01321 antibody. 
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Figure 3.30. Anti-NPA sandwich assay using the consortium anti-NPA antibodies 105 and 109. 
Anti-NPA and anti NPB antibodies were arrayed as shown in (panel a). The arrays were incubated 
with NPA and the concentrations written above each image in panel (b) and then with biotin-105 and 
streptavidin-HRP. The sandwich assay detects the NPA at the concentrations of 20ng/ml and 4ng/ml. 
The fluorescence caused by the 0.8 ng/ml solution is of the same level as that on the negative control 
array.  
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3.5 Performance of the developed 
microarray immunoassay with viral 
samples 
 
3.5.1 Detection of human influenza viruses 
The combined anti-NPA and anti-NPB microarray immunoassays were evaluated in 
the detection of influenza viral samples provided by the European consortium. 
Influenza B/Malaysia/5606/2004 at the concentration of 107 PFU/ml was tested. The 
sample was tested undiluted (‘neat’) and diluted 1:2. The dilution was achieved with 
two alternative buffer preparations. One, the NP diluents (pH 8) is the standard 
buffer utilised in the previous experiments of optimisation of the assay (prepared as 
described in paragraph 2.8); the second was the extraction buffer included in the 
commercial rapid diagnostic kit DirectigenTM EZ Flu A/B (BD). The non-specific 
fluorescence caused by each buffer was controlled with two negative control arrays. 
These were processed identically to the other arrays but only the buffer was added 
instead of the virus.  
Arrays were printed with anti-NPA antibody C01321M and anti-NPB antibody 2B4 at 
the same concentration as previously described (paragraph 2.7). The arrays were 
processed with the viral samples following the ‘protocol 4’, described in 2.10. Briefly, 
the virus was incubated on the array for 20 minutes. Then the biotin-2B4 was 
incubated for 5 minutes. And then streptavidin-HRP and the fluorescence substrates 
for the HRP were incubated for 10 minutes each.  
The neat virus produced strong fluorescence on the spots containing the 2B4 
antibody, and very low fluorescence on the spots with the C0321M (Figure 3.31). 
The 1:2 dilutions with both buffers produced lower, however considerable signal. The 
sample diluted in the buffer from the Directigen kit was more reactive than that 
diluted in the standard NP diluent.  However, the negative control relative to the 
Directigen buffer produced background signal on the non-spotted surface of the 
array. The background fluorescence was not homogeneous. One of the 2B4 spots 
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generated relatively high fluorescence, while the other spots remained close to zero 
(figure 3.31).   
A titration of nucleoprotein (NPB4) was run along with the virus. NPB4 was detected 
at the concentrations of 20 ng/ml, 5 ng/ml and 2.5 ng/ml in order to compare the 
amount of signal produced by the detection of known concentrations of nucleoprotein 
to that produced by the virus. 
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Figure 3.31. Detection of the spiked samples of influenza B.  
Anti NP B antibody 2B4 is printed together with anti-NPA C01321M (panel a). Then, influenza 
B/Malaysia/5606/2004 is incubated on the array for 20 minutes and revealed with biotin-2B4 and 
streptavidin-HRP. The virus is tested neat and diluted. The dilutions are achieved in the standard 
buffer optimised for the NPs (NP diluent), or in a commercial extraction mix (Directigen EZ Flu A+B 
kit) (panel b). The signal is recorded, normalised against non-specific signal recorded on the spots 
with printing buffer alone, and then plotted against the dilutions of the virus (panel c). In the 
experiment, a titration of NPB4 at 20, 4, and 0.8 ng/ml)was performed in parallel. The arrays for the 
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titration are not reported in panel b, however the quantification of the signal generated by the capture 
of the NPB4 is reported in the graph in panel c.  
 
 
3.5.2 Detection of avian influenza viruses 
A panel of samples obtained from the ISS and UNIBO were tested next. Arrays were 
generated with antibodies anti-NPA 105, 109 and C01321M and with the anti NPB 
antibodies 4A11 and 2B4. All antibodies were printed at 1 mg/ml and 0.5 mg/ml apart 
from mAb 105, printed only at 0.5 mg/ml. The virus samples were applied neat and 
diluted. The dilutions were achieved in the NP diluents (pH 8). The arrays were 
processed as described in paragraph 2.10 (‘protocol 5’). Briefly, the virus samples 
were incubated on the array for 40 minutes. Then the viruses of type A were 
detected with the biotin-109 and the viruses of type B with biotin-2B4 for 5 minutes. 
Then the streptavidin-HRP and the fluorescent HRP substrates were added for 10 
minutes each. 
For the type A viruses, the analysis of the results focused on spots generated with 
the least spotting concentration of the anti-NPA antibodies 105 and 109 (0.5 mg/ml).  
For the type B viruses, the analysis of the results focused on spots generated with 
the least spotting concentration of anti-NPB antibodies 4A11 and 2B4 (0.5mg/ml). 
One negative control test was included in each experiment. In this case, the virus 
was omitted, and only NP diluent was incubated instead. The other steps of the 
assay remained identical.  
All the influenza A samples produced fluorescence on the anti-NPA antibodies 105, 
109 and C01321M (Figure 3.32 to 3.34). In the majority of the cases, the signal 
decreased along the dilution scales. Low background fluorescence on the non-
spotted surface of the array was observed occasionally. Visual analysis of the 
negative control arrays showed clean background. However fluorescence was 
produced on the C01321M spots, and therefore they were excluded from the 
analysis 
A degree of cross reactivity with the area of the array with the anti-NPB spots was 
observed. However this non-expected fluorescence was only observed with the 
highest dilutions; for example for A/Mallardi/Italy/23/95, A/Mallardi/Italy/Unibo/196/07 
(Figure 3.32) or A/Mallardi/Italy/228090/05 (Figure 3.34) 
  162 
 
Figure 3.32. First experiment of detection of the avian influenza samples using the developed 
microarray immunoassay.  
A microarray was generated using the anti-NPA antibodies C01321M, 105 and 109 and the anti-NPB 
antibodies 4A11 and 2B4 (a). Virus samples provided by the UNIBO were incubated on the arrays for 
40 minutes and then detected with the biotin-109 detector antibody and with the streptavidin-HRP. 
The viral strains are listed on top of each box along with the viral concentration of the preparation 
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from where they were diluted. The concentration is provided with different units of measures (EID50 
and HA units), and therefore it is difficult to compare results obtained for different viral preparations.  
 
 
Figure 3.33. Second experiment of detection of the avian influenza samples using the 
developed microarray immunoassay.   
A microarray was generated using the anti-NPA antibodies 105 and 109 and the anti-NPB antibodies 
4A11 and 2B4 (a). Virus samples provided by the UNIBO were incubated on the arrays and detected 
with the biotin-109 detector antibody and the developed protocol as described in previous image. The 
viral strains are indicated at the top of each box along with the concentrations of their stock solutions. 
From there, they were diluted as indicated underneath each array image. . 
  164 
 
 
 
Figure 3.34. Third experiment of detection of the avian influenza viruses using the developed 
microarray immunoassay.   
A microarray was generated using the anti-NPA antibodies 105 and 109 and the anti-NPB antibodies 
4A11 and 2B4 (a). Virus samples provided by the UNIBO were incubated on the arrays and detected 
with the biotin-109 detector antibody and the developed protocol. The viral strains and the stock 
concentrations they were provided at are listed on top of each box.  
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Two influenza B samples provided by ISS were tested neat and diluted. The neat 
samples caused very strong fluorescence on the background area of the array. The 
background fluorescence dropped when the virus was diluted, however background 
remained very bright. Only the lowest dilutions (1:360) for each samle produced a 
specific signal on the spots generated with the 4A11. No specific fluorescence was 
detected on the 2B4 spots. (Figure 3.35). However, these samples will need to re-
tested for a more robust analysis of their reactivity. 
 
 
Figure 3.35. Detection of the influenza B virus using the developed microarray immunoassay 
The samples were detected with the microarray immunoassay using the antibodies produced by 
UNIPG. The scheme of the array is shown in (a). For each strain, the dilutions of the samples are 
shown under each array image. The blue boxes inside the arrays indicate the spots with the anti-NPB 
antibodies 4A11 and 2B4..  
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3.5.3 Performance of the microarray assay against the rapid 
antigen diagnostic tests 
 
In the last phase of the project parallel experiments were carried out to compare the 
performance of the microarray assay to that of Rapid Antigen Diagnostic Tests 
(RADTs) purchased from commercial sources.  
Three commercial kits were purchased: BD Directigen™ Influenza Test Kit, (BD), 
BinaxNOW® Influenza A & B (Inverness Medical), and QUICKVUE INFLUENZA 
A+B TEST (Quidel corporation). The kits are lateral flow devices that exploit the 
principle of the antigen-antibody interaction, with a colorimetric reaction occurring in 
a defined location in the device. The performance of the tests was assessed on the 
base of: a) presence of expected positive control bands, and b) presence of the 
NPA- or NPB-specific band.  
The first comparison experiment (Figure 3.36) focused on the detection of two viral 
samples, A/Mallard/Italy/Unibo/167/07 and A/Mallard/Italy/228090/05. 
The microarrays used in the experiments were generated with the anti-NPA 
antibodies 105 and 109, and anti-NPB antibodies 4A11 and 2B4 printed at 0.5 
mg/ml. The viral samples were diluted in the NP diluent prepared as in 2.8 and then 
revealed on the array using the protocol described in paragraph 2.10 (‘Protocol 5’). 
Briefly, the samples were incubated on the array for 40 minutes and then revealed 
with biotin-109 for 5 minutes. Then, streptavidin-HRP and the fluorescent HRP-
substrates were added for 10 minutes each. 
For the RADT tests the viral samples were diluted in the buffer provided with the kit. 
Instructions of the manufacturer were carefully followed during the procedure. 
Equivalent dilutions were loaded on the microarray and in each of the commercial 
tests. 
As shown in figure 3.36, the microarray revealed fluorescence on the anti-NPA spots 
105 and 109 in response of both viruses. The recorded fluorescence is very weak, 
however well distinguishable from the background. Antibody C01321M produced 
fluorescence in the negative control array, and therefore was excluded from the 
analysis. No fluorescence was observed on the 2B4 and 4A11 spots.  
  167 
In all commercial tests the band indicating presence of NPA was observed. However 
no negative control test was carried out to verify the specificity of the result for the 
commercial kit. 
 
 
Figure 3.36. Comparison of the microarray assay against three commercial RADTs. 
The scheme of he array is reported in panel (a). Detection of the virus with the microarray and with 
three commercial kits is shown in  panel (b). In each square the microarray experiment is compared to 
three rapid kits (from left to right in each square, BinaxNOW® Influenza A & B (Inverness Medical), 
BD Directigen™ Influenza Test Kit (BD), and QUICKVUE INFLUENZA A+B TEST (Quidel 
corporation)). Tests are photographed ~20 after loading of the sample. The red arrows on each kit 
indicate the position where the expected NPA-specific band was observed. The orange and yellow 
squares in each array indicate the spots with the anti-NPA antibodies 109 and 105 respectively. One 
negative control experiment for the microarray experiment was carried out. 
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A second experiment of comparison evaluated the detection of an influenza B 
sample achieved with the microarray assay against that achieved with the BD 
DirectigenTM Influenza Test Kit, and BinaxNOW® tests. The experiment focused on 
the parallel detection of virus B/Milano/10/2011. The virus was tested with the 
protocol described in paragraph 2.10 (‘protocol 5’). Briefly, the samples were 
incubated on the array for 40 minutes and then revealed with biotin-4A11 for 5 
minutes. Then, streptavidin-HRP and the fluorescent HRP-substrates were added for 
10 minutes each.  
The microarrays revealed all the dilutions tested (Figure 3.37, panel d). No 
fluorescence was observed on the anti-NPA spots. No fluorescence was observed 
on the negative control test.  
The Directigen kit produced invalid result due to the presence of a band in the 
negative control test (Figure 3.37, panel b). 
The BINAXNOW test proved more specific, instead, as no band was observed in the 
negative control test. The expected NPB-specific band was observed when the 
sample was loaded to the dilution at 1:200 and 1:400, but not when I was diluted at 
1:800 (Figure 3.37, panel c). 
In conclusion, the microarray assay revealed the influenza B one dilution higher than 
the BINAXNOW test. 
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Figure 3.37. Comparison of microarray assay against two RADT tests for the detection of 
influenza B. 
The scheme of the microarray is shown in panel (a). Detection of virus B/Milano/10/2011 with the 
microarray and with two commercial RADT tests is shown. Panel b: BD Directigen™ Influenza Test 
Kit (BD), Panel c: BinaxNOW® Influenza A & B (Inverness Medical). Panel d: microarray assay. Tests 
are photographed ~20 after loading of the sample. The red arrows on each kit indicate the position 
where the expected NPA-specific band is observed. Blue squares in each array in panel (d) indicate 
the spots with the anti-NPB antibody 4A11. 
  170 
 
 
  171 
4 Discussion 
 
In the course of this PhD an antibody microarray immunoassay was developed to 
detect influenza viruses. The work was carried out in the frame of the European 
project termed Fluarray (FP7), a collaboration of academic and private partners 
described in paragraph 1.5.  
The protein microarray technology has been investigated in many published studies 
involving the multiplex analysis of protein-protein interactions, and holds promise to 
fulfil the essential requirements of the influenza diagnosis including multi-analyte 
detection, rapidity, and applicability to automated portable devices. In the antibody 
microarray then the affinity of the monoclonal antibodies for specific protein targets is 
harnessed to simultaneously screen hundreds of different antigen-antibody reactions 
on a miniaturized surface. Microtest Matrices (MtM), who kindly sponsored this PhD, 
possess a know-how in the field of the protein microarray, as well as key technology 
necessary to develop microarray-based diagnostic systems. Additionally, MtM in 
collaboration with SEAC-Italy developed an Automated Diagnostic Analyser for 
Microarrays (ADAM). This instrument automates, simplifies, and standardizes 
complex assay procedures based on microarray chips, as demonstrated by work 
carried out at MtM in the field of allergy screening (proprietary technology of MtM).  
The goal of the Fluarray was to combine the multiplex potential of the microarray 
technology, with the powerful detection properties of the monoclonal antibodies and 
the laboratory automation offered by the ADAM instrument to generate an automated 
system for the diagnosis of influenza.  
 
The work described in this thesis focused on the construction and validation of the 
antibody microarray immunoassay. The test was initially designed to detect and 
differentiate human and avian subtypes of influenza A H1N1, H3N2, H5N1, H7N2, 
H7N3, H7N7, and H9N2, and influenza B by detecting the type-specific 
nucleoprotein (NP) and the subtype-specific haemagglutinin (HA) and neuraminidase 
(NA). For this, the microarray was predicted to display antibodies against each of 
these antigens, as well as spots for the negative and positive controls and for 
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calibration curves. Crucially, two alternative immunoassay formats were investigated, 
the competitive format and the non-competitive (or ‘sandwich’) assay.  
The initial work focused on the competitive-format. Here two variants of the same 
antigen, the sample-derived viral antigen and a recombinant, 6xHis-tagged form 
representing a ‘tracer’ compete for a limited number of binding sites constituted by 
the capture antibodies located on the spots of the array. The assay was initially 
designed to comprise the following components: a) a microarray made of 
monoclonal antibodies specific for nucleoproteins, selected haemagglutinins and 
selected neuraminidases; b) a panel of recombinant, 6xHis-tagged tracer proteins 
corresponding to each of the selected NP, HA and NA proteins; and c) a monoclonal 
antibody specific for the 6xHis tag for use in detecting tagged tracers captured by the 
arrayed antibodies. These three components interact in a ‘sandwich type’ 
conformation. The presence of viral antigens (NPs, HAs and NAs) in the sample 
competes with the tracers for antibody capture, thus causing a measurable decrease 
in the level of fluorescent signal recorded at the corresponding microarray spot.  
As the work progressed then, the non-competitive format was studied. In this case, 
the viral antigens, not the traces, are captured directly on the microarray and an 
increasing signal is recorded from the spot in presence of increasing concentration of 
target antigen. 
Crucially, the work employed reagents produced by the collaborating partners of the 
Fluarray; while the monoclonal antibodies were developed at UNIPG, the 
recombinant viral antigens and the tracers were synthesised by Protein 
Therapeutics, and viral samples were prepared at HPA, ISS, and UNIBO for the 
validation phase of the assay.  
 
The initial part of my PhD focused on studying the feasibility of the microarray 
detection of the recombinant nucleoprotein tracers. This phase employed anti-NP 
antibodies purchased from commercial sources indicated in the thesis with their 
catalogue numbers (AA5H, 10-I55G, MAB8258B). Additionally, the anti-6xHis tag 
antibody 4D11 (courtesy of professor Crisanti) was employed as detector agent to 
reveal the 6xHis-tagged proteins. For this, 4D11 was purified from hybridoma 
supernatant as described in paragraph 3.2.2.1. 
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Meanwhile monoclonal antibodies were developed at UNIPG (Italy) with the 
hybridoma technology. For each antibody candidate, a preliminary characterisation 
conducted at UNIPG, at ISS and HPA indicated the potential reactivity for the human 
or avian NPA or NPB. The antibodies with the best (predicted) specificity and affinity 
for either NP variant were selected for further evaluation and introduced in the study. 
Importance in the selection was given to the concordance of the results obtained at 
UNIPG and HPA. The candidates that produced discordant or unclear results were 
excluded from the work.  
 
Chosen antibodies were sent to Imperial College in three different phases.  
In the first phase, five hybridoma supernatants were received at Imperial College: 
clones 4A11, 5D12, 7G11, 11B11 and 21H8. The supernatants were tested to 
identify their isotype (paragraph 3.2.1). Two antibodies were then selected for 
purification, clones 4A11 (paragraph 3.2.2.2) and 21H8 (paragraph 3.2.2.3)  
In the second phase, additional antibodies were received. The isotype determination 
for these candidates was carried out at the University of Perugia. Two antibodies of 
this panel were selected for purification, clones 2B4 (paragraph 3.2.2.4) and 3F6 
(3.2.2.5). 
In the third phase, two purified antibodies were received, clones 105 and 109.  
 
All the purified antibodies, along with the commercial candidates were characterised 
for their anti-NP specificity and affinity. The characterisation was carried out using 
two methods, the western-blot (paragraph 3.2.4) and the protein microarray 
(paragraph 3.2.5).  
 
The first activity that was carried out consisted in the identification of the isotype of 
the antibodies. The information is essential for a proper handling and application of 
these reagents, as the peculiar structural characteristics associated to different 
isotypes translate into different physio-chemical properties. The heavy chains of the 
IgG antibodies (IgG2a, IgG2b and IgG3) differ from those of the IgAs and the IgMs in 
terms of amino acid composition, size, degree of glycosilation, and pattern of 
disulfide bridges. Additionally, while the antibodies of isotype IgG are normally 
present in solution as monomers, the IgAs can form dimers, and the IgMs typically 
associate in pentamers. These characteristics require isotype-dependent purification 
  174 
strategies, as well as specific reagents to detect them in solution and in a microarray 
application.  
The mouse IgGs can be purified using chromatography resins embedded with 
ligands such as the protein A or the protein G, that show high affinity for the heavy 
chain of this isotype but not for those of the others; a suitable method for the 
purification of the IgAs instead is the protein L-chromatography, while the IgMs can 
be purified by exploiting the affinity of the 2-mercaptopyridine in the thiofilic 
chromatography.  
The first panel of supernatants received at Imperial College included five clones with 
predicted anti-NPA and anti-NPB specificity. The isotype results for these 
candidates, as illustrated in paragraph 3.2.1, utilised a lateral flow test where the 
supernatant solution migrates along a membrane and is captured by embedded 
isotype-specific antibodies. A colorimetric reaction caused by the reagents included 
in the kit then reveals a coloured band localised in specific positions. The result is 
decided on the base of a visual observation of the banding pattern at the end of a 10 
minutes-incubation, as indicated by the manufacturer. No quantification-methods are 
suggested.  Considering the visual, and therefore empiric evaluation method of the 
test, and the importance of the isotype information, the results obtained by myself 
were confirmed at a later stage with experiments conducted at Protein Therapeutics 
using an alternative test. Among the antibodies contained in this first panel of UNIPG 
reagents, one, clone 4A11, tested IgG2a, and the others tested IgM.  
 
The generation of a microarray requires solutions of purified antibodies. Normally, for 
one spotting run 10-50 micrograms of pure antibody are needed. Presence of 
contaminants can be problematic because non-pure samples can cause unexpected 
reactions with the downstream reagents of the protocol. Unwanted proteins then can 
compete for the binding to the surface of the slide thereby dropping the density of 
spotted antibodies and, ultimately, the analytical sensitivity of the assay. Additionally, 
the optimisation of the immunoassay involves protein-modifications steps of the 
antibody, such as for example the labelling with fluorescent molecules or the 
conjugation with enzymes. Such reactions require a defined chemical environment to 
take place, and the presence of impurities can affect the performance of the bio-
conjugations.  
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For these reasons, the quality of the purifications was controlled by SDS-PAGE, and 
assessed on the base of the observed banding pattern produced by the antibody. In 
some cases, an additional control was done by blotting the proteins and revealing 
them with a detector, in order to verify that the observed bands belonged to the 
wanted antibody. 
Three IgG antibodies were purified by myself during the project. One, 4D11, specific 
for 6xHis tagged proteins, and two, 4A11 and 2B4 specific for the NPB. Normally, the 
banding pattern of an IgG in a denaturing polyacrylamide gel includes in two bands; 
one represents the heavy chain of the antibody, and runs at approximately 50 kDa, 
and the other represents the light chain and runs at 22-25 kDa. If other bands are 
seen, these indicate either a non-optimal purification, or a degradation of the purified 
protein. In the SDS-PAGE experiments described in this thesis, one additional IgG 
antibody was run in order to confirm the expected banding pattern. The purification 
of the three IgGs proved satisfactory, as no bands were seen in the gel apart from 
the two expected. Quality of the purification of 2B4 was also confirmed by western-
blot analysis using an HRP-conjugated anti-mouse reagent (DAKO) that detects 
mouse immunoglobulins.  
Antibody 21H8, an IgM, was purified using the thiofilic chromatrography. Three 
bands were visualised in the polyacrilamide gel. While two (25 and 70 kDa) 
represent the light and the heavy chains, the third band was unexpected. This band 
migrated at approximately 50 kDa and was detected in western-blot by an anti-IgM 
antibody. The detection of the band with this detector seems to rule out the 
possibility that the band be caused by a contaminant; it was hypothesised instead 
that a fraction of the antibody underwent damage during the purification thereby 
causing the 50 kDa band.  
It was also observed that the supernatant and the flow through contained proteins 
that migrated at the same height as the BSA, and these were not visible in the 
purified solution. Instead, the supernatant showed the light and the heavy chain of 
the immunoglobulin. Although the two bands were very faint in the supernatant lane, 
their appearance intensified in the purified fraction. The loss of the BSA band, 
together with the intensification of the bands of the light and heavy chain indicate 
good quality of the purification. It was noted that the post-elution purification fraction 
also contained a considerable fraction of pure antibody. This fraction was not 
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quantified, however it indicated that the amount of antibody present in the original 
hybridoma supernatant exceeded the binding capacity of the column. 
The purification of 3F6 was also judged good, based on observation of the bands.  
 
The anti-NP reactivity was carefully examined for each antibody. While all 
candidates were tested by protein microarray, some antibodies were also tested as 
probes in western-blot assays.  
The first reagents to be analysed in this way were the commercial antibodies 10-
I55G, AA5H. These were purchased on the base of the expected specificity against 
the human NPA and NPB respectively. Clone MAB8258B then was purchased 
because guaranteed by the manufacturer as reactive to the avian NPA reagent. 
Initially, the reactivity of the three candidates was evaluated in western-blot analysis 
against a panel of recombinant nucleoproteins that included both 6xHis-tagged and 
untagged nucleoproteins. The analysis also tested the 4D11 antibody for its affinity 
to 6xHis tagged proteins. The antibodies confirmed the expected reactivity and didn’t 
cross-react with targets different from those expected (i.e. the anti-NPA with the 
nucleoprotein B, or the 4D11 anti-6xHis tag against untagged proteins). The anti-
NPB 10-I55G was then tested against the NPB3 and the NPB4 when these became 
available. Both the 6xHis-tagged and the GST-tagged versions of the proteins were 
tested, and the antibody proved reactive against both variants.  
 
The analysis of the reactivity pattern was repeated against nucleoproteins spotted on 
a microarray. The three commercial antibodies, as well as the 4D11 confirmed their 
reactivity pattern. It was noted that the weak fluorescence was produced on the 
spots in the negative control experiment. A similar fluorescence was observed on all 
arrays on the non-specific spots, however it was not quantified because the visual 
analysis was sufficient to indicate a drastic difference with the expected spots.  
The reactivity of clone 10-I55G was observed to vary between the two types of NPB 
tested, with the NPB of the Yamagata line less reactive than the NPB from the 
Victoria line.  
The 4D11 antibody confirmed its reactivity against the 6xHis-tagged proteins 
however also in this case the NPB4 proved more reactive than the others. 
The protein microarray analysis was preformed for the UNIPG antibodies. The anti-
NPB 4A11 and 2B4 proved very reactive and specific against the NPB, as shown in 
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the figures 3.11 and 3.12. The test shown in figure 3.12 included nucleoproteins 
printed with different spotting volume, that explain the difference in the spot-
diameters observed for even for proteins printed with at same concentration. 
The performance of consortium-antibody 3F6 proved very disappointing instead, as 
only weak fluorescence was produced against the NPBs. Additional experiments 
with 3F6 didn’t show any improvement of the antibody reactivity.  
An additional two UNIPG antibodies, clones 105 and 109 were received during the 
last phase of the project pre-purified. When tested for their anti-NP reactivity, they 
confirmed very good anti-NPA, reacting with both the human and avian NPAs. No 
observed cross-reactivity for the NPBs. 
 
The work described in section 3.3 illustrates the experiments carried out to set up a 
competitive immunoassay. An essential prerequisite for this was the construction of 
a well-defined sandwich assay for the capture of the tracers. 
Three elements are essential for the construction of a microarray assay: a) the 
capture agents spotted on the array, b) the physicochemical conditions for the 
incubation of the target analyte, and c) the detection method chosen to reveal the 
captured analytes.  
To study these three aspects, one microarray was generated with the commercial 
anti-NPA and anti-NPB antibodies. Solutions of NPA and NPB tracers were added 
and captured by the two antibodies and they were then revealed using the Alexa 
555-conjugated 4D11. 
The immobilisation of the antibodies on the surface of the slide depends on the 
occurrence of physicochemical conditions that cause the immobilisation. The 
aldehyde-coated glass slides used in the study bind the antibodies via the reaction of 
Schiff’s base formation between the amine groups of the amino acid residues and 
the aldehyde groups on the slide. The reaction determines the covalent binding of 
the antibodies via potentially any amino acid residue where a free amine group is 
available. The orientation of the immobilised antibody is typically random, and 
therefore only a fraction of the antibodies (those that have an appropriate orientation) 
will capture the target protein.  
The pH and composition of the printing buffer then is a key factor in determining the 
affinity and the specificity of the antibody. Indeed, any chemistry of immobilisation 
can be affected by the pH of the printing solution. The printing buffer then should not 
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contain components that cause competition for the binding sites on the slide. Finally, 
different buffers dry in different ways, thereby affecting the stability of the antibody 
over time. 
In this PhD four buffers were tested for the printing procedure. The PBS (pH 7.4) 
Glycine, (pH of 2.4) and Borate (pH 9.4). One preparation containing glycerol was 
also included in the test. Glycerol was tested because it is predicted to retain a good 
hydration level in the spots (Olle et al. 2005). And therefore it’s been indicated to 
likely improve the stability of the arrays. 
One additional factor considered in the construction of the microarray was the 
morphology of the spot. Morphology is important for the quantification of the spots 
and correct evaluation of the specific fluorescence. Detergents and amphiphilic 
reagents are employed in protein microarray because they drop the surface tension 
of the spot and therefore they can improve their quality and morphology of the spot. 
For this, the concentration of the additive needs to be carefully evaluated, as 
excessive concentrations result in disruption of the stability of the spotted protein. 
 
Conditions for the incubation of the tracers were carefully evaluated. The influenza 
nucleoproteins are located inside the viral structure, their predicted isoelectric point 
is approximately 9.4. To study an appropriate pH for the immunoassay, the tracers 
were presented at a range of pHs. The different pH values could be achieved using a 
range of buffers. However, it was preferred to use one unique buffer, defined in the 
test as ‘Universal buffer’ (paragraph 2.8).  
This first experiment produced a number of data on the most promising conditions 
for the production of the array and for the development of the assay. The best 
spotting conditions were decided on the base of the signal measured on the spot 
with antibodies printed in different conditions. The signal recorded on those spots 
generated with the same conditions was normalised against the fluorescence level 
measured on the spots generated with only printing buffer in order to exclude non-
specific signal.  
 
Two different signal generation strategies were initially tested with the aim to 
maximize assay sensitivity while minimizing total assay time, the conjugation of the 
detector antibody with Alexa 555 fluorophore and the conjugation with HRP 
enzymes. In the latter method, fluorescent substrates are introduced in the assay. 
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Following iterative investigations, microarray immunoassay conditions were identified 
that permitted the simultaneous, differential detection of 10 µg/ml of 6xHis-NPA, 
6xHis-NPB, and 6xHis-avian NP tracer proteins with a protocol of the duration of 25 
minutes (paragraph 3.3.1 and 3.3.2). The direct HRP-conjugation resulted in a boost 
in the fluorescence level as compared to the fluorescence generated with the direct 
Alexa 555-labelled protocol.  
Using this sandwich assay as a foundation, experiments were continued for NPA 
and NPB in which untagged and differentially tagged nucleoproteins were co-
incubated with corresponding 6xHis-tagged tracer proteins in order to simulate the 
competition that would occur when testing positive clinical samples. These studies 
confirmed successful competition as a substantial drop in the signal was recorded in 
the presence of the competitor (paragraph 3.3.3). The most considerable signal drop 
was observed when 100 µg/ml of untagged antigen were co-incubated with 10 µg/ml. 
Signal drop was also observed when 10 µg/ml of antigen where added, instead the 
addition of 1 µg/ml couldn’t be distinguished from the zero-antigen condition. The 
experiment was confirmed in the detection of both the untagged NPA and the 
untagged NPB. The competition test was repeated using a different version of the 
competitor, the GST-tagged NPs. In this case, more concentration points of 
competitor were studied, and the lowest antigen concentration that caused a visible 
signal drop was 25 µg/ml. The difference in the fluorescence levels measured in 
correspondence of 1, 5, and 10 µg/ml of competitor was not due to the competition 
effect but rather to the variability in the signals obtained from the different spots 
within each array, as indicated by the standard deviation illustrated in the graph in 
figure 3.19. Two main drops in the signal were observed along the competition 
curve. The first, when 25 µg/ml, and the second when 75 µg/ml of GST-competitor 
were added.  
Evaluating the lowest concentration of competitor that causes a measurable signal 
drop is essential, as this value indicates the concentration of viral antigen that the 
assay will ultimately be able to detect. While in the first competition experiment, the 
addition of 10 µg/ml of an untagged nucleoprotein seemed sufficient to determine a 
fluorescence drop, the second experiment required approximately 25 µg/ml of the 
GST-tagged nucleoprotein.  
It is important to stress that the two experiments cannot be compared directly. The 
second experiment utilised a variant of the NPB, called NPB4, that was synthesised 
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by Protein Therapeutics using sequence information that mimic that of the currently 
circulating nucleoprotein B of the Victoria line. Additionally, the nature of the 
competition is different. In the first experiment in fact, competition takes place 
between two proteins with the same molecular weight, the only difference being the 
presence of the 6xHis tag. In the second test instead, the competitor is endowed with 
a GST tag (molecular size approximately 25 kDa), and therefore its mass is 25 kDa 
bigger than that of the tracer. These initial experiments however demonstrated the 
feasibility of detecting recombinant nucleoproteins with a competitive immunoassay. 
Yet, the concentration of nucleoproteins in a viral sample is likely to be in the order of 
pg/ml to ng/ml. The recorded detection limit of the assay in this form, few µg/ml was 
at least 1000-fold less sensitive than the detection limit needed to detect viral 
samples.  
 
In the following phase of the experimentation, an alternative molecular strategy for 
the generation of fluorescent signal was evaluated. In the new method the affinity 
between biotin and streptavidin was exploited to generate stable conjugates between 
the detector antibody and the HRP, the affinity of binding of these two molecules 
being very high (Kd 10-15). Also, given the smaller molecular size of the biotin 
molecule (244 Dalton), compared to the HRP (approximately 45 kDa), this approach 
could in theory simplify the antibody labelling procedure and result in improved signal 
generation. Accordingly, a biotin-conjugation of the 4D11 antibody was carried out. 
The biotinilated 4D11 was used along with a streptavidin-HRP reagent and 
fluorescently labelled tyramide. The reaction of biotin-conjugation used a biotin 
reagent, Sulfo-NHS-LC-LC-Biotin that reacts with the amine groups of lysine forming 
an amide bond. The biotin reagent was chosen for its water solubility and for the 
presence of a spacer arm that minimizes the steric hindrance caused by enzyme 
conjugation.  
The biotin-conjugation can potentially occur anywhere along the antibody where free 
–NH2 residues are present. If the conjugation takes place next to the antigen-binding 
site, the biotin molecule may interfere with the immunogenic properties of the 
antibody and therefore drop the affinity and/or the specificity. For this reason, the 
specificity of the biotinilated-4D11 for 6xHis-tagged proteins was confirmed before 
proceeding (3.3.4).  
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Next, the biotinilated-4D11/streptavidin-HRP protocol was applied to a sandwich 
assay for the detection of the tracers, and its performance compared to that of the 
HRP-4D11 protocol. The new signal generation strategy permitted the detection of 
the 6xhis-tagged nucleoproteins diluted at the concentration of 10 ng/ml. This value 
represented an improvement of approximately 1,000 folds as compared to the 
concentration revealed in the experiments performed with the directly HRP-
conjugated reagent, HRP-4D11. And thus, the achievement was considered an 
important milestone of the project. However, this result was not interpreted as an 
absolute superiority of a biotin-mediated conjugation of HRP particles over a direct 
HRP-conjugation to the antibody, because the lowest detection limit of the HRP-
4D11 was never thoroughly tested with limiting dilutions. Also, the experiments of 
comparison of the HRP-4D11 with the biotin-4D11 compared a suboptimal 
preparation of HRP-4D11 (i.e. stored at + 4 °C for several months) with a new 
preparation of biotin-4D11.  
The results, however, clearly demonstrated that the 4D11 antibody retained its 
capacity to specifically bind the 6xHis tagged proteins even after iotin-conjugation, 
and could be successfully employed together with the streptavidin-HRP reagent to 
produce specific, localised signal.  
Optimisation of the new biotin-4D11 based protocol resulted in detection of 10 ng/ml 
of 6xHis-tagged A and B nucleoproteins with a 25 minutes assay procedure 
(paragraph 3.3.5).  
 
Upon determination of this new detection range, the physicochemical parameters for 
the incubation of the nucleoprotein on the array were re-evaluated by re-testing the 
optimal pH of incubation of the nucleoproteins. Whilst pH 4 had proved to generate 
the best signal/noise with 10 #g/ml nucleoproteins, this condition was verified with 
the concentration value representing the new detection limit (10 ng/ml). A second pH 
titration experiment identified 8 as the optimal pH to maximise detection of 10 ng/ml 
of 6xHis-tagged NPA. Based on these experiments of pH titration then, it was 
decided to routinely incubate the NPs at pH 8 during the following assay procedures.  
 
The detection of 10 ng/ml of 6xHis-NPA and 6xHis-NPB was tested further in 
experiments where the capture antibodies were replaced with one monoclonal 
produced at UNIPG, clone 4A11. The main variable associated with replacing a 
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capture antibody regards the affinity of the new candidate for the target protein, and 
therefore the capability of 4A11 to capture the NPB was tested against that of the 
commercial reagent 10-I55G.  Similarly to the experiments for the initial set up of the 
microarray (paragraph 3.3.1), the new antibody was spotted at a range of possible 
printing buffers and the fluorescence level produced by the spots was compared 
against that generated by 10-I55G.  The experiment demonstrated that the 
fluorescence generated by the two antibodies was very similar, with 4A11 performing 
as good as the commercial counterpart. The achieved detection limit was further 
challenged in titration experiments using the couple 4A11/capture and bitoin-
4D11/detector. Three titration curves were generated in order to evaluate more 
precisely the detection limit of the developed assay, as well as the consistency of the 
previous result. In this experiment, the NPB4 (Victoria line) was detected. The lowest 
detectable concentration of NPB4 tracer was observed to be between 5 and 2.5 
ng/ml (paragraph 3.3.9).  The uncertainty about the precise value representing the 
detection limit was due to the occurrence of one negative control experiment that 
produced a basal level of non-specific fluorescence. This fluorescence resulted 
higher than that recorded for the lowest concentration of NPB4 (see titration n.2 in 
figure 3.26). However, importantly, these experiments demonstrated the consistency 
the detection of the recombinant nucleoproteins at concentrations in order of low 
ng/ml. 
 
The new protocol was implemented in the set up of the competitive immunoassay. 
Experiments were carried out where increasing concentrations of GST-tagged NPB4 
were tested to displace the 6xHis-tagged NPB4 (described in 3.3.10).  
In this case solutions of 4A11 at three different concentrations were spotted, (800, 
400, and 200 #g/ml) in order to evaluate which of these more closely represented 
ideal conditions for a competitive binding of the tracers and the antigens. Then NPB4 
tracers were incubated on the array at the concentration of 40 ng/ml. The tracers 
were incubated either alone, or together with GST-tagged NPB4 at the concentration 
of 10 ng/ml and 80 ng/ml. Similarly to the previous competition experiments, the aim 
of these tests was to determine a tracer/antigen ratio that would cause a signal drop 
as compared to the signal measured when only tracer was incubated.  
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None of the conditions tested, however, produced a visible competition.  The 
fluorescence intensity generated by the 6xHis-tagged NPB4 remained the same with 
and without the GST-tagged NPB4.  
One of the hypotheses formulated to explain the failure to achieve competition was 
that the number of capture sites available on the spots during the assay exceeded 
those necessary for the tracers and the antigens to bind simultaneously. As a 
consequence, both the 6xHis-tagged and the GST-tagged nucleoproteins could bind 
the spot without any displacement taking place. Indeed, the essential theoretical 
requirement for a competition format immunoassay is the availability of a limited 
number of capture sites. This parameter cannot be defined precisely, but only with 
empirical experiments. Indeed, in the course of this project arrays were generated by 
deposition of solutions prepared at known concentrations of antibody. The routine 
spotting concentration of the antibodies typically range between 500 #g/ml and 1 
mg/ml. Importantly, however, although the number of antibody molecules deposited 
on the array can be calculated on the base of their molecular weight, concentration 
of the solution, and spotted volume, such calculation does not provide any 
information regarding the density of actual binding sites on the array during the 
assay. Random orientation of the antibody molecules on the surface are likely to 
take place on aldehyde slides Also, estimation of the stability of the antibody 
molecules after array generation is very difficult, as proteins tend to degrade when 
non-optimal physicochemical conditions occur. Degradation and random molecular 
orientation of the antibody molecules are therefore two relevant issues which render 
the calculation of the actual amount of available capture sites very empirical.  
The lack of competition observed when ng/ml of 6xHis and GST-tagged 
nucleoproteins are co-incubated on the array may indicate that “too many” capture 
sites are displayed on the slide, and therefore binding of the GST-tagged antigen 
doesn’t displace the tracer. Interestingly, however, when one incubation condition 
(for example 40 ng/ml of 6xHis-tagged NPB4) was applied on three microarrays 
printed with 800 #g/ml, 400 #g/ml, and 200 #g/ml 4A11 respectively, the 
fluorescence generated were correspondingly lower. As shown in figure 3.27, for 
example, spots generated from 4A11 solutions printed at the concentration of 200 
#g/ml, incubated with 40 ng/ml tracers generated lower fluorescence than that 
produced upon the identical processing of spots printed at 800 #g/ml. If the 
abovementioned hypothesis, that the density of capture sites is ‘not’ a limiting 
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condition (i.e. ‘too many antibodies are displayed) is true, incubations with one 
identical 6xHis-tagged antigen solution would generate the same, constant 
fluorescence level. The observed drop of the signal instead seems to indicate that 
the concentration of antibody is, indeed a limiting factor relatively to the described 
experiment.  
The incongruence could be partially explained considering the fact that the 
optimisation of the printing conditions described in this thesis was performed by 
evaluating concentrations of capture antibody ranging from 500 #g/ml to 1 mg/ml. 
Deposition of solutions with lower concentration may require further and more 
thorough optimisation. Importantly, in fact, spots generated from solutions at lower 
antibody concentrations constantly show two characteristics, a non-round shape and 
a non-homogeneous distribution of the fluorescence, with the signal being stronger 
on the outer border of the spot than in the inner area (figure 3.27). Such non-ideal 
features render evaluation and quantification of the signal difficult and somewhat 
empirical. Importantly, suboptimal signal distribution and spot shape are ultimately 
due to non-homogenous localization of the capture antibody after the deposition 
process, and improvement of the printing conditions reasonably necessitate an 
optimisation study additional to the one presented in this thesis. This requires a more 
thorough evaluation of the composition of the printing buffer and the use of additives 
to aid the spot formation. Factors that need further investigation are, for example the 
hygroscopic properties of the additives and their tensioactive characteristics. In fact, 
while hygroscopy presumably has an impact on the hydratation of the printed 
molecules, tension-active properties affect the surface tension of the printed droplet 
and hence its shape and morphology. Examples of additives that can be employed in 
protein microarray include BSA, glycerol, Triton-X, Tween 20. Certain additives, for 
example the BSA may compete with the antibody for the binding to the surface. 
Glycerol is exploited as additive because of its hygroscopic properties that contribute 
to maintain the spots hydrated and with good morphology. Glycerol, nevertheless, 
could in principle react with the aldheydes in acidic conditions via formation of a 
hemiacetal. Accordingly, although the selection of the printing buffers described in 
this thesis led to the construction of the microarray that has been used for the 
reported immunoassay, further optimization of the spotting conditions and also more 
thorough testing of tracer/antigen ratios was required to detect the nucleoproteins by 
competition.   
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In early 2010 a new panel of anti-nucleoprotein antibodies was made available by 
UNIPG. Based on availability of these new reagents it was decided to focus the 
activity on a sandwich-type assay that would rely on the use of capture/detector 
antibody pairs for the detection of the nucleoprotein. For this 6xhis tag-independent 
detection system, microarrays were constructed using two anti-NPB antibodies, 
4A11 and 2B4, and two anti-NPA reagents. Initially, the anti-NPA antibodies were 
two commercial reagents, indicated in this thesis as C01321M and C01323M. The 
two antibodies were purchased because indicated by the manufacturer for optimal 
use in sandwich-format immunoassays. For the detection of the NPB aliquots of 
4A11 and 2B4 were biotin-conjugated and used to reveal nucleoproteins captured on 
spots generated with the same two (non-biotinilated) antibodies. Four antibody pairs 
were then available to reveal the NPB. Capture/4A11 and detector/biotin-4A11, 
capture/4A11 and detector/biotin-2B4, Capture/2B4 and detector/biotin-4A11, and 
Capture/2B4 and detector/biotin-2B4. The detection of the NPA instead initially relied 
on the format represented by capture/C01321M and detector/biotin-C01323M.  
In the experiment described in paragraph 3.4.1 chips were realised by spotting 
C01321M, 4A11, and 2B4. The NPA and the NPB4 were added at the concentration 
of 100 ng/ml and they were then revealed using the biotin conjugates of 2B4 and 
C01321M and the described streptavidin protocol.  The experiment demonstrated 
differential detection of the NPA and the NPB4. 
 
One consideration is very important when designing the sandwich immunoassay. For 
the two antibodies to bind protein target simultaneously and generate fluorescence, 
they have to recognise two different epitopes on the protein. Epitopes are normally 
divided in two categories. The linear epitopes are composed of linear stretches of 
amino acids that assume a linear conformation. Conformational epitopes instead are 
represented by more complex three-dimensional structures assumed by one or more 
polypeptides. For a protein to be detected by two antibodies in sandwich 
conformation their epitopes must be spatially separated in order to avoid reciprocal 
steric hindrance. The epitopes recognised by the antibodies employed in this project 
are not known, the characterisation carried out both at UNIPG and by myself at 
Imperial College was limited to the demonstration of detection using one single 
antibody in the western-blot and/or protein microarray format. 
  186 
To explain how two identical antibodies interact with the nucleoprotein, two hypotesis 
were formulated. The first one considers the possibility that the NP monomer 
contains a repeated epitope, and that these repeated structures are located in two 
spatially distant regions of the protein. The second option considers the property of 
the nucleoproteins to form oligomers in solution. The NP monomers indeed tend to 
associate with one, two, or three other units. Although bigger oligomers have also 
been observed, the predominant forms include up to five monomers. The 
nucleoproteins likely present themselves to the arrayed antibodies as oligomers. As 
such, they can present different epitopes and be bound by more antibodies 
simultaneously. 
Next, two new antibodies were made available from the UNIPG, clones 105 and 109. 
These were indicated as reactive towards the human NPAs and this was confirmed 
with the microarray experiments shown in paragraph 3.2.4.3. Antibody 109 was 
biotin-conjugated and tested as detector agent. 
 
The most critical analytical characteristic of the investigated immunoassay is the 
detection limit, defined as the lowest concentration of the antigen that the 
immunoassay can detect. While it is essential to achieve a detection limit sufficient to 
detect viral infection at an early stage, it is difficult to precisely define the 
concentration of viral antigens in clinical samples. Depending on the type of sample 
(nasal or throat swab, for example), infection stage, pathogenicity of the viral strain, 
collection and transport method, the concentration of viral proteins can change 
dramatically. Also, different viral antigens are represented in the virus in different 
amounts, with certain proteins (the nucleoproteins) more represented than others 
(the neuraminidases, the hemagglutinins). In general, it is predictable that the 
developed immunoassay needs to be sensitive enough to detect nucleoproteins in 
the range of few tens of picograms/ml to nanograms/ml.  
Viral load of clinical samples however, is normally reported in literature in terms of 
TCID50/ml, EID50/ml, HA/ml or PFU/ml. These units refer to the effect of whole, live 
particles to cause a visible effect on cell cultures (TCID50/ml, HA/ml, PFU/ml) or on 
chicken embryos (the EID50/ml). As such, they indicate the amount of those virus 
particles that have retained the capability to carry out an infectious cycle. Non-
functional virus particles are not accounted for in these units of measure and 
quantification methods. And thus, the amount of viral particles that contribute to the 
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concentration of nucleoproteins is likely to be higher than that quantified with the 
above-mentioned methods/units. Partially or fully degraded viral particles are likely to 
be present in a clinical sample, however their proportion compared to the live 
particles is unknown. Importantly, different samples and transport methods are likely 
to determine very different ‘whole virus’ : ’degraded virus’ ratios, and there is little 
published information in this respect.  
A second consideration that was done before proceeding to the next phase regards 
the availability of the nucleoprotein to interact with the antibodies during the 
immunoassay. Nucleoproteins are found inside the viral core, encapsulated by a 
layer of matrix proteins and by the viral envelope. Degradation of the outer layer of 
the virus is essential in order for the antibody-NP interactions to take place. A 
number of detergents can be employed to dismantle protein and lipid layers. For 
example, amphiphilic substances such as the SDS, Tween 20, Triton, are used in a 
number of biochemical procedures to aid the denaturation of proteins and lipid 
structures. Lysolecitin has been used in a number protocols for the isolation of the 
ribonucleoprotein subunits of influenza. On the other hand, the Rapid Antigen 
Diagnostic Tests available on the market rely on proprietary reagents that are added 
to the viral samples immediately before the loading phase in the kit. The composition 
of the reagents is typically not disclosed. Importantly, and one such rapid kit requires 
blunt addition of the viral sample without previous mixing with any such reagent. 
These considerations indicate that the degraded (dead) fraction of virus in a 
biological sample could be a consistent or even the predominant target of antigenic 
detection of the virus. 
The choice of a good extraction buffer, also consider the effect these would have on 
the microarray application. Fluidity of the sample on the surface of the chip is 
essential for the good performance of the immunoassay. The experiments in the 
course of this PhD diluted all the reagents in salt buffers with a known controlled pH 
and low viscosity. However, clinical samples for influenza detection normally derive 
form naso-pharingeal washes and nasal or pharyngeal swabs. The mucus normally 
contained in these samples gives them a viscous nature. Additionally, the addition of 
detergents notoriously increases the viscosity of a solution. Realistically, therefore, 
the viscosity of the sample will limit the flow of the important components of the 
immunoassay on the chip and will interfere with the interactions between the 
different components of the immunoassay.  
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In the next phase of the work the developed immunoassay was assessed in the 
detection of a panel of influenza samples provided by the HPA, the ISS and the 
UNIBO. The HPA kindly provided Crisanti lab with three samples that included two 
human viruses of type A, A/NewCaledonia/20/1999 and A/Wisconsin/67/2005, and 
one human virus of type B B/Malaysia/5606/2004. The samples were composed of 
known amounts of viruses spiked into a viral transport medium of use at HPA and 
were titrated at the concentration of 100, 101, 102, 103, 104, 105, 106, 107 PFU/ml. The 
highest viral concentration, 107 PFU/ml was tested on the microarray assay, thus 
replacing the recombinant nucleoproteins. The sample was tested neat and at serial 
dilutions achieved with two alternative buffers preparations. In one case, the virus 
was diluted in the ‘NP diluent’ employed in the course of the work to dilute and 
incubate the recombinant nucleoproteins. In the second case the virus was diluted in 
the extraction mix included in one Rapid Antigen Detection Test (Directigen EZ Flu 
A/B, BD). The aim of this preliminary experiment was to demonstrate the 
immunoassay with viral samples. For every condition, background noise associated 
with each buffer was controlled with one negative-control array. The virus diluted in 
Directigen buffer was more reactive than the virus diluted with the standard NP 
diluent. However the Directigen buffer also produced high background on the 
negative control array. The background was not homogeneous and therefore it 
couldn’t be quantified. The results of the experiment demonstrate that the detection 
of pure recombinant NPB can be translated into detection of a B virus. The pattern of 
fluorescence produced in the experiment then indicates that the concentration of 
nucleoprotein likely to be found in the sample is above the detection limit of the test.  
  
A second panel of antibodies was received at a later phase of the project from ISS 
and UNIBO. The samples, listed in table 2.3, included both human and avian strains, 
grown in chicken embryo or in cell cultures by the providing partners. 
Each sample was first applied ‘neat’ on the slide, in preliminary tests in order to 
evaluate the reactivity of the untreated sample. Then, based on the pattern and 
intensity of fluorescence and on the concentration of the stock preparation, the 
samples were diluted to different extents and again tested on the array, as shown in 
figures 3.32-3.35. For this, three anti-NPA antibodies were spotted, mAbs 105, 109, 
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and C01321M, at equivalent concentration. The antibody C01321M was excluded 
from the analysis because it produced fluorescence on the negative control arrays. 
Instead, all the samples produced fluorescence on the spots generated with 
antibodies 105 and 109 and the corresponding spots remained black in the negative 
control arrays.  
 
The viral detection seemed to be rather specific, as no cross-reaction was observed 
on the spots with the anti-NPB antibodies.  
Similar results were achieved for the detection of the influenza B samples 
B/Milano/5/2011 and B/Milano/10/2011.  However the experiments performed with 
these two samples resulted in very intense fluorescence on the non-spotted surface 
of the array, and therefore evaluation of the results was difficult. It was noted that 
specific fluorescence on the anti-NPB spots was obtained predominantly for the 
spots generated with the 4A11, while the spots generated with 2B4 produced a 
fluorescence of the same level as the background.  
It was tempting to compare the results achieved with the different viral strains. 
However, these samples were quantified by the providing partners in terms of HA 
units and EID50 alternatively. And therefore, the concentration values couldn’t be 
compared directly. The experiments performed with each viral sample were 
evaluated independently from the others. 
These tests represent preliminary experiments that are affected by occasional 
background fluorescence, likely caused by the components contained in the sample. 
Nevertheless, clearly, localised fluorescence can be associated to presence of the A 
or B virus on the array.   
 
The results demonstrated with the viral samples indicated that the microarray 
immunoassay is feasible for viral detection. A range of techniques is available to 
evaluate the goodness of the result achieved. In principle, ELISA tests and RT-PCR 
protocols could be reproduced in Crisanti laboratory and be used as ‘gold standard’ 
techniques to compare my microarray immunoassay. However instead it was 
decided to compare the performance of the microarray test to that of three RADT 
tests. The reason for this choice is that the RADT tests better compare with the 
  190 
microarray immunoassay for simplicity of the protocol. The design of RT-PCR 
protocols requires availability and optimisation of pairs of primers, as well as the 
optimisation of the thermo-kinetic parameters of the PCR. Both problems require 
custom-made optimisation for each of the viral samples and this would go beyond 
the scope of the feasibility study. ELISA tests were also contemplated as possible 
candidate for the comparison of the results. However also in this case, parameters 
need to be optimized for the available viral samples.  
The RADT were chosen on the base of literature screening where the RADT where 
either compared one to the other or against gold standard techniques. It was 
therefore decided to test the RADTs with published information concerning their 
clinical sensitivity and clinical specificity.  
Importantly, the cost of the tests (£10-£20 per single test device) was too high to 
allow a complete titration of the nucleoproteins or the viral samples. Therefore, it was 
decided to only test the limiting dilutions that the microarray immunoassay was able 
to detect.  
The procedure indicated in the datasheet of each of the RADTs was followed 
carefully. It is important to note that two of the tests (DirectigenTM Influenza Test Kit, 
(BD), BinaxNOW® Influenza A & B (Inverness Medical), and QUICKVUE 
INFLUENZA A+B TEST (Quidel corporation) included a proprietary reagent to be 
added to the viral sample during the procedure.  
All the RADTs are visual tests. A coloured band is visualised on each device and the 
result is deducted by its visual observation by the operator. Quantification of the 
bands is not suggested by the manufacturers. A positive control band on each 
device indicates the correct procedure and can be utilised to compare the intensity of 
the bands indicating the virus. However, importantly, evaluation of the results for 
weak bands is rather empirical and operator-dependent. 
In one first comparative test, two human influenza A were diluted 1:200 form the 
initial stock solution and then tested on each of the three RADTs. This first test didn’t 
indicate a detection limit for the RADTs because a titration was not carried out. 
However, the experiment demonstrated that the results achieved with the microarray 
assay are in good agreement with those achieved with the commercial kits. It is 
important to note that, while the microarray experiments were completed by a 
negative control that demonstrates (to a certain extent) the specificity of the result, 
no negative control was carried out in the commercial tests in this instance. 
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The next experiment included a virus B. In this case two RADTs were tested. The 
microarray experiment detected all the dilutions tested, also the lowest one, 1:800. 
The Binax Now test could only reveal the second diluton, 1:400, the Directigen test 
produced a band in the negative control experiment and therefore results obtained 
with this test were not considered for the experiment. 
The results achieved indicate agreement of the detection achieved with the 
microarray and that achieved with the commercial kits. Also, they indicate the 
microarray assay is specific.  It is important to note, that the protocol indicated for the 
RADTs is 20 minutes long, while the length of the microarray protocol is 
approximately 1 hour.  
 
One other very important outcome of the comparative experiments is that, although 
the detection limit of the RADTs couldn’t be calculated with statistical significance, 
the viral concentration range seems to be in the same range as the microarray 
immunoassay. In two instances, the microarray assay could detect the sample at a 
dilution equal or higher as compared to the RADT tests. 
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5 Conclusion 
 
 
The work conducted in this PhD generated a miniaturized immunoassay capable of 
detecting the influenza virus. In the test, influenza nucleoproteins are captured by 
monoclonal antibodies immobilised in a microarray format. Presence of the viral 
nucleoproteins is then revealed with a highly sensitive detection protocol that reveals 
concentrations in the range 1-10 ng/ml. Several features of the test are very 
promising: a) the capability to detect both influenza A and influenza B 
nucleoproteins; b) the possibility to differentiate between the A and B type; c) a 
duration of the test, of less than 30 minutes. The assay was demonstrated in the last 
part of this PhD against a panel of viral samples that included both human and avian 
viruses.   
The importance of the test goes well beyond the simple academic research. Indeed, 
international concern about the occurrence of pandemic events that can be caused 
by novel influenza viruses has increased over the last twenty years. The influenza 
pandemic caused by the ‘swine flu’ in 2009 in fact, together with the numerous cases 
of human infection caused by the avian H5N1 prove that influenza is a current threat 
to man. Prompt response to pandemics relies on measures such as the selective 
antiviral administration to patients and their hospitalization, the set up of quarantines, 
and the culling of large numbers of infected animals; these decisions require a fast 
identification of the pathogen, including type and subtype, before the infection 
spreads.  
Current diagnostic systems are predominantly laboratory-bound and require 
specialised personnel to carry out lengthy experimental protocols that cannot stand 
the challenges posed by a typical pandemic scenario. There exist ‘rapid’ diagnostic 
tests (RADTs) that provide a fast and straightforward screening of samples and are 
designed to be used at Point-of-Care locations. However, RADTs are hampered by 
poor and very variable clinical sensitivity, between 20 and 80%, and they do not 
provide information to the subtype level.  
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Therefore, the development of more powerful and reliable diagnostic systems that 
can be handled by not high-skilled operators and provide type and subtype 
information in useful time, ideally less than 20 minutes, is an absolute requirement to 
promptly confront pandemic threats.  
The immunoassay evaluated by myself during this PhD is a basic, but very promising 
option that could fill the gap that exists in the modern diagnostic landscape. While 
the detection limit (1-10 ng/ml) was demonstrated with pure nucleoproteins, the 
assay proved capable to detect viral preparations containing strains of different 
subtypes, and to also differentiate the A and B types.  
Importantly, the test is designed for future integration into an automated platform 
developed by MtM. The instrument, Automated Diagnostic Analyser for Microarrays 
(ADAM), replaces the operator in all the phases of the immunoassay, including the 
preparation of the reagents, the actuation of the sequential steps of the procedure 
(i.e. addition of the reagents, washing, drying), and the scanning of the arrays after 
processing. The integrated software then reads the pattern of fluorescence of the 
array and analyses the results. Key element of the ADAM is a protein/antibody 
microarray, displayed on a slide. The slide is integrated into a proprietary lateral-flow 
device that permits the handling of the immunoassay in a time-controlled manner. 
The instrument requires only minimal hands-on time of the operator, and can 
process up to five samples in each experimental run. Evaluation of the instrument is 
currently being carried out at MtM in tests for the screening of the allergies, and is 
showing great potential. 
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Figure 5.1. The Automated Diagnostic Analyser for Microarrays (ADAM) and the lateral-flow 
device (courtesy of MtM). 
 
 
While the ADAM instrument is a very promising aid in the laboratory diagnosis, its 
automated and straightforward use, together with the relatively compact size 
78x37x42 cm, open up options for a use at the Point-of-Care.  
Future work will focus on three important aspects.  
1) The introduction of the assay in the ADAM instrument will be evaluated. 
Automation of the manual procedure will simplify the experimental protocol and will 
likely allow the speed up of further optimisation of the assay. However, the 
parameters of the test may require improvement and fine-tuning in order to fit 
mechanical constraints posed by the lateral-flow device. Assay steps, such as for 
example the loading of the sample and its incubation on the microarray, the washing 
steps, and the preparation of the reagents differ from the manual procedure and will 
need optimisation. 
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2) The microarray platform will be enlarged with a panel of antibodies that include 
subtype-specific reagents. Indeed, a sub-set of antibodies developed at UNIPG has 
already shown a reactivity pattern that could help in differentiating important 
subtypes such as, for example, H1N1 and H3N2. The integration of new antibodies 
in the microarray platform will likely proceed through a feasibility study using 
recombinant surface antigens first. 
3) The assay developed by myself will be validated against a larger panel of 
samples, likely with the collaboration of medical laboratories. Importantly, clinical 
samples will have to be included in the experimentation in order to better evaluate 
the diagnostic potential of the test. 
It is envisaged that, upon further optimisation and introduction in the ADAM 
instrument, the assay developed during this PhD will generate a powerful diagnostic 
system for the diagnosis of influenza. 
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